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Abstract 
Drug resistant tuberculosis (TB) is increasing worldwide and it is now 
estimated by the World Health Organisation (WHO) that 7% of TB cases globally are 
resistant to isoniazid (INH). INH is a key drug for the treatment of TB, alongside 
rifampicin (RIF). Understanding factors which influence the emergence and 
propagation of INH resistance and the influence of INH resistance on TB treatment 
success are vital in improving global TB control efforts. 
Vietnam is ranked 12th of 22 high burden countries for TB and has a high 
prevalence of INH resistance (25%) with a relatively modest prevalence of TB 
resistant to both INH and RIF (multi-drug resistant, MDR TB) (2.7%) 
The first study in this thesis developed rapid screening tests for both RIF and 
INH resistance in Mycobacterium tuberculosis isolates which showed high accuracy. 
The specificity and the sensitivity of the MAS-PCR test for INH resistance compared 
to the conventional phenotypic DST were 100% [95% Cl 92.9-100%] and 90% [95% 
Cl 82.4-95.1 %], respectively. 
The second study demonstrated that the minimum inhibitory concentration 
(MIC) for INH is influenced by both the mutation responsible for resistance to INH 
and the lineage backbone of the M.tuberculosis isolate. A two-way ANOV A of MIC 
including both strain lineage (p=()'003) and resistance mutation (p<O.OOI) showed 
highly significant independent effects of both factors on MIC level. MIC to INH of 
isolates with a katG315 mutation (2I1g1rnl) was significantly higher compared to MIC 
to INH of isolates with an inhA-15 mutation (O.2511g/ml) and wild-type isolates (0-
O.IJlg/ml) (p<O.OOI).The independent effect of the strain lineage on INH MIC was 
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predicted to correspond to a 2.68-fold (95% Cl 1.52-4.73, p<O.OOl) increase for 
Beijing lineage strains and a 1.40-fold (95% Cl 0.72-2.74, p=O.32) increase for Euro-
American lineage strains in comparison with strains of the Indo-Oceanic lineage. 
The third study investigated the impact of INH resistance on outcome in 
patients with HIV-associated TB meningitis (HIVrrBM) and showed that HIVrrBM 
patients infected with INH resistant M.tuberculosis which remains susceptible to RIF 
have significantly worse outcomes than patients infected with fully susceptible 
strains. The adjusted hazard ratio for MDR patients in comparison with fully 
susceptible or streptomycin (STR)-monoresistant isolates was 5.21 [95% Cl 2.38-
11.42], p<O.OOOI compared with HR= 1.78 [95% Cl 1.18-2.66], p=O.005 for patients 
with INH resistant isolates (+I-STR resistance). 
The final study investigated the distribution of N-acetylator-2 (NA TI) 
phenotypes for INH metabolism in healthy volunteers from the Vietnamese Kinh 
population and correlated this with phenotypes using caffeine as a surrogate indicator 
for INH metabolism. This study showed that characterisation of 3 single nucleotide 
polymorphisms is sufficient to determine the acetylator status of individuals of 
Vietnamese Kinh ethnicity and that there is a predominance of fast acetylators (65%) 
in this popUlation. A simple PCR-RFLP test was developed to enable rapid 
determination of acetylator status for further studies. 
Collectively, these results contribute to our understanding of INH resistance in 
M.tuberculosis and provide molecular tools for further studies of this crucial drug. 
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Chapter 1 
Introduction 
1.1 Background 
There is a lot of evidence showing that Mycobacterium tuberculosis 
(M. tuberculosis) has coexisted with humans since antiquity. The disease tuberculosis 
(TB) has been known under many different names, such as Phthisis (Greek), 
Consumptione (Latin) or White-plague (Europe, 17th_midl9th centuries) (Daniel, 
Bates et al. 1994). Without knowledge of the precise cause of the disease. people 
described the epidemic as a wasting disease or consumption. These diseases had all 
symptoms of TB with wasting, pale skin, fever, haemoptysis, sweats. and had been 
described by many ancient authors (Daniel and Daniel 1999). including Hippocrates. 
Mummies excavated from ancient tombs have shown skeletal traces of TB and 
molecular techniques have also confrrmed the positive identification of 
M.tuberculosis infection (Crubezy. Ludes et al. 1998; Zink, Sola et al. 2003). It seems 
that TB has been a major cause of human mortality for thousands of years. 
M.tuberculosis is an extremely successful pathogen and has evolved a number 
of mechanisms to evade the host immune response including the ability to survive 
within the acidic phagosome and tolerate oxidative radicals (Chan and Kaufmann 
1994). M.tuberculosis transmission occurs when an infected individual coughs up 
infectious droplet nuclei which are inhaled by a susceptible individual. M.tuberculosis 
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may subsequently cause active symptomatic diseases or establish a latent infection in 
the host, which can reactivate later, especially when the host immune system has 
weakened due to age, malnutrition or disease (Smith and Moss 1994). With the 
discovery and development of chemotherapy for TB infection in the mid 1940s and 
1950s, people was able to treat the disease effectively for the first time and the hope 
that TB would one day be eradicated were raised. However, only a few months after 
streptomycin (STR) was first administered to patients in 1947, the limitations of 
mono-therapy became apparent as individuals, initially responsive to therapy, 
relapsed (D'Arcy Hart 1999). Drug resistant strains were isolated from a number of 
patients in the first cohorts receiving the drug (McDermott 1948; Patterson and 
You mans 1970). As further anti-tuberculous drugs, para-aminosalicylic acid (PAS, 
1948), isoniazid (INH, 1952), rifampicin (RIF, 1963), ethambutol (EMB, 1962) and 
pyrazinamide (pZA, 1952), were discovered and introduced to TB treatment, these 
drugs were gradually incorporated into multidrug treatment regimens to prevent the 
emergence of drug resistance (Youmans, Raleigh et al. 1947; Dunner, Brown et al. 
1949; Sarkar and Suresh 2011). A landmark series of trials by the British Medical 
Research Council (MRC) and the International Union Against Tuberculosis and Lung 
Disease (IUATLD) eventually led to the development of a 6-month Multi-drug 
regimen which is still in use today (WHO 1999; Volrnink and Garner 2(07). INH and 
RIF are the two most important drugs forming the backbone of standard first line 
therapy. The World Health Organisation (WHO) has supported a strategy of directly 
2 
observed treatment short-course (DOTS) to control TB through National TB 
Programmes (NTP) (WHO 1999). 
The emergence of Human Immunodeficiency Virus (HIV) in the last decades 
has led to a resurgence in TB cases globally (Smith and Moss 1994). Infection with 
HIV leads to a gradual decline in an individual's immune function through the 
destruction of helper T cells or CD4 T cells; and eventual progression over 
approximately 10 years, to acquired immunodeficiency syndrome (AIDS) (Smith and 
Moss 1994). The continuing decline in cell-mediated immunity renders an individual 
more susceptible to TB and develops more severe disseminated forms of TB 
infection. The second major challenge to global TB control is the increasing 
prevalence of primary TB cases infected with drug resistant M.tuberculosis strains. In 
particular, multi-drug resistant TB (MDR TB), which is resistant to at least INH and 
RIF, requires a minimum of 18 months for treatment with second line drugs which are 
more expensive, higher toxicity and less potent. 
Until recently, the number of TB infections worldwide incessantly increased 
as well as the emergence of multidrug resistant M.tuberculosis, that in 1993 WHO has 
announced TB as a Global Health Emergency (WHO 1993). Since then, coordinated 
actions between governments and international non-governmental organizations 
(NGOs), such as WHO, have been established to try to improve the effectiveness of 
treatment with DOTS, which increases the supply of TB drugs at affordable prices or 
increases global funding for the developing world for treatment and research on the 
disease. The Stop TB Strategy along with Millennium development Goals of WHO 
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with the target of reducing 50% of global burden of TB and death rate by 2015 
relative to that in 1990, as well as set the goal of eliminating TB by 2050 (WHO 
2(06). 
1.2 TB in the world 
It has been estimated that one third of the world population is infected with 
M.tuberculosis. Only around 10% of infected individuals develop active symptomatic 
TB, the majority remain latently infected and form a reservoir of the disease. 
Approximately 5% will develop reactivated TB disease as the immune system 
becomes impaired due to age, disease or malnutrition (Raviglione, Snider et al. 1995; 
WHO 2009). TB kills approximately 2 million people each year (1.35 million deaths 
from TB in HIV negative individuals and 456,000 deaths in HIV co-infected patients 
in 2(07). According to the WHO, the estimated global incidence of TB in 2007 was 
9.27 million cases (1391100,000) and the estimated prevalence was 13.7 million cases 
(206/100,000) (WHO 2009). With all of the effort to control TB infection, the 
infection rate is slightly decreased with the estimated incidence of TB in 20 I 0 was 8.8 
million cases (128/100,000) and the estimated prevalence was 12 million cases 
(1781100,000) (WHO 201l). 
Approximately 95% of TB patients and 98% of deaths due to TB are reported 
from low income countries; three quarters of TB patients are in the most economically 
productive ages (15-45 years old). For this reason, TB is often named a disease of 
poverty and the disease in turn intensifies poverty through morbidity in TB patients 
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unable to work and the financial burdens of TB treatment. Almost 80% of TB cases 
occurred in 22 high burden countries in 2004, of which Vietnam is one (WHO 2006). 
The distribution of TB prevalence varies widely among countries (Figure l.l), 
apparently because of differences in wealth and health care systems. India had the 
largest total incidence 0.96 million estimated new cases each year) and also the 
biggest prevalence of TB (3.3 million estimated cases) in the world in 2007. China 
was ranked second with a prevalence and incidence of 1.3 million and 2.58 million 
cases, respectively. For this reason, Asia accounts for 55% of global TB cases. The 
African region accounts for 31 %; the other three regions (the Americas, European and 
Eastern Mediterranean regions) account for small fractions of global cases (around 3-
6%). However, when stratified by the number of prevalent TB cases per 100,000 
population, African regions were among the countries with the highest rates, and the 
prevalence was also relatively high in Asia (WHO 2009). 
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Figure 1.1: Estimated TB incidence rates by country in 2010, WHO 2011 
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According to WHO reports in 2009 and 2011, the overall treatment success 
worldwide was 85% in 2006 (based on treatment outcome), 86% in 2009, but the 
detection rate was only 57% in 2005, 65% in 2010 among new smear positive cases 
(WHO 2009; WHO 2011). There are a significant proportion of TB cases that are not 
detected - of particular concern is the 35% of sputum smear negative TB cases. These 
cases mostly remain untreated and become an infectious source for TB transmission. 
1.3 TB in Vietnam 
The estimated incidence of TB in Vietnam was 180,000 cases with 52,142 
smear positive cases in 2010, for which Vietnam was ranked 12 of22 high TB burden 
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countries in the world (WHO 2009; WHO 2011). Despite investment from the 
government and international organizations in establishing DOTS since 1985 (WHO 
200 I), achieving coverage for the whole country by 2000, the incidence of pUlmonary 
TB in Vietnam has not decreased significantly (WHO 2009). The notified new extra-
pulmonary cases have constantly increased since 1995 from 6,194 cases to 18,333 
cases in 2009 (WHO 2010), which could be a result of improvement in extra-
pulmonary diagnosis and the exponential increase in mv infection (Marais, Thwaites 
et al. 2010). 
Despite the fact that Vietnam had a relatively low GNP per capita ($370 in 
1999, source: hnp:/Iwww.nationsencycJopediacomleconomieslAsia-and-the-PacificIVietnam).it 
was one of the first countries to reach WHO targets for TB detection and cure in 1999 
(WHO 2001)_ The Vietnamese Ministry of Health has established a national fund for 
TB and also developed partnerships with international organizations to establish and 
obtain targets and to address the health system constraints of the country_ The NTP 
had been established at the end of 1994 and rapidly scaled up DOTS coverage to 
100% of the population in 2000. Principal targets for the NTP are to decrease TB 
related morbidity and mortality decrease TB infection and transmission, and eliminate 
the development and transmission of drug resistant strains. To achieve these 
objectives, case detection and treatment success must be improved (WHO 200 I). 
However, TB rates have not substantially declined in Vietnam, despite the 
notable achievements of the NTP and there are still many issues that need to be 
tackled. As globally, there is a desperate need for improved diagnostic tests to 
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increase case detection and operational research is required to determine how best to 
apply these tests within the existing NTP. Novel drugs are needed to improve existing 
treatment regimens and treat drug resistant forms. Neonatal vaccination with Baccilus 
Calmette Guerin (BCG) is applied in Vietnam but remains largely ineffective and an 
effective vaccine remains elusive (Andersen and Doherty 2005). Research is needed 
into the relative contribution of factors influencing the outcome of patients on 
standardised regimens. Drug resistance is known to be a major contributing factor to 
poor outcome, alongside adherence (Quy, Lan et a1. 2003). The relative contributions 
of host genetic and pathogen virulence factors of different TB genotypes are only 
beginning to be studied (Caws, Thwaites et a1. 2008; Thuong, Dunstan et a1. 2008). 
Resistance to the fust line drugs is prevalent, although MDR TB rates remain 
relatively low (2.7%), it is slowly increasing (Quy, Buu et al. 2006). Contributing 
factors are likely to be the treatment of TB in the private sector, undetected relapse 
and a lack of available funds to manage drug resistant TB. Many patients go to the 
private sector for TB treatment which is a well-documented risk for poorly 
standardised treatment (Lonnroth, Thuong et al. 2003) and the private sector is likely 
to increase in importance as Vietnam transitions to a middle-income nation. 
Treatment for multi-drug resistant TB in the NTP has only become available in 2010 
at one centre in Southern Vietnam (Pham Ngoc Thach Hospital) and many patients 
carrying multi drug resistance are still being treated with WHO standard re-treatment 
regimen with rust-line drugs (Quy, Lan et al. 2(03), which is known to be ineffective 
(Burugina Nagaraja, Satyanarayana et al. 2011). 
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1.4 TB and HIV 
TB incidence has increased in many parts of the world in conjunction with the 
HIVepidemic. Globally, WHO reported that there were 1.1 million new HIV -positive 
TB cases in 2010 (out of a total of 8.8 million incident cases of TB) (WHO 201 I). 
The African Region accounts for 79% of estimated HIV-positive TB cases; most of 
the remaining cases (11 %) are in the South-East Asia Region (WHO 2009). People 
infected with HIV are more likely to develop active TB when they are infected with 
the M.tuberculosis bacteria. Compared with an individual who is not infected with 
HIV, an individual infected with HIV has 10 times increased risk of developing active 
TB (WHO 2004). In fact, the HIV pandemic had increased the number of TB patients 
by at least 10% (WHO 2004). 
With sixty percent of the global population within the most sexually active age 
group (15-49 years), Asia is home to one of the fastest-growing HIV epidemics in the 
world (Ruxrungtham, Brown et aI. 2004). Despite many efforts from WHO, 
governments and other non governmental organizations, which has led to one-third of 
those needing antiretroviral therapy (ART) being put on treatment, the majority of 
patients in these developing countries are still unable to access ART. As a result, most 
HIV-infected patients in Asia present with an opportunistic infection, usually TB 
(WHO and UNAIDS 2009). This not only increases the burden of TB in the region 
but also increases morbidity and mortality in HIV patients with TB co-infection 
(Gandhi, Moll et al. 2006; Quy, Cobelens et al. 2006). 
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The diagnosis of TB is complicated in a patient with HIV co-infection. 
Further, HIV co-infected patients often develop more severe disseminated forms of 
the disease and are less likely to have a successful outcome even when diagnosed 
correctly. HIV-infected patients are more likely to have either disseminated, 
genitourinary, intra-abdominal, lymph node or pulmonary TB (Shafer, Kim et al. 
1991). Diagnosis of TB in HIV infected patients is difficult and often delayed because 
these individuals are more likely to be sputum smear negative or have atypical chest 
X-ray presentation (Samb, Sow et al. 1999; Swaminathan, Paramasivan et al. 2004). 
The differential diagnosis is also broader. HIVrrB patients who are on ART also 
suffer from increased toxicity and drug:drug interaction because of the large number 
of drugs; thus present further treatment adherence and failure problems in this 
population (Amuha, Kutyabami et al. 2(09). 
1.5 TB and HIV in Vietnam 
Estimates extrapolated from sentinel surveillance data suggested that about 
122,000 people in Vietnam were infected with HIV in 2000, with a prevalence rate of 
0.29% in the 15-49 year-old age-group (WHO and UNAIDS 2(09). As in other 
settings with an emerging epidemic HIV infection, the survey was focused on the 
high-risk groups, including injecting drug users and commercial sex workers. The 
number of HIV infected people in Vietnam was rising exponentially in 1995 and has 
been increasing slightly during the last fifteen years, partly due to improvement in 
access to HIV treatment (WHO and UNAIDS 2(09). Effective ART dramatically 
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reduces the viral load of an HIV-infected individual, reducing the probability of 
transmission occurring (Wagner, Kahn et al. 2010; Williams, Lima et al. 2011). 
However, as mY-infected individuals on ART remain healthy for longer, and are 
likely to remain sexually active, the long term impact on HIV transmission is not 
known (Wagner, Kahn et al. 2010). To date, the epidemic remains focused in core 
high-risk groups: commercial sex workers, intravenous drug users and men who have 
sex with men. Rising HIV prevalence rates in Vietnam have complicated TB control 
efforts and are likely to be a major contributing factor to the slow rate of decline in 
TB incidence. According to the WHO in 2010, the estimated incidence of TB in 
Vietnam was 180,000 cases (l99I100,OOO) and the estimated prevalence was 290,000 
cases (3341100,000). Of those, 7,600 cases were in HIV co-infected patients (4.2% of 
total TB incidence cases) (WHO 2011). The increasing rate of mv in this population 
not only fuels TB prevalence but also decreases the effectiveness of the TB control 
program. HIV infected individuals with TB are more likely to be smear negative and 
present a normal chest X-ray (CXR), therefore TB often remains undetected in mv-
infected individuals, resulting in high mortality (Quy, Cobelens et al. 2006). A multi-
country study has been conducted to develop a diagnostic algorithm to improve TB 
diagnosis in mv patients in Cambodia, Thailand and Vietnam (Cain, McCarthy et al. 
2010). Globally, the mortality of TBIHIV co-infection is extremely high with 33% 
mortality among HIV-positive incident TB cases (WHO 2009). 
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1.6 Global TB phylogeny 
M.tuberculosis is a fascinating pathogen. Despite a long history of co-
existence with humans, M.tuberculosis genomes appear to be quite preserved or have 
low diversity in comparison with other pathogen genomes (Garnier, Eiglmeier et al. 
2(03). Various typing schemes have been devised for M.tuberculosis, including 
IS6110 restriction fragment length polymorphism (RFLP) , spoligotyping, variable 
number tandem repeat (VNTR) typing and large sequence polymorphism (LSP) 
typing. Early typing systems for M.tuberculosis, RFLP and spoligotyping, were 
devised largely by examining diversity within isolates from Europe or North America 
and the discriminatory power of such systems was therefore low for isolates from 
Asia. The global diversity of M.tuberculosis was therefore underestimated. 
The differences between different M.tuberculosis genotypes are very small, 
which are >99.95% identical at the nucleotide level in genome comparison (Gamier, 
Eiglmeier et al. 2003; Zheng, Lu et al. 2(08) meaning extensive translocations, large 
deletions or insertions rarely occur. Unlike other bacilli, M.tuberculosis does not 
appear to acquire DNA by horizontal transfer and genome variation occurs by 
homologous recombination or deletion events, often mediated by mobile repetitive 
elements such as IS6110 (Hores, Van et al. 2007; Zheng, Lu et al. 2008). 
Spoligotyping is a typing method based on the detection of deletions in the 
direct repeat region which consists of 36 base pair repeated elements interspersed with 
variable 'spacer' regions. The presence/absence of the variable spacers is detected to 
generate a 'spoligotype' for the strain. This method is discriminatory for 
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M.tuberculsois isolates among the Euro-American lineage. but does not discriminate 
the Beijing lineage. which is predominate in Asia (de long, Antonio et al. 2009). LSP 
detects the absence of large DNA sequences (region of deletion - RD) and defines 6 
major M.tuberculosis lineages. which are named after the geographic region in which 
they predominate (Flores, Van et al. 2007). Both spoligotyping and LSP have been 
used widely for both phyJogeny and molecular epidemiological studies of 
M.tuberculosis (Gagneux, DeRiemer et al. 2006). Recent studies have examined the 
diversity within the Beijing genotype family. Using LSP typing, the Beijing genotype 
is a sub-group of the East-Asian lineage. The RD 105 deletion defines the East-Asian 
lineage. This deletion when presents in additional with RD207 deletion (which 
containing spacers 1-34), defines the Beijing genotype on spoligotyping. 
BeijingIW genotype is a M.tuberculosis lineage which has a unique 
spoligotype pattern with spacers 1-34 missing on standard 43-spacer spoligotyping 
(Kremer, Glynn et al. 2004). The Beijing genotype has generated significant interest 
due to the high prevalence of this strain in some regions of Asia and its association 
with an outbreak of drug resistant TB in the United States (Niemann, Diel et al. 2010) 
and many parts of Eastern Europe (Cox, Kubica et al. 2005). Beijing genotype has 
also been reported to be associated with MDR TB in Vietnam (Caws, Thwaites et al. 
2006; Buu, Huyen et al. 2009). Animal models infection with this genotype have 
suggested that the Beijing lineage is hypervirulent in comparison with other strains of 
M.tuberculosis (Tsenova, Ellison et al. 2005); however, the evidence for this 
hypervirulent is inconsistent and controversial (Parwati, van Crevel et al. 2010). 
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1.7 TB phylogeny in Vietnam 
Three of the six major global lineages of M.tuberculosis are found in Vietnam; 
the Beijing. Indo-Oceanic and Euro-American lineages. Beijing genotype is a 
predominant genotype in Asia and is increasing in prevalence in other regions of the 
world. such as South Africa (Johnson. Warren et al. 2(06). The prevalence of Beijing 
genotype in Vietnam is around 40-50% (Caws. Thwaites et al. 2006; Buu. Huyen et 
al. 2009). Several studies in Vietnam showed that Beijing genotype was associated 
with MDR TB (Caws, Thwaites et al. 2006; Buu, Huyen et al. 2009). 
The Indo-Oceanic lineage is the predominant genotype in Indonesia, the 
Philippines and other regions of South East-Asia. Isolates of this lineage are 
designated with East-Asian-Indian (EAO spoligotype classifications (Comas, 
Homolka et al. 2009). The Indo-Oceanic lineage is also prevalent in Vietnam, 
accounting for approximately 40% of M.tuberculosis strains. A single strain of this 
lineage, which has a single IS6J 10 copy on RFLP typing and a unique spoligotype 
(EAI-VNM) has been referred to in the literature as the 'Vietnam genotype' or the 
'Ha Noi genotype' and appears to be a geographically specific genotype in this region 
(Buu. Huyen et al. 2009). However, there is limited data on M.tuberculosis genotypes 
in the surrounding countries or regions (Cambodia. Laos, Southern Thailand and 
Southern China). and so the geographical extent of this genotype is not clear. 
The Euro-American lineage strains of M.tuberculosis are also present in 
Vietnam and account for approximately 20% of strains. A limited diversity of Euro-
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American lineage isolates is found, possibly due to a relatively recent introduction to 
the region in the last two centuries. Euro-American lineage strains show spoligotype 
patterns: LAM, Haarlem, Tl and T3 (Caws, Thwaites et al. 2006; Buu, Huyen et al. 
2009). It is not clear which strains are emerging in Vietnam due to a lack of historical 
material for analysis and further study would help to elucidate the evolution of the 
M.tuberculosis popUlation in Vietnam. 
1.8 TB pathogenesis 
The genus mycobacteria contain two major human pathogens: Mycobacteria 
leprae, which causes leprosy in humans and M.tuberculosis, which causes TB. Other 
mycobacteria of the M.tuberculosis complex (M.africanum, M.bovis, M.canettti) can 
also cause TB disease. The non-tuberculous mycobacteria (NTM) are classified in two 
sub-groups as slow or rapid growers. Some species are also pathogenic in humans, 
particularly in immune compromised individuals. Of these, the most important ones 
are M.avium-intracellulare and M.kansassii which cause pulmonary disease and 
M.ulcaerans, which causes buruli ulcer. Others, such as M.marinum, can cause 
opportunistic infection in humans (Tonjum, Welty et al. 1998; Corbett, Churchyard et 
al. 1999). 
M.tuberculosis is a rod-shaped bacillus, 2-4Jlm in length and O.2-0.5Jlm in 
width, non-motile, non-spore forming, obligate aerobe which stains weakly with 
Gram dyes. Mycobacteria are classified as acid-fast bacilli because the lipid-rich cell 
wall renders them relatively resistant to acid and this property is exploited in acid fast-
staining techniques such as Ziehl-Neelsen (ZN) smear. M.tuberculosis is a slow 
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growing bacillus with a generation time of 16-24 hours (for comparison, Escherichia 
coli has a generation time of 20 minutes) (Wayne 1994). Despite its slow growth, 
M.tuberculosis is one of the deadliest pathogens. 
M.tuberculosis is transmitted when a patient with active TB coughs, sneezes 
or spits, expelling infectious aerosol droplets containing M.tuberculosis bacilli (Smith 
and Moss 1994). Destruction or survival of the bacillus depends on the interplay 
between the bacilli and the host. A strong immune response can destroy or inhibit a 
weak bacillus before replication occurs. If the bacilli are not successfully eliminated, a 
latent infection may be established in which the bacilli remain in the body but the 
infection does not progress and the individual stays asymptomatic (latent TB) or 
individuals may progress to active pulmonary TB (primary TB). 
In individuals with latent TB, the infection may 'reactivate' after years or 
decades, most commonly when the immune system is weakened by other co-
morbidities or infections (such as diabetes or mv infection), or the use of 
immunosuppressive drugs, such as anti-TNFa (Dannenberg, Jr. et al. 1994). 
Some individuals develop active TB directly following initial infection, 
especially those with immune compromise. In others, active TB develops after many 
years of latent TB infection. At this stage, the bacteria begin to actively multiply 
within the body. The growth of M.tuberculosis creates lesions in the lungs principally 
via immune destruction of surrounding tissue. As immune cells are recruited to the 
site of infection. a granuloma is fonned. If containment is not established at this stage, 
individuals develop active TB and gradually become infectious and able to transmit 
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M.tuberculosis as bacilli are expectorated in the sputum until the infection is 
effectively treated (Dannenberg, Jr. et al. 1994; Schluger 2(05). 
Without appropriate treatment, the majority of TB patients will die. One study 
showed that 90% of TB patients, who did not receive appropriate chemotherapy, often 
due 10 delayed diagnosis, died (Chiang, Lee et al. 2(09). This report demonstrates the 
importance of early diagnosis and instigation of appropriate chemotherapy in 
preventing death from TB. 
1.9 Clinical symptoms of TB 
Symptoms of pulmonary TB include a productive prolonged cough for more 
than three weeks, chest pain, haemoptysis, shortness of breath, fever, chills, tiredness, 
night sweats, appetite loss, weight loss and pallor (Hopewell 1994). 
Extra-pulmonary TB may co-exist with pulmonary TB, thus may present as 
'classic' pUlmonary TB. Weight loss, fever and night sweats are common symptoms 
among all forms of TB. Other symptoms and signs of extra-pulmonary TB depend on 
the affected organs; for example, lymphadenopathy occasionally with pus drainage 
when lymph nodes are infected or arthralgia when joints are involved (Hopewell 
1994). Patients with TB meningitis may present with headache, stiffness of the neck 
and decreased consciousness (Hopewell 1994). All these symptoms are non-specific 
and are only suggestive for extra-pulmonary TB (WHO 2(09). Demonstration of 
M.tuberculosis in clinical samples is the gold-standard for TB diagnosis, but is often 
difficult, even in settings with culture facilities, due to the difficulty of obtaining 
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adequate samples and the frequently paucibacillary nature of clinical samples in extra-
pulmonary disease. 
1.10 Tuberculous meningitis (TBM) 
TBM is the most severe form of TB infection, causing death or disability in 
more than half of those infected (Hosoglu, Geyik et al. 2002). TBM is caused by 
dissemination of M.tuberculosis to the brain resulting in inflammation of the 
meninges. The severity of the disease is thought to be largely a consequence of the 
immune response, rather than the bacilli themselves, since the bacterial load within 
the cerebrospinal fluid (CSF) is thought to be very low, although bacilli may be 
sequestered and therefore not present in the sampled fluid (Radhakrishnan and Mathai 
1993). Death from TBM is strongly associated with delays in diagnosis and treatment 
(Hosoglu, Geyik et al. 2(02). The stage of TBM is normally defined by the Glasgow 
coma scale (GCS). GCS is measured by performing clinical assessment of eye 
opening (1-4 points), best verbal response (1-5 points) and best motor function (1-6 
points), where lower values indicate more severe neurological dysfunction. TBM 
severity is also assessed by the MRC grades 1-3 for TBM. The MRC grading system 
defines patients in grade I if they have a GCS of 15 (fully conscious) and no focal 
neurology; patients in grade 11 have a GCS of between II and 14 and/or focal 
neurological deficit; and patients in grade III have severe coma with a GCS of less 
than 11 (Donald and Schoeman 2004). 
Treatment regimens for TBM have never been optimized through adequately 
powered randomized controlled trials (RCT), and are extrapolated from trials of 
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pulmonary TB treatment. As a consequence, national and international guidelines for 
TBM treatment vary widely (Thwaites. Fisher et al. 2009; Kadhiravan and Deepanjali 
2010). and generally recommend extended treatment duration. due to the severe 
consequences of relapse. It is unlikely that these regimens represent optimal 
treatment, due to the poor penetration of many first line anti-TB drugs across the 
blood:brain barrier (Donald 2010). Of the existing drugs. only INH and PZA penetrate 
well. while EMB. STR. and crucially RIF. penetrate very poorly. particularly if the 
meninges is not inflamed (Ellard. Humphries et al. 1993; Thwaites. Lan et al. 2005). 
Despite use of the standard anti-TB chemotherapy. around 30% of patients still die 
and many of the survivors have a significant neurological deficit (Hosoglu. Geyik et 
al. 2002; Thwaites. Lan et al. 2005). Neurological sequelae are caused largely by 
infarction and subsequent damage to brain tissue. Adjunctive steroids have long been 
advocated for TBM treatment. but their efficacy has been disputed. especially in 
patients with MRC grade 1 disease. which is those with a GCS of 15. A RCT of 
adjunctive dexamethasone in 545 patients with TBM in Vietnam has shown a 30% 
reduction in mortality but despite this. uptake of the recommendation into guidelines 
has been slow (Thwaites. Nguyen et al. 2004; Prasad and Singh 2008). 
mv infection increases individual risk of developing extra-pulmonary 
disease. especially TBM (Berenguer. Moreno et al. 1992). Consequently. TBM has 
become a common and serious clinical problem in populations with a high prevalence 
of both TB and HIV infection. such as Africa and South East Asia. Co-infection with 
mv results in increased mortality in TBM (Thwaites. Duc Bang et al. 2005; Torok. 
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Chau et al. 2008). For HIV-infected patients in the dexamethasone study the relative 
risk of death was, 2.91, 95% Cl [2.14 - 3.96], p<O.OOl) in comparison to HIV-
uninfected individuals. However, none of the patients in this trial received ART 
(Thwaites, Duc Bang et al. 2005). A subsequent trial of immediate versus delayed (8 
weeks) ART in antiretroviral naive TBM patients showed no overall impact on 
mortality in HIVffBM patients. However, the median CD4 count in these patients 
was extremely low, which may have contributed to the findings of the trial. This study 
is discussed further in chapter 4. The WHO recommends treating extra-pulmonary TB 
with the same regimens as pulmonary TB (2HRZS/4HR), except for TBM. As TBM 
is more severe form of extra-pubnonary TB, some experts recommend a prolonged 
treatment from 9-12 months. WHO also suggests that EMB should be replaced by 
STR in TBM patients (WHO 2009). British Infection Society guidelines recommend 
2HRZEllOHR regimen and adjunctive corticosteroids (either dexamethasone or 
prednisolone) should be given to all patients with TBM, regardless of disease severity 
(Thwaites, Fisher et al. 2009). 
1.11 TBM in Vietnam and cbaUenges 
TBM is difficult to diagnose due to a broad differential diagnosis and non-
specific symptoms at the early period of the disease (Donald and Schoeman 2004). At 
the point where the signs of TBM are clear such as neurologic deficits, loss of 
consciousness or convulsions, the disease is already at the severe state, when 
diagnosis starts to take place (Donald and Schoeman 2004). The CSF is paucibacillary 
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in TBM and therefore the diagnosis is rarely confIrmed microbiologically, through 
smear or culture, in most laboratories (Bhigjee, Padayachee et al. 2007). Delays in 
treatment are the strongest predictor of mortality and poor outcome, and therefore 
early diagnosis and instigation of appropriate treatment is paramount (Don aid and 
Schoeman 2004). 
The Hospital for Tropical Diseases (HTD) and Pham Ngoc Thach Hospital for 
Tuberculosis and Lung Diseases (PNT) in Ho Chi Minh City (HCM) treat 
approximately 700 cases of adult TBM each year, due to the referral patterns within 
the Vietnamese health system. The largest RCT of TBM was completed at these two 
hospitals, enrolling 545 adults with TBM. This randomized, double-blinded, placebo-
controlled trial showed that adjunctive dexamethasone treatment was associated with 
a reduced risk of death (relative risk of death, 0.69; 95%CI [0.52 - 0.92]; p=O.OI) 
(Thwaites, Nguyen et al. 2004). As a result of this study, adjunctive dexamethasone 
has been adopted as part of routine care for the treatment of TBM in Vietnam and 
other countries (Thwaites, Fisher et al. 2(09) and incorporated into WHO guidelines. 
The mortaIity rate in mv infected patients in this study was 65%, compared with 
32% in HIV-negative patients. 
Consistent with the literature, results from previous studies at Oxford 
University Clinical Research Unit in Vietnam (OUCRU) show that early diagnosis 
and early treatment have a significant positive impact on the outcome (Thwaites, 
Nguyen et al. 2004). The classical diagnostic methods to confirm a diagnosis for 
TBM are smear microscopy and culture from CSF samples. Smear is a fast and 
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specific way to detect mycobacteria in clinical samples; however, the sensitivity of 
the test is low, approximately 50% for pulmonary TB and less than 10% for TBM in 
many settings. Culture methods can improve sensitivity but have a long turn-around 
time. Conventional solid culture on Lowenstein-lensen (U) media takes 20-28 days 
to become positive (Coban, Birinci et al. 2004). Commercial automated culture, such 
as Bactec system (Beckton Dickinson, USA), has a median time to positive of 
approximately 13 days (Ha, Lan et al. 2009). However, these turn-around times are 
too long to be clinically useful for the diagnosis of TBM, and at best are used to 
confIrm a diagnosis and provide isolates for drug susceptibility testing. An accurate, 
quicker method to identify TBM is urgently needed. Attempts to rapidly diagnose 
TBM through nucleic acid amplification tests (NAAT) or serology have met limited 
success (Pai, Flores et al. 2003; Deshpande, Kashyap et al. 2007) because of the low 
sensitivity or specificity, respectively. of the tests. Other tests such as adenosine 
dearninase assay or bromide partition test have been proposed but are not specific for 
the differential diagnosis of bacterial meningitis (Girgis, Farid et al. 1990; Tuon, 
Higashino et al. 201 0). 
Clinical features are the principal method for TBM diagnosis in the absence of 
microbiological confIrmation. Common clinical signs are headache, fever and 
meningismus with a prodromal stage exceeding 7 days. Typically, the CSF protein is 
raised, blood:CSF glucose ratio is low with a lymphocyctic predominance (Bhigjee, 
Padayachee et al. 2007). However. atypical CSF findings are common and a high 
neutrophil count has often been reported in HlV-associated TBM (Bhigjee, 
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Padayachee et al. 2(07). Neuroimaging, contrast computerized tomography (CT) and 
magnetic resonance imaging (MRI) can be informative with classic indicators of 
TBM including enlarged ventricles, hydrocephalus and basal enhancement, although 
features are non-specific (Murthy 2010). CXR for concurrent pulmonary TB may also 
inform the diagnosis of TBM, although in areas highly endemic for TB, should be 
interpreted with caution. 
1.12 TB diagnosis 
Early detection and effective treatment of TB reduces morbidity and mortality 
and interrupts chains of transmission. NTPs detect TB cases using sputum smear 
microscopy, which has a poor sensitivity for active TB, particularly in patients with 
mv co-infection. Sputum-smear negative cases may be diagnosed based on clinical 
presentation, CXR findings and disease history. Diagnosis by clinical factors and 
CXR can be SUbjective and depends on the skill and experience of the treating 
clinician. There is an internationally recognized need for improved, simple diagnostic 
tests for TB which can be applied at the point of care in resource limited, high burden 
settings. 
A wide range of techniques have been applied in the development of 
diagnostic tests for TB. However, no test has yet achieved sensitivity and specificity 
approaching 100%. The Foundation for Innovative New Diagnostics (FIND) 
(website:http://www.finddiagnostics.orglprogramsltb/tb diagnostics.html) has 
developed a systematic approach to evaluation of novel diagnostic tests for TB. 
aiming to generate an evidence base for adoption, implementation and scale up of 
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these tests in resource-limited settings. FIND collaborative studies to date have 
resulted in a series of recommendations by WHO Strategic and Technical Advisory 
Group (STAG) for TB in the last decade (Pai, Ramsayet al. 2(08). TB diagnostic 
tests are classified into direct and indirect tests according to the method of detection. 
TBM is difficult to diagnose and remains a serious health problem in the 
developing world and regions of high TB prevalence. The number of the bacteria 
found in CSF of TBM patients are lower than in sputum of pulmonary TB patients 
(Radhakrishnan and Mathai 1993), thus more difficult to identify for diagnosis. 
Difficulty in early diagnosis of TBM is one of the major barriers to improving 
outcomes. Many tests have been proposed to detect TBM because the delay in 
diagnosis is strongly associated with mortaIity however none have proven effective 
(Hosoglu, Geyik et al. 2(02). 
1.12.1 Direct tests 
Direct tests for TB have lower sensitivity than indirect tests but the specificity 
is high (approaching 100%) because they detect the M.tuberculosis bacteria or acid 
fast bacilli directly. 
Sputum smear microscopy is the most widely applied technique, usually ZN-
staining method (Heifets and Good 1994). The principle of the method is based on the 
acid-fast nature of the lipid-rich cell wall of the bacilli. This property allows an acid 
wash step to remove carbo I fuschin dye stain from other bacilli while leaving the 
mycobacteria stained red. A blue methylene blue counter-stain is usually used to 
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highlight the red organisms against a blue background. ZN-staining is a low-cost 
method, approximately $1 USD per test, and can be applied in most settings as it 
requires little in the way of capital equipment. The specificity is extremely high 
however the sensitivity of this technique varies depending on the disease stage, the 
skill of the technicians, the processing method for sputum (most importantly whether 
direct or homogenous smear is applied) and the time available for examining each 
slide (Pai, Ramsayet al. 2008). Recently much effort has focused on optimizing the 
sensitivity of smear microscopy through application of alternative sputum processing 
methods such as bleach decontamination (Merid, Yassin et al. 2009; Cattamanchi, 
Davis et al. 2010), application of fluorescence microscopy and implementation of 
qUality control systems such as lot quality assurance sampling (LQAS) or external 
qUality assessment (EQA) of smear microscopy in NTPs (Selvalrumar, Murthy et al. 
2(05). Sensitivity of smear microscopy is generally reported to be around 50% of all 
clinical TB cases, however, in patients who are HIV positive, smear microscopy has 
lower sensitivity and the global HIV pandemic has therefore increased the need for a 
more sensitive TB diagnostic test which can be applied in resource-poor settings. 
Bacterial culture on U or using commercial liquid culture systems such as 
MGIT is the gold standard method for bacterial confirmation because of its high 
sensitivity and specificity (Cruciani, Scarparo et al. 2004). These methods are more 
expensive and ideally require an appropriate biological containment laboratory to 
perform, to prevent laboratory acquired nosocomial infection. In Europe and the US, 
M.tuberculosis is cultured at biohazard level 3 containment (Drobniewski, Hoffner et 
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al. 2(06). However, in most resource-poor settings, M.tuberculosis culture is 
performed in laboratories of biosafety level 2 or lower. Worldwide, there is a lack of 
laboratories able to perform TB culture for diagnosis and the Global Laboratory 
Initiate (GLI, website: http://www.stoptb.org!wg!gljb has recently been developed to 
address this issue, Microscopic Observation Drug Susceptibility (MODS) is a new 
cultural method which had been developed in Peru (Moore, Evans et al. 2(06) 
(website: http://www.modsperu.org!) and evaluated in many places, including PNT 
hospital in southern Vietnam (Ha, Lan et al. 2(09). It shows a similar specificity to 
the conventional culture methods but the result returning time is shorter (around 7 
days). 
Many nucleic acid amplification tests (NAA T) have been developed to 
diagnose TB as well as to rapidly detect drug resistance (Pai, Flores et al. 2003). 
These PCR-based tests detect M.tuberculosis by amplifying target pathogen-specific 
DNA sequences in the clinical sample. NAAT have several advantages in 
performance such as reducing risk of infection, reduction in turn-around times and 
increased sensitivity. However, NAAT can suffer from contamination problem; 
reducing specificity and PCR based tests for mycobacteria have suffered from sub-
optimal sensitivities compared to tests for other bacteria, probably due to the 
difficulties of obtaining high DNA yields from mycobacteria with simple sample-
processing protocols. The sensitivity and the specificity of commercial PCR-based 
tests for TB are normally low for routine diagnostic tests (Greeo, Girardi et al. 2(06). 
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The commercial line probe assays (LPA) are recommended by WHO for rapid 
screening of TB. MDR TB and XDR TB suspects (Albert. Bwanga et al. 2010). 
However. these tests are only applicable on smear-positive sputum and therefore 
cannot replace conventional testing. The commercial MTBDRplus test (Hain 
Lifesciences, Germany) is a LPA endorsed by WHO as a rapid test for TB and the 
mutations which confer INH and RIF resistance. MTBDRplus amplifies target genes 
associated with drug resistance (IwtG. inhA and rpoB) and uses reverse hybridization 
to specific probes to identify the genes amplicons and the relevant mutations. This test 
has an advantage of detecting both RIF and INH resistant isolates directly from smear 
positive samples. The sensitivity and specificity in detecting RIF resistance were 
98.1 % and 97.8%, respectively; and for INH 90.2% sensitivity and 100% specificity 
(Hillemann, Rusch-Gerdes et al. 2007). 
In 2010, a novel commercial diagnostic test, the Xpert MTBIRIF for use in the 
GeneXpert system (Cepheid company, US) was reported to show promising results in 
identifying M.tuberculosis in clinical samples (Helb, Jones et al. 2010). The 
advantage of Xpert MTBIRIF is to minimize the sample preparation process by 
automating the concentration, purification, extraction, amplification and detection of 
M.tuberculosis DNA directly from clinical samples within a closed cartridge based 
system. Pre-processing of the sample is limited to addition of a sample liquefaction 
reagent with intermittent manual shaking at room temperature for 15 minutes. The 
real-time PCR performed within the cartridge to amplify the rpoB gene. which 
sequence is unique for M.tuberculosis. The test uses probes to detect mutations 
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conferring RIF resistance and reports the results on screen. An evaluation study in 
South Africa showed that the sensitivity and the specificity of MTBIRIF test were 
90.2-99.8% and 98.1-99.2%. respectively. compared with M.tuberculosis culture in 
clinical sputum samples (Boehme. Nabeta et al. 2010). 
1.12.2 Indirect tests 
Indirect tests normally have higher sensitivity but lower specificity. They are 
generally used in TB screening or to detect TB forms that are difficult to confirm with 
direct tests. such as latent TB or extra-pulmonary TB. 
Tuberculin skin test (TST) 
The Tuberculin skin test is a traditional test which was developed in the 1920s 
(Tisdall and Brown 1926). The test is based on the immune response to mycobacterial 
proteins after infection. Purified protein derivative (PPD). a precipitate of non-specific 
polypeptides obtained from M.tuberculosis cultures. is injected intradermally in both 
the Mantoux and Heaf tuberculin skin tests. The individual returns to the clinic 2-3 
days after injection to check for a delayed-type hypersensitivity reaction visible as 
raised rash at the site of injection. The circumference of the rash is used to indicate 
whether that person has been infected with M.tuberculosis. Positive TST results do 
not generally discriminate well between old infection. current active infection. latent 
TB or BCG vaccination. although different cut-off measures are generally used in 
areas with and without universal BCG vaccination and to discriminate between latent 
or active TB(Ewer. Deeks et al. 2003). Specificity of the test is higher in places with 
low TB prevalence and low in high burden areas. The test is also confounded by 
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cross-reaction with atypical mycobacteria and specificity is lower in areas where 
exposure to mycobacteria is high, such as tropical settings (Farhat, Greenaway et al. 
2(06). The TST is cheap and simple to perform. The test is still widely used in most 
places, and is used in TB prevalence surveys. 
Serodiagnostics 
Enzyme linked immuno-sorbent assay (ELISA) can be used to detect specific 
anti-mycobacterial antibodies or antigens in blood, urine or other clinical samples. A 
recent WHO evaluation of 19 commercial serodiagnostic tests for TB concluded that 
none reached a sensitivity or specificity which justified their use for TB diagnosis 
(WHO 2(08) and has led to an unprecedented negative statement by WHO on a 
diagnostic test recommending against their use (WHO 2011). Use of the tests is 
especially widespread in the private sector in India, despite there being no diagnostic 
value to the tests. Efforts are ongoing to find improved biomarkers for use in 
serodiagnostic tests since such a test could potentially be used as a low-cost, simple 
and rapid near-patient test. However, despite large studies, no strong leading 
candidates have emerged for development to date. 
Interferon-gamma release assays (IGRA) 
In vitro interferon-gamma release assays (including QuantiFERON-GOLD 
(Cellestis Limited, Australia) and T-SPOT (Oxford Imrnunotec Limited, OK» 
measure the IFN-gamma released from whole blood or isolated white blood cells after 
incubating them with M.tuberculosis specific antigens. These tests use M.tuberculosis 
specific antigens such as ESA T -6 and CFP-IO and are therefore more specific than 
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TST with the ability to discriminate between TB infection and prior BCG vaccination. 
However, IGRA have limited value in resource-limited settings and WHO has 
recommended against their application in endemic settings (WHO 2011). 
1.12.3 Other TB diagnosis tools 
CXR is a widely-applied tool for TB diagnosis and provides vital information 
for TB diagnosis, alongside microbiology and clinical history. However, CXR 
changes can be non-specific and interpretation is highly dependent on the skill and 
experience of the radiologist or clinician reading the CXR. The CXR is useful to 
assess the extent of disease and response to treatment. 
Cranial computed tomography (CT) and magnetic resonance imaging (MRI) 
scan are also applied for TB diagnosis. CT imaging of the lungs can provide a more 
detailed picture of lesions. MRI and CT scanning can assist the diagnosis of 
extrapulmonary TB and radiological features can often assist the differential diagnosis 
of TBM. The cost of MRI imaging limits its application in resource-limited settings. 
Algorithms can assist in the diagnosis of TB in settings with limited laboratory 
facilities. Several have been developed for application to paucibacillary forms of TB 
which are hard to confirm by smear rnicroscopy, such as pediatric TB, HIV-associated 
TB and TBM. A simple clinical algorithm for TBM evaluates factors including 
patient age, blood white cell count, history of illness, CSF white cell count, CSF 
neutrophil percentage and showed high sensitivity (99%) but limited specificity (68%) 
in prospective evaluation (Torok, Nghia et al. 2(07). 
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1.13 The WHO DOTS treatment strategy for TB 
DOTS is the central WHO strategy recommended to combat TB (WHO 2009). 
Under DOTS, the average global treatment success rate was 83% among the new 
smear-positive TB in 2003 (WHO 2006) and increased to 85% in 2006 (WHO 2009). 
By contrast, if untreated, the mortality rate of active pulmonary TB cases is more than 
60%, ranging from 83% in HIV-positive smear-positive to 20% in mY-negative 
smear-negative cases (WHO 2009); showing the crucial role of DOTS in TB control. 
The DOTS strategy includes 5 main strands or 'pillars': 
1) Political commitment from the government with increased and 
sustained financing. 
2) Case detection by smear microscopy and quality-assured bacteriology. 
3) Standardised treatment with direct observation by a healthcare worker 
or community health worker for at least the first two months (the 
intensive treatment phase). 
4) A sustainable, uninterrupted and effective drug supply and 
management system. 
5) A standardised monitoring and evaluation system with recording and 
reporting to allow assessment of treatment outcomes. 
In the DOTS strategy, WHO has defined targets for detection of new sputum 
smear positive TB cases and treatment cure rates of at least 70% and 85%, 
respectively. The target was defined base on the ZN smear, the most widely used 
diagnostic test for TB, which needs at least 10,000 bacilli per rnilliliter in sputum as a 
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threshold of detection (Hobby, Holman et al. 1973). Further, estimated case detection 
is based on often inaccurate estimates of total smear positive cases. HIVrrB co-
infection and MDR-TB have also been identified as challenges for TB control. 
Interventions to reduce HIVffB co-infection and development of MDR-TB treatment 
programmes have been implemented by collaboration and management among NTPs 
and international organizations but scale-up is challenging. An effective TB control 
programme should have specific strategies to address vulnerable populations such as 
prisoners, refugees and homeless people (WHO 2006). 
In addition to increasing coverage by the DOTS strategy research on 
development of new diagnostics, drugs and vaccines has been intensified. Many 
studies are developing new diagnostics or drugs in the attempt to control TB more 
effectively and move towards eventual eradication (Hillemann, Rusch-Gerdes et al. 
2007; Helb, Jones et al. 2010; Sarkar and Suresh 20ll). The BCG vaccine has very 
poor effectiveness in adults, ranging from 0%-80% with adults in high TB burden 
countries receiving the lowest protection level from BCG, possibly due to prior 
exposure to atypical mycobacteria (Andersen and Doherty 2005), and a novel vaccine 
with enhanced effectiveness in developed settings is urgently required. A WHO report 
in 2009 showed that the global pulmonary TB case detection rate was estimated to be 
63% in 2007 and the treatment success rate apparently reached the target 85% in 
2006. Even though the WHO targets for detection and treatment were not reached by 
2005, the overall prevalence of TB worldwide started decreasing slightly from 13.9 
million cases in 2006 to 13.7 million cases in 2007 (WHO 2009). The TB incidence 
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rate trends vary in different WHO geographic regions. For example in Central Europe, 
and Latin America rates are decreasing but increasing in Eastern Europe, Eastern 
Mediterranean and Africa (WHO 2(09), suggesting that further sustained, intensified 
efforts are required to have substantial impacts on TB globally. 
1.14 Chemotherapy for TB treatment 
DOTS is the standard short course therapy for TB treatment with the 
combination of four to five drugs: STR (or S), INH (or H), RIF (or R), EMB (or E), 
PZA (or Z). The standard regimen is a 6-month regimen in which patients are treated 
with INH, RIF, EBM and PZA daily for two months, followed by four months of INH 
and RIF given daily or intermittently (2HREZl4HR). An alternative eight-month 
regimen (2SHRZI6HE) was the standard regimen in use in Vietnam (Quy, Cobelens 
et al. 2006) until 2010 when a phased transition to the 6 month regimen was 
introduced, following a revision of WHO recommendations to recommend phase-out 
of the 8-month regimen (WHO 2009). The six-month regimen was demonstrated to 
have lower failure and relapse rates in a clinical trial conducted by the IUATLD and 
referred to as • study A' (Jindani, Nunn et al. 2004). 
The eight-month regimen consists of an intensive phase of two months using 
four drugs SHRZ and a continuation phase of six months using two drugs Hand E 
given daily (2SHRZI6HE) (Quy, Cobelens et al. 2006). A minimum of three drugs to 
which the bacilli is susceptible is essential to treat TB due to spontaneous drug 
resistance mutations. Four drugs are used in NTP treatment programmes to maintain 
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efficacy if undetected resistance to one of the agents is present due to the lack of 
capacity for programmatic drug susceptibility test (DST). 
The 6-month regimen is also recommended to treat extra-pulmonary TB, 
except that of the central nervous system, bone or joint for which a longer duration of 
therapy is recommended (WHO 2009). Cases with meningial involvement are 
recommended to receive 9-12 months of chemotherapy but the evidence base for this 
recommendation is weak and principally due to the severe consequences of a relapse 
in the case ofTBM (Thwaites, Fisher et al. 2009). 
According to the National TB treatment guidelines of Vietnam (NTP-Vietnam 
2(08), new TB patients receive 2SHRZI6HE, which is being phased out in favour of 
2HRZF14HR. Retreatment patients receive the category 11 regimen: 
2SHREZllHREZl5R3H3E3. TBM cases receive the same drugs as pulmonary TB with 
a longer duration and EMB is replaced by STR. mv infected TB patients are treated 
with 6 months regimen of pulmonary TB, and receive EMB in place of STR with 
daily dosing recommended during continuous phase (WHO 2009). TB treatment 
regimens in children are also different with 2HRZ14HR for smear negative, 
2SHRZI4HR for smear positive and 2SHREZll HREZ15HRE for retreatment patients. 
1.14.1 First line drugs 
STR was the first effective anti-tuberculous drug to be administered in the mid 
1940s. STR is an aminocyclitol glycoside antibiotic which inhibits the translation 
process of protein synthesis by targeting the M.tuberculosis ribosome. The drug 
targets a small subunit of the ribosome which is fonned by the RpsL protein and 16S 
34 
sRNA (rrs gene). However, the bactericidal activity of STR is not very potent. Within 
a few months of its use, resistance was reported to this drug and the failure of 
monotherapy was recognized (McDermott 1948). 
INH (isonicotinic acid hydrazide) was ftrst synthesized in 1912 by Meyer and 
Malley during a doctoral thesis. It was subsequently forgotten for nearly 40 years. The 
anti-TB properties of INH were discovered in 1951 by pharmaceutical companies 
(Mitchell 1955). After the ftrst clinical trial in 1951, the enormous potential of INH 
with high potency against M.tuberculosis and M.bovis was reported to the public in 
1952 (Mitchell 1955; Mitchison 2005). Despite the very simple structure, INH is a 
very powerful anti-TB drug with a very complex mechanism of action which is only 
active against mycobacteria. As a prodrug INH needs to be activated by the bacterial 
catalase-peroxidase enzyme. The activated reactive components attack mUltiple sites 
and pathways in the cell. Well-known targets of activated INH are enzymes involved 
in cell wall mycolic acid synthesis (InhA, KasA). 
With the discovery of para-aminosalicylic acid (PAS) in 1946 and the 
rediscovery of the anti-tuberculous property of INH in 1951 (Youmans, Raleigh et al. 
1947; Dunner, Brown et al. 1949), combination therapy was developed in a series of 
landmark clinical trials and became the standard for TB treatment from the mid 
1950s. 
EMB was discovered in 1961 and showed anti-TB effects in mice (Thomas, 
Baughn et al. 1961). The ocular toxicity of EMB which was evident in the ftrst 
clinical trial, limits the dosage and thus the potency of the drug (Carr and Henkind 
35 
1962). EMB inhibits M.tuberculosis cell wall synthesis via a different targeted 
pathway from INH, thus cross-resistance between INH and EMB is limited. EMB 
inhibits biosynthesis of arabinogalactan, the major polysaccharide in M.tuberculosis 
cell wall, which has a vital role in growth and replication (Takayama and Kilbum 
1989). For this reason, EMB is only active against the replicating bacilli. 
Despite the ocular toxicity, combination therapy containing EMB showed 
better tolerance and efficacy than combinations containing STR (Bobrowitz 1971). 
STR has the further drawback of requiring administration by injection and therefore 
EMB now widely replaces STR in ftrst-line regimens, especially for HIvrrB patients, 
in whom injection carries higher risks (WHO 2009). 
RIF is a semi-synthenthic drug which was produced in 1959 and was 
introduced to TB treatment in 1967(Baronti and Lukinovich 1968). It showed very 
strong bacterial clearance effects in TB patients who received TB combination 
chemotherapy containing RIF. The antituberculous activities of RIF are stronger than 
INH and serum levels are more stable (Canetti, Le Lirzin et al. 1968). RIF has high 
affinity to the beta-subunit of bacterial RNA polymerase, thus inhibits activity of this 
crucial enzyme and prevents RNA transcription. When the RNA polymerase enzyme 
is inhibited, no mRNA is produced and consequently no protein is synthesized and the 
bacterium is killed. 
With the introduction of EMB in 1962 and RIF in 1967, TB treatment was 
shortened to 9 months with a new combination of RIF, INH and STR (Nitti 1972). 
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PZA was fIrst synthesized in 1936 in Germany and was soon being tested as 
an anti-TB candidate in early 1950s due to the analogue structure to nicotinamide 
component. The testing results from animal models and in clinical trial (Cordice, Hill 
et a1. 1953) showed good anti-TB activity of PZA. Similar to nicotinamide and INH, 
PZA is a prodrug which only has antituberculous activities after activation. The 
defInitive target of PZA after activation is still unclear. Antituberculous activity of 
PZA was observed in-vivo but not in-vitro, due to the need for the acidic in-vivo 
environment. Activated PZA may target the cell membrane and dysfunction ion 
exchange membrane channels. This change eventually changes the pH in the cell, thus 
disrupts enzymes activities in M.tuberculosis and kills the cell (Salfinger, Crowle et 
al. 1990). 
When initially used in a combination with INH, PZA gave good sputum 
conversion, however severe hepatotoxicity was observed and thus PZA was 
abandoned as a fIrst line drug for TB treatment and was used only as a second line TB 
drug (Somner and Brace 1962). In the 1980s, with the rediscovery of PZA sterilizing 
activity against dormant M.tuberculosis and the trial of a new multi drug regimen, TB 
chemotherapy was further reduced to 6 months (Steele and Des Prez 1988), 
establishing the standard short course chemotherapy in use today. 
The targets of frrst line anti-TB drugs is described in Figure 1.2 
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ATP Synttanls 
Figure 1.2: First line anti-TB drugs and activities in M.tuberculosis ceH. 
Source: hnp:/Iwww.niaid.gih.gov!topicWbqcu!osi!!IVndergaodinglWhatIsTBIScientificlliustration<IPagey 
fiptIJneJlJusration.aw 
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1.14.2 Second-line drugs 
Second-line drugs are classified by WHO as secondary choices for the 
treatment of TB due to their low bactericidal activity against TB or high toxicity. 
These antituberculous drugs are normally reserved for use in MDR or XDR TB 
patients when the first-line drugs are no longer effective. 
The most important classes of second-line drugs are aminoglycosides 
(amikacin, kanamycin), polypeptides (capreomycin, viomycin, enviomycin) and 
fluoroquinolones (ofloxacin, levofloxacin, gatifloxacin, moxifloxacin). Other second-
line drugs are thioamides (ethionamide, prothionamide), cycloserine and PAS which 
are even less effective and more toxic than the previous group(Sarkar and Suresh 
2011). 
The first fluoroquinolone (nalidixic acid) was discovered in 1960s. However, 
fluoroquinolones (FQN) were not used as an anti-tuberculous agent until after the 
synthesis of second generation of FQNs, ofloxacin and ciprofloxacin in the 1980s 
(Tsukamura, Nakamura et al. 1985; Truffot-Pemot, li et al. 1991). Ciprofloxacin is no 
longer recommended for the treatment of TB due to its weak bactericidal activity and 
potential for generating resistance to the more effective FQNs. The later generation 
FQNs levofloxacin, gatifloxacin and moxifloxacin show very high antituberculous 
activities with mild adverse effects, similar to first line drugs. Despite this high 
potency in TB treatment, FQNs are currently used as second line drugs. Treatment 
trials are underway to establish the potential role of these compounds in first-line 
39 
treatment (Nuennberger, Yoshimatsu et a1. 2(04), with the hope that a 4-month FQN-
containing standard regimen can replace the current 6-month regimen. 
FQNs have been used as broad spectrum antibiotics for both gram-positive 
and gram-negative bacterial infection for a long time. They are often administered as 
a broad spectrum antibiotic in patients with cough to aid differential diagnosis. This 
wide use of FQN in general bacterial infection leads to the accumulation of many 
FQN resistant bacteria, include FQN resistant M.tuberculosis. A study in lohns 
Hopkins showed a rapid development of FQN resistance in M.tuberculosis in an HlV 
patient after 13 days of mono-FQN treatment for an urinary tract infection (Ginsburg, 
Woolwine et al. 2(03). 
1.15 Isoniazid preventive therapy (IPT) 
HlV infection increases the risk of TB development approximately 10 fold 
(WHO 2004). Treatment of latent TB in HlV-infected individuals can reduce TB 
incidence and also help to prevent onward transmission. 
Prophylactic treatment options for HlV infected patients or latent TB include 
INH daily (6H, 9H) or twice weekly (6H2, 9H2) for 6-9 months. Because of the long 
duration of IPT, adherence can be a problem. To shorten the treatment period, some 
novel combinations have been tested, such as a 2-month regimen of daily RIF and 
PZA. However, these alternatives increased the fatal risk of severe hepatotoxicity in 
some cases (Kaplan, Benson et al. 2(09). When INH is given intermittently (twice a 
week) it should be administered only as DOTS. 
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Treatment with INH for 6 months reduces the overall risk of TB by 33% in 
individuals with HIV infection (WHO 2(09). The effect is much greater when using 
with other combinations such as co-trimoxazole preventive therapy for opportunistic 
infection (Thuy, Shah et al. 2007) or ART. IPT is generally safe and well-tolerated 
but it is important to rule-out active TB before commencement of IPT, due to the risk 
of INH resistance if IPf is given to a patient with active TB disease. It can be difficult 
to rule-out active TB in HIV-infected individuals due to the low sensitivity of smear 
rnicroscopy in these patients. A recent multi-centre study in Vietnam, Thailand and 
Cambodia developed an algorithm which can rule-out TB with 93% sensitivity and 
36% specificity in HIV-infected patients and is therefore suitable as a screening tool 
prior to implementation of IPT while waiting for culture confirmation, in these 
settings (Cain, McCarthy et al. 2010). The generalizability of this algorithm to other 
settings remains to be evaluated. 
1.16 Drug resistance 
Drug resistant TB is a global issue and the prevalence of drug resistance is 
increasing all over the world (WHO 2008). Soon after the introduction of new drugs, 
resistant isolates were identified in most early clinical trials using mono or dual 
therapy (McDermott 1948; Dunner, Brown et al. 1949). In M.tuberculosis, drug 
resistance is generated by spontaneously occurring mutations at a rate of 11106_11108 
bacilli, depending on the drug. It was rapidly established that triple therapy with high 
adherence is required to prevent the emergence of resistance. The DOTS programme 
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was developed by WHO specifically to manage TB treatment through NTPs (WHO 
2(06). In fact, drug resistance usually arises as a result of non-adherence to 
standardized TB treatment, incomplete or inappropriate treatment (Amuha, 
Kutyabami et al. 2(09), or substance abuse (Matthys. Rigouts et al. 2009). This 
phenomenon happens more frequently in the private sectors in many settings where 
treatment is often non-standardised and is not controlled by the NTP (Quy, Lonnroth 
et a!. 2003; Choi, Lim et al. 2007). The use of fixed-dose combination (FDC) tablets 
has recently been advocated to reduce the potential for partial drug adherence to 
multi-drug regimens. In a multi-centre trial, known as 'study C', FDC tablets were 
shown to be effective (Lienhardt, Cook et al. 2011; Monedero and Carninero 2011) 
and are now advocated for use by NTPs by IUATLD, WHO and others. 
MDR TB is caused by M.tuberculosis which is resistant to at least the two key 
first-line drugs, INH and RIF. MDR TB has been a global concern for many years 
because treatment is more complex, toxic, expensive and outcomes worse than in 
drug-sensitive TB. Treatment for MDR TB requires administration of more toxic and 
less effective drugs that are given for at least three times longer than standardised 
regimens (Pablos-Mendez, Gowda et al. 2(02). The success rate in MDR treatment is 
relatively low compared to treatment for drug-sensitive TB; MDR treatment success 
is highly variable, with reports as low as 37% (Ohkado, Aguiman et a!. 2006; 
Johnston, Shahidi et al. 2009; Matthys, Rigouts et al. 2(09). A recent meta-analysis 
reported a pooled treatment success of 62% of 31 treatment programs from 21 
countries (Johnston, Shahidi et al. 2(09); even though some studies impressively 
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showed similar success rate of MDR with susceptible TB (72-86%) (Ward, Marciniuk 
et al. 2005; Karagoz, Yazicioglu Mocin et al. 2009). The cost for MDR treatment is, 
however, extremely high in comparison with a treatment regimen for susceptible TB 
($8,700-$160,000 comparing to $350; 25-450 times) (Resch, SaIomon et al. 2006). 
There has never been a RCT for MDR TB and these studies are crucial to allow 
treatment scale-up and reverse transmission trends. A recent study from Bangladesh 
reported a novel MDR treatment regimen developed in stepwise modification of the 
regimen in serial small cohorts (Van Deun, Maug et al. 2010). The final regimen, 
often referred to as 'the Bangladesh regimen' is now being trialed against the current 
WHO recommended regimen of 18 months in a multi-country trial funded by the 
MRC and Treat-TB. This trial, "Standardised treatment regimen" of anti-TB drugs for 
patients with MDR TB (STREAM trial - Registration code: ISRCTN78372190) is 
expected to commence recruitment in Vietnam in 2012. 
MDR TB prevalence is increasing in many countries; and recently the 
emergence of extensively drug resistant TB (XDR TB) threatens the attempt to 
control TB worldwide (Gandhi, Moll et al. 2006; Velayati, Masjedi et al. 2(09). XDR 
TB is MDR TB which has further resistance to a FQN and one of the injectable 
second-line drugs (amikacin, capreomycin, or kanamycin) (WHO 2(07). Although 
XDR TB is curable in HIV negative patients (Mitnick, Shin et al. 2008), the success 
rate is very low (48%) (Keshavjee, Gelmanova et al. 2(08) that it is often described as 
virtually untreatable (2006; Chauhan 2(07). 
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Data from WHO showed that there were around 30,000 notified MDR cases in 
2007, whereas the number of estimated MDR cases was approximately 500,000 
globally. The data suggested that at least 100,000 MDR TB patients (including 10,000 
patients with XDR TB) worldwide need to be on specific MDR treatment to combat 
the development of drug resistance and reverse upward trends in MDR prevalence 
(WHO 2009). This means TB detection rates should be increased (more than current 
63% (WHO 2(09) alongside capacity building for MDR detection. With the attempt 
to curb the increasing rate of MDR TB the principal 2010 WHO targets for MDR TB 
have been set: (i) to offer diagnostic DST to all previously treated and chronic TB 
cases as well as to 90% of new TB cases with a high risk of having MDR TB (for 
example, contacts of MDR TB cases and those for whom treatment is failing after 
three months); and (ii) to enroll all those in whom MDR TB is diagnosed in Green 
Light Committee (GLC) (WHO 2009) approved or equivalent treatment programs. 
GLC is a subgroup of the MDR TB Working Group of the Stop TB Partnership to 
promote access to MDR TB treatment. It helps reduce the significant costs of second 
line drugs for government programs by bulk-purchase agreements. Despite the 
progress that has been made in some countries, the number of MDR TB patients 
notified in 2007 and the number of MDR TB patients to be enrolled on treatment in 
2008 and 2009 fall far behind the expectations of the Global Plan in that only a third 
of notified MDR TB were enrolled on the treatment (WHO 2(09). 
44 
1.17 Anti-tuberculous drug resistance in Vietnam 
The Vietnamese WHO national drug resistance survey in 1996 showed that 
the prevalence of MDR TB in Vietnam was 2.3% in new cases (WHO 2006). 
According to the International Organization for Migration (IOM) in Vietnam, 
reviewing data from 1989 to 2000, the prevalence of MDR TB was around 4.5% 
(Ward, Marciniuk et al. 2005). This high prevalence of MDR in the latter study might 
be caused by bias in the selected population, whereas the national drug resistance 
survey sampled NTP patients throughout all regions of Vietnam, the IOM patients are 
more likely to be urban, where drug resistance rates are higher, and wealthy enough to 
afford private treatment. 
The most recent WHO survey showed an estimated prevalence of MDR TB in 
Vietnam of 2.7% in 2007 (WHO 2(09). Despite some inconsistencies in these data, 
the indication is that MDR TB prevalence in Vietnam is increasing, along with other 
forms of drug resistance. The fourth Vietnamese National Drug resistance survey was 
conducted in 2011, but has not finish yet. 
INH, which is widely used globally, plays a key role in TB prevention and 
treatment. Resistance to INH is normally the first step in the development of MDR 
TB since mono-resistance to RIP is rare. In addition, Vietnam has a high burden of 
primary drug resistance with a prevalence of resistance to any TB drug of 32% in new 
patients in 1996 (WHO 2004). This prevalence increased to 36.6% by 2000. In a 
sample collection from pulmonary TB cases in HeM city from 1995 to 2000, the 
prevalence of INH resistance was 25 % among primary TB patients (one of the highest 
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rates of first line drug resistance in the world) (Quy, Buu et al. 2(06). In previously 
treated patients, the prevalence of resistance to any drug and INH was 65.8% and 
54.5%, respectively (Quy, Buu et al. 2(06). It is not known whether the high rate of 
primary INH resistance in this country would increase treatment failure, but data from 
other settings suggest it is a contributing factor (Faustini, Hall et al. 2005; Quy, 
Cobelens et al. 2006; Lew, Pai et al. 2008; Menon, Lodha et al. 2011). A better 
understanding of the resistance mechanisms to INH and their impact on clinical 
treatment outcomes is essential to combat the development of drug-resistant strains. 
Figure 1.3: WHO mapping countries with XDR cases in 2010 
Recently, Vietnam has reported the detection of XDR to WHO and is now one 
of 58 countries with more than one cases of XDR TB were identified (Figure 1.3) 
(WHO 2010). The exact number of XDR TB cases in Vietnam is still unknown; due 
46 
o 
.. 
~ 
.-.. 
to lack of surveillance; yet the burden of untreated MDR TB in this population 
implies that XDR number might be significant and more research is urgently required 
to determine the extent of XDR TB in Vietnam. 
1.18 Drug resistance mechanism (RIF and INB) 
Drug resistance in M.tuberculosis is caused by single-step acquisition of single 
nucleotide polymorphisms in genomic DNA. M.tuberculosis does not carry plasmids, 
and so does not acquire resistance by lateral transfer. The role of efflux pump 
mechanisms is not clear but is likely to contribute to resistance to some drug classes 
(da Silva, Von Groll et al. 2011; Rodrigues, Ainsa et al. 2011; Balganesh, Dinesh et 
al. 2012). Compensatory mutations can reduce the fitness costs of drug resistance 
mutations (Comas, Borrell et al. 2011). Understanding the drug resistant mechanism 
is important not only for the development of rapid diagnostic tests but also to 
understand cross-resistance and find ways to reduce or stop drug resistance 
development. Moreover, gaining knowledge about the protein structure, the drug 
target site and finding a new target are the fundamental factors to design new drugs, 
potentially open a new era of anti-tuberculous drugs. 
1.18.1 RIF resistance mechanism 
RIF is one of the most important agents used to treat TB. Resistance to this 
drug arises due to mutations in the beta-subunit of DNA-dependent RNA polymerase 
encoded by the rpoB gene. The emergence of mutations associated with RIF 
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resistance follows a single-step mutation that occurs spontaneously at the frequency 
of 11109 which can lead to high level of RIF resistance (Lee, Cho et al. 1998). Single-
base substitutions, insertions and deletions have been documented worldwide in a 
region of 81 bp on rpoB gene in which 96% of all these mutations can be found and 
has been termed the rifampicin-resistance determining region (RRDR) (GiIIespie 
2(02). 
Worldwide, the three most prevalent single-mutations were observed in three 
codons: 531, 526 and 516 (Nikolayevsky, Brown et al. 2004; Sajduda, Brzostek et al. 
2004; Hillemann, Rusch-Gerdes et al. 2007). A previous study on RIF resistant 
isolates in Vietnam also showed a similar distribution of mutations in rpoB with the 
three hot spot codons 531 (43%),526 (31 %) and 516 (15%) (Caws, Duy et al. 2006). 
Understanding the frequency and distribution of these mutations helps 
researchers develop accurate and rapid tests for detecting RIF resistant M.tuberculosis 
isolates which is very helpful in clinical diagnosis. Until now, there are many reports 
about new mutations in the rpoB gene; however, most of the RIF resistance mutations 
are located in the 8 I-bp RRDR region which implies that the development of rapid 
tests should focus mainly on the RRDR. However, since the frequency and 
distributions of the mutations have been shown to vary geographically, rapid tests 
should be evaluated in the location where they will be applied. 
48 
1.18.2 INH resistance mechanism 
Although INH has been used since 1952 and the first clinical INH-resistant 
isolates were reported in the early 1970s (Lancet_report 1973), its mechanism of 
action and the development of resistance to this drug are still not fully understood. 
There are at least four genes that are known to contribute to the resistance to 
this drug (Hazbon, Brimacombe et al. 2006), of which mutations at katG and inhA 
have been well investigated confirmed to be associated with INH resistance (Zhang 
and Telenti 2000). Mutations of katG, normally at loci 315, or deletion of the whole 
gene (which is rare), confer resistance to INH at high MIC, whereas mutation in the 
inhA promoter confers an intermediate level of resistance (Lavender, Globan et al. 
2005). 
A previous study from Vietnam reported a very high prevalence of mutations 
at ktltG315 (79%) (Caws, Duy et al. 2006). This dominant genotype in INH resistance 
population may suggest that katG315 mutation has a low fitness cost as compared 
with other INH resistance mutations. 
INH is a prodrug which requires conversion into active forms by the bacterial 
catalase-peroxidase enzyme encoded by ktltG gene. After being activated, the drug 
agents target multiple sites and pathways in the cell. One of the target proteins of this 
drug is NADH-dependent enoyl ACP reductase, an enzyme encoded by inhA (Zhang 
and Telenti 2000). Thus, mutations at these genes consequently confer resistance to 
INH. 
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1.18.2.1 katG 
Catalase-peroxidase, the enzyme encoded by the kalG gene, has a central role 
in the activation of the pro-drug INH; therefore mutations in the katG gene region 
encoding the active site can confer resistance to INH. These mutations can be: 
deletions (of the whole gene or several codons), insertions or single-base 
substitutions. A study using site-directed mutagenesis (Rouse, DeVito et al. 1996) 
showed that the Arginine to Leucine substitution reported in some isolates at residue 
463 is a phylogenetic mutation and has little effect on either enzymatic activity or 
resistance to INH, whereas substitution of Threonine for Serine at position 315 does 
confer resistance and is the most prevalent genotype among clinical isolates of INH 
resistant M.tuberculosis. 
Other rare katG mutations have been reported at residues 270, 275, 315, 321, 
3S1, 138, and 148 may play a direct role in eliminating enzymatic activity, while 
others such as RI04L or HIOSQ may act primarily by inducing protein conformation 
changes which are unstable in the mycobacterial host (Zhang and Telenti 2(00). The 
net effect is still the same: a loss of enzymatic catalase-peroxidase activity which 
subsequently causes resistance to INH because the prodrug remains inactivated or is 
activated at a reduced efficiency. 
Deletion of the whole katG gene results in a high level of INH resistance 
(MIC>50llglml) (Musser 1995). However, further studies showed that deletion of this 
gene is normally observed via in vitro mutation generation experiments (Bergval, 
Schuitema et al. 2009) but is very rarely detected among clinical isolates (Guo, Seet et 
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a1. 2006; Hazbon, Brimacombe et a1. 2006). The reason for this is likely to be a 
reduced fitness of katG deleted bacilli since the catalase-peroxidase activity is 
essential to resist oxidative stress in the macrophage during host infection. 
Many studies have shown that INH resistant isolates which have either 
mutation at katG315 or total deletion of katG acquire high level resistance to INH 
which are 5-101lglml or >50llglml, respectively (van Soolingen, de Haas et a1. 2000). 
1.18.2.2 inhA 
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Figure 1.4: inhA gene orientation in the operon and the promoter 
containing INH resistance mutation. 
Molecular genetic studies have identified a two-gene operon with a contiguous 
Open Reading Frame (ORP) designatedfagGI and inhA, which encodes for mycolic 
acid biosynthesis and is involved in resistance to both INH and ETH (Figure 104). The 
protein product offagGl (or alternatively named mabA) has greatest identity with 3-
oxoacyl-acyl carrier protein (ACP) reductase encoded by fabG of E.coli, 
M.smegmatis, M.avium, an enzyme involved in fatty acid biosynthesis pathway (first 
reduction step). The mycobacterial inhA-encoded enoyl ACP reductase, is an enzyme 
involved in the second reductive step in fatty acid biosynthesis. Protein InhA from 
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M.tuberculosis was purified, crystallized, and shown to be an NADH-dependent 
enoyl-ACP reductase with specificity for long-chain enoylthioester substrates. The 
sum of evidence suggests that FabGl and InhA participate in mycolic acid 
biosynthesis. Mutations in the promoter of this two-gene operon or mutations inside 
inhA confer resistance to INH and ETH at low level (Larsen, Vilcheze et al. 2(02). 
INH is a prodrug which requires activation to generate the active compounds. 
One of the active agents, isonicotinic acyl NADH, has been identified and shown to 
have an extremely high affinity to the InhA protein (Lei, Wei et al. 2(00). This 
provides the strong evidence that InhA is the target of INH, and explains the observed 
association between mutation in the inhA promoter and INH resistance phenotype. 
Mutations in the promoter region (-8 and -15 upstream from start site of 
fabGl translation) in INH resistant strains which carry wild type katG suggests that 
these mutations result in increased InhA protein expression; thereby compensating for 
the InhA damaged protein cause by activated INH. This was proved by cloning and 
transformation experiment on M. smegmatis and M.tuberculosis (Banerjee, Dubnau et 
al. 1994). The results indicated that the mutations had no measurable effect on INH 
resistance in M.smegmatis but had a modest effect on M.tuberculosis. 
Many mutations in the inhA structural gene have been identified in low-level 
INH resistant isolates without katG mutations. Crystal structure analysis and 
enzymatic characterization has shown that all amino acid substitutions would be 
located in the NADH binding site and INH resistance in these strains is related to the 
reduced NADH binding affinity for enoyl reductase (Dias, Vasconcelos et al. 2007). 
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Even thoughfagGI and inhA are located in the same operon and have similar 
function involved in long-chain fatty acid biosynthesis, all INH resistant mutations 
Occur outside encoding sequence offagGI and the gene remains intact. Experimental 
results from over expression of FagG 1 from M.tuberculosis suggest it does not confer 
the ability to titrate either INH or ETH (Banerjee, Sugantino et al. 1998). This rules 
out the possibility of FagGI being a direct target in vivo for active INH derivative, 
like isonicotinic acyl-NADHlNADPH. This result is consistent with the fact that, until 
now, no mutations have been mapped on fagGJ gene in INH-resistant organisms 
(Banerjee, Sugantino et al. 1998). 
1.18.2.3 Mutations in oxyR-ahpC intergenlc region 
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Figure 1.5: oxyR-ahpC intergenic region showing the region characterized 
between two primers 
Further investigation of INH resistant M.tuberculosis isolates has shown that 
the oxyR-ahpC intergenic region (or the ahpC promoter sequence, Figure 1.5) 
contains many mutations. The ahpC gene encodes alkyl hydroperoxide reductase, a 
protein involved in the oxidative stress response. It is proposed that increased AbpC 
activity could compensate for the loss of catalase-peroxidae activity in the 
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detoxification of organic peroxides. Some mutations in this region were found in INH 
resistant isolates only (Kelley, Rouse et al. 1997). Western blot analysis showed that 
several of these mutations had enhanced transcriptional activity. However, some 
common mutations found in ahpC exist in both INH sensitive and resistant isolates 
and thus are polymorphisms (Baker, Brown et al. 2005). Other mutations are 
relatively rare among a broad spectrum of INH resistant strains and most of them 
occur in catalase-negative INH resistant isolates. These facts suggest that these 
mutations appear to be compensatory and are presumably selected after reduction in 
catalase-peroxidase activity attributable to katG changes arising with INH therapy. 
AbpC itself does not appear to directly mediate INH resistance. 
1.18.2.4 A new target protein 
In 2006, Argyrides et al. published a paper in Nature showing that 
dihydrofolate reductase (an enzyme essential for nucleic acid synthesis) is a new 
target of INH (Argyrou, Vetting et al. 2006). However, a recent paper showed that 
dihydrofolate reductase is not a relevant target to the anti-tuberculous activity of INH 
(Wang, Jain et al.). The discrepant result indicates that INH activity and its resistance 
mechanism is not simple. The fact is that sometimes the in vitro results do not reflect 
the actual effects of a drug in vivo, such as is the case with PZA (Bergval, Schuitema 
et al. 2(09). 
1.18.2.5 Other INH resistance mechanisms 
A study in Vietnam in a set of 100 INH resistant isolates (Caws, Duy et al. 
2(06) showed that no single mutation was found in the resistant associated genes, 
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kata and inhA, among 10 INH resistant isolates (10%). Similar results have been 
shown worldwide with 15-25% of INH resistant clinical isolates having both wild-
type kata and inhA genotypes. The implication is that mutations in kata or inhA do 
not account for all INH resistant strains, and suggests that some other unknown 
mechanisms may lead to INH resistance. 
Unlike other forms of drug resistance, for example RIF resistance which has a 
hot-spot region conferring resistance in more than 70-98% of RIF resistant isolates 
(Heep, Brandstatter et al. 2001; Garcia de Viedma, del Sol Diaz Infantes et a1. 2002; 
Cavusoglu, Turhan et a!. 2(06), resistance to INH can occur via alterations in several 
different genes including enzyrnatic structural genes as well as alteration in promoter 
regions. The relationships of kata and inhA mutations with INH resistance were well 
characterized. However, the evidence of mutations in other genes such as ahpC. kasA, 
oxyR. ndh. gif and oot is still unclear. Further investigations in the search for new 
mechanism of drug resistance in TB are necessary. 
1.19 Drug resistance diagnosis 
Knowledge of drug susceptibility patterns improves treatment outcomes by 
allowing appropriate therapy. However, drug susceptibility testing is not usually 
available for patients in resource limited settings such as Vietnam. DST is often 
limited by resource constraints to failure and retreatment patients, and in many high-
burden regions is not available at all. 
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Within Vietnam, DST is only officially available in two reference laboratories 
in Ha Noi and HeM city and is only perfonned following the request of the 
physicians, usually after treatment failure or relapse. When the conventional DST is 
applied, it takes at least 2 weeks (when using MO IT) and several months (when using 
U media) to return the result. This results in delays to diagnosis which leads to the 
delay in giving appropriate chemotherapy. Direct DST on MOIT or by the MODS 
method can be used to shorten the turnaround period because the method can do DST 
by inoculated directly from sputum (Moore, Mendoza et al. 2(04). However, the 
MODS technique is human-resource intensive because plates must be examined 
manually and repeatedly to detect growth of M.tuberculosis cords under inverse-
microscope and MOIT DST is prohibitively expensive. Thus, a cheap and rapid 
molecular DST for TB is urgently needed. 
So far, some fast methods for DST such as Mycobacteria-phage and NAAT 
based techniques have been developed. In the phage-based assay, live M.tuberculosis 
is detected in clinical samples by infection with phage. The sample is plated onto a 
lawn of M.smegmatis where plaques of lysed bacilli indicate the presence of phage 
which has replicated inside any M.tuberculosis in the clinical sample. The addition of 
drug to incubation media can be used to detect resistance. In contrast, NAA T methods 
amplify the target gene(s) and detect mutations which confer resistance to the drug of 
interest. LP A are also widely used for drug resistance testing. With the ability to 
differentiate multiple mutations using multiple specific probes, LPA report consistent 
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results with high sensitivity and specificity. The commercial MTBDRplus test is a 
successor of LP A that is recommended by WHO and widely used to screen MDR TB. 
1.20 Phannacokinetics of INU 
INH is eliminated via acetylation by N-acetyltransferase (NA T2) enzyme 
system in kidneys. The speed of INH metabolism shows inter-individual variation due 
to genetic variation in the N-acetyltransferase genes (NAn). Individuals classified as 
fast metabolizers have lower Cmax values of INH in the sera. 
Although pharmacokinetic-pharrnacodynamic (PK-PD) index has been used 
for dosing, little infonnation was available to define the PK-PD index of anti-TB 
drugs until the past 5 years. Microbial PK-PD concepts relate to the shape of the 
concentration-time profIle and the minimum inhibitory concentration (MIC) which 
was used to optimize the efficacy of the drug toward the pathogen (Ambrose, 
Bhavnani et al. 2(07). 
A recent population pharmacokinetic analysis revealed that 88% of the 
variation in INH serum clearance is driven by NAT2 gene; ethnicity, sex, and body 
weight accounting for very little to the variability (Kinzig-Schippers, Tomalik-Scharte 
et al. 2005). INH effect is best explained by peak concentration Cmax:MIC ratio, and 
INH doses should be combined together and administered as high intennittent doses. 
Thus the area under the concentration-time curve (AUC) of INH is mostly driven by 
the dose of INH intake and the patient genotype. A study by Donald et aL showed that 
with INH administration over lOmg/kg, the INH serum concentration reaches Cmax 
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despite the genotypes, but with the lower INH oral dose (3mg/kg) the contribution of 
genotype became predominant (DonaId, Parkin et al. 2007). This suggests that in 
some ethnic groups where NAT2*4 genotypes are dominant (associated with a high 
serum clearance), higher doses of INH may be needed, whereas people carrying NAT2 
SS genotype and being severity attacked by the side effect should be modified to 
lower doses that remain effective but minimize toxicity. 
The pharmacokinetics of INH in children was also not well known until 
recently (McIlIeron, WiIlemse et a1. 2(09). Interestingly, many studies showed that 
the process to eliminate INH in children is much faster than that of adults, therefore 
INH serum concentration in children is much lower when administered the same 
doses with adults, according to body weight (Schaaf, Parkin et a1. 2005).The treatment 
guidelines for pediatric TB have been recently revised to reflect this (WHO 2010). 
1.21 Phannacogenetics of INH in Vietnamese 
INH is eliminated by NAT2 enzyme system in humans. It is known that NA T2 
genotype affects the serum concentration of INH (Donald, Parkin et a1. 2007), 
therefore may also impact on the efficacy of INH therapy in some TB patients. The 
Vietnamese are likely to be predominantly fast acetylators as Chinese, Japanese and 
Thai ethnic groups (Zhao, Seow et al. 2000; Kita, Tanigawara et a1. 200 1), in contrast 
to USA, where the majority are slow acetylators. The acetylator status may play an 
important role in TB treatment based on its role in INH metabolism. 
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Caffeine and INH share the same pathway of metabolism in humans in which 
NAT2 is the key enzyme; therefore caffeine can be used to investigate acetylator 
phenotype in healthy volunteers. 
Aims of the Thesis 
The specific aims of this thesis are: 
I. Develop rapid diagnostic tests for MDR TB and INH resistance based on 
identifying gene mutations (rpoB, katG, inhA and ahpC). 
2. Confmn the association of katG315 mutation with higher MIC to INH 
compared to inhA-15 mutations in Vietnamese strains and determine the impact of the 
genotype backbone on MIC to INH. 
3. Determine if INH resistance without RIP resistance is associated with poor 
outcome in HIV -associated TBM patients. 
4. Determine the correlation between genotype and phenotype for NAT2 
acetylation in Vietnamese Kinh population. 
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2.1 General methods 
2.1.1 Study location 
Chapter 2 
Materials and Methods 
Laboratory work for studies in chapter 3, 4, 5 and 6 of this thesis was 
conducted at OUCRU. Clinical isolates were collected from patients at two hospitals 
in HCM city, Vietnam: HTD and PNT. 
HTD is a 500-bed tertiary reference hospital for infectious diseases, serving a 
popUlation of 38 million in southern Vietnam. 
PNT is a 800-bed tertiary reference hospital in HCM city which also houses 
the WHO accredited national reference TB laboratory for southern Viet Nam. Clinical 
isolates from pulmonary TB patients were collected at PNT hospital for chapters 3 
and 4. 
TBM patients were recruited at both hospitals for enrolment into the clinical 
trial which provided the isolates for the work described in chapter 5. 
OUCRU is funded by the Wellcome Trust, UK. The Unit was established in 
1991 with in HTD as a collaboration eenter between HTD and Oxford University to 
study tropical diseases, initially to study malaria but subsequently diversifying to 
include groups working on dengue, typhoid, influenza, TB, enterics, and zoonosses 
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supported by pharmacology, statistics, bioinfonnatics, host genetics and modeling 
departments. 
2.1.2 Sample preparation. 
Sputum sample decontamination 
Sputum samples were decontaminated by NALC-NaOH decontamination 
using sputa prep kit from Nam Khoa company, Vietnam. The kit contains 4% NaOH 
and 2.9% sodium citrate and N-Acetyl L-Cysteine (NALC) powder. 
NALC powder (0.5g) was dissolved in 100 ml of 4% sodium hydroxide-2.9% 
sodium citrate solution. The solution was vortexed until completely dissolved and 
used as decontamination solution within 24 hours after adding NALC. 
Sputum sample (less than lOmI) was collected in a 50 ml clean capped 
container. An equal volume of decontamination solution was added to the container to 
obtain the final concentration of 2% NaOH. Both NaOH and NALC act to liquefy and 
decontaminate the sputum. The container was left to stand for 2-3 minutes for 
liquefaction before transferring the specimen from the container to a plastic 20ml 
centrifuge tube. The tube was tightly capped, vortexed and left to stand for 15-20 
minutes for optimal decontamination. A balance must be achieved to obtain maximal 
killing of organisms other than M.tuberculois in the sputum without rendering the 
M.tuberculosis non-viable. The specimen was later diluted with sterile phosphate 
buffer solution (pH 6.8) or sterile distilled water to lessen the viscosity and decrease 
alkaline concentration to a final volume of 45ml prior to centrifugation for 15 minutes 
at a speed of 3,OOOrpm. 
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The supernatant was subsequently discharged carefully and the pellet was 
resuspended with sterile phosphate buffer solution (pH 6.8) or sterile distilled water to 
achieve a final volume of 0.5-1ml. This deposit was divided for smear preparation, 
inoculation of culture and an aliquot was stored in Eppendorf tube at -20°C. 
CSF sample preparation 
Two to ten mililitres of CSF was collected by lumbar puncture into a 20 ml 
clear sterile tube from all patients with suspected TBM. The sample was centrifuged 
at 3000rpm for 15 minutes, followed by culture and smear as soon as possible after 
processing. CSF samples are sterile and therefore decontamination is not required. 
After centrifugation most of the supernatant was removed using a sterile 
pipette, and stored in an Eppendorf at -20°C. The deposit was vigorously resuspended 
in the remaining 300-400J.11 of supernatant. Two drops (approximately lOOJ.11 each 
drop) were used for smear, two drops were frozen at -20°C for later use and the 
remaining deposit was divided equally for culture on U and MGIT media. 
2.1.3 ZN or AFB smear 
Two drops of sample deposit was applied onto a clean glass slide. The slide 
was laid on a heater block at 80°C for approximately five minutes until dry in order to 
fix the material onto the slide. Carbol-Fuchsin was applied to cover the sampling area. 
The slide was then moved in a circle over a flame until the Carbol-Fuchsin steamed 
without boiling and laid on a bench for further 5 minutes for optimal penetration of 
the dye. Carbol-Fuchsin on the slide was washed with running tap water, 1 % acid 
70% alcohol solution and again with running tap water before applying Methylene 
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Blue solution (1.4mglml). After 30 seconds, the slide was rinsed with water, 
dehydrated and covered with a cover slip and observed under the microscope to read 
the result. A positive AFB sample shows a bright red rod shape of mycobacteria 
bacilli in the blue background of other material which is stained blue with Methylene 
Blue. A negative slide shows only blue background. 
2.1.4 M.tuberculosis culture 
Sputum and CSF samples were processed as detailed above (section 2.1.2) 
prior to inoculation for culture. 
U culture 
The U tube (Becton Dickinson, USA) was labeled with the study code and 
date of the sample. Around 100",1 of sample deposit was used to inoculate on U 
media. The U media tube was capped and gently turned so that the inoculated 
suspension was spread across the sloped surface of the solid U media. The tube was 
secured to stand in a rack and kept in an incubator at 37°C. The tubes were fIrst 
visually checked for positive growth two weeks after the innoculation. Negative tubes 
were continually incubated and checked weekly for positive samples. A sample was 
reported negative only if no growth was observed after 8 weeks of incubation. 
MOIT culture using BACTEC 960 system 
MOIT culture (Becton Dickinson, USA) was performed using the commercial kits 
according to manufacturer's instructions. Each MOIT tube was labeled with study 
code and date of the tested sample. Eight hundred microliters of OADC (Oleic-acid-
albumin-dextrose-catalase) supplement (Becton Dickinson, USA) was added into the 
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MGIT tube. With sputum samples an additional looul of PANT A antibiotic 
supplement (Becton Dickinson, USA) was added into each MGIT tube to inhibit the 
growth of micro organisms other than mycobacteria. One hundred micro litres 
PANTA contains polymixin B (lOO units), amphotericin (10 units), nalidixic acid (40 
units), trimethoprim (ID units), azlocillin (20 units). 
Around lOOul of decontaminated sample deposit was inoculated into the 
MGIT tube. 1be tube Was tightly capped and inverted twice to mix the solution well 
with the innoculum. The bar code on MGIT tube was scanned before the tube was put 
into the indicated slot in BACfEC960 system. BACTEC960 is an automatic system 
that incubates MGIT tubes at 37°C, monitors the growth of micro-organisms in MGIT 
tubes every hour and automatically reports positive samples during 42 days of 
incubation. Growth is detected via an increased fluorescence, emitted in response to a 
decrease in oxygen concentration within the tube, caused by oxygen consumption of 
growing micro-organisms. A positive signal on MGIT does not confIrm the presence 
of mycobacteria and positive samples must be confrrmed by AFB microscopy, and 
M.tuberculosis identifIcation. Negative samples are only reported after 42 days (6 
weeks) when no growth is recorded. The initial incubation date, positive date and 
negative date are recorded and reported by the system. 
2.1.5 Phenotypic DST 
Conventional phenotypic DST on solid U media by 1 % proportion method 
was performed at PNT according to standard WHO methods (WHO 2009). 
M.tuberculosis isolates are considered resistant if growth occurs on the media 
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containing the relevant drug at ~1 % of the growth observed on the drug-free media. 
Critical drug concentrations are 0.2 JIg/ml INH, 40 JIglml RIF, 2 JIg/ml ETB and 4 
JIg/ml STR in accordance with the WHO standard protocol (Canetti, Fox et al. 1969). 
The microbiology laboratory is a WHO international reference laboratory undergoing 
and consistently passing supranational quality assurance with the WHO supervisory 
reference laboratory in Adelaide, Australia In principle, one sample is inoculated 
equally on both drug-containing medium and drug-free medium. The number of 
colonies growing on drug-free medium is compared with the number on drug-
containing medium and the proportion of resistant organisms is calculated. A resistant 
isolate is defined if the number of colonies on the drug-containing medium is 1 % or 
more of the number developing on the drug-free medium. 
Indirect DST in liquid media was perfonned using the MGIT SIRE kit on 
BACTEC960 system (Becton Dickinson, USA) at the HTD according to the 
manufacturer's guidelines. Standard critical concentrations in liquid media are lower 
than those for solid media testing: INH (0. 1 Jlg/ml) , RIF (lJlg/ml), ETB (5 JIg/m!) and 
STR (1 JIg/ml). In principle, one sample is inoculated into both drug-containing 
medium and drug-free medium with different amount of inoculum. 
Innoculation suspensions were prepared using the manufacturers' guidelines 
for preparation from MGIT culture. Positive cultures were used on undiluted for 
preparation of organism suspension on days 1-2, cultures on day 3-5 positivity were 
diluted 1:5 in sterile saline solution. 0.1 m! organism suspension was pipetted into 
10ml sterile saline to prepare 1: 1 00 growth control suspension, which was then mixed 
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by vortex. 0.5ml of growth control suspension was then inoculated into the drug free 
media and O.5ml organism suspension to the drug containing wells. 
A resistant isolate is defined based on the proportional growth relative to the 
inoculum size. The control-growth tube (drug-free) is only incubated with I % of the 
bacilli in comparison with that used in the drug-containing medium. Once the control-
growth tube becomes positive, detection of bacterial growth in the drug-containing 
medium identifies a resistant strain. 
These DST results were used as gold standard for comparison with molecular 
tests in our studies. 
2.1.6 Extraction of M.tuberculosis chromosomal DNA 
DNA extraction of M.tuberculosis was perfonned using CTAB/chlorofonn 
method after cUlturing on U media (Honore-Bouakline, Vincensini et al. 2003). The 
purified DNA was dissolved in Tris-EDTA (TE, 10 mM Tris and 1 mM EDTA) 
buffer, quantified, diluted to the final 15ngl~1 concentration and stored at -20°C 
DNA extraction was perfonned when sufficient M.tuberculosis grew on U 
media. First, 0.6ml TE buffer was dispensed into labelled screw-cap tubes. The 
colonies of M.tuberculosis were scraped with a plastic disposable loop and dispersed 
in the tube with TE. The tubes were placed in a hot block and heated at 80°C for 20 
minutes. 
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The tubes were allowed to cool before adding 50111 fresh lysozyme solution 
(lOmglml) (Roche, Viet Nam). The mixture was vortexed before incubation at 37°C 
overnight. 
On the following day, 10111 proteinase K (lOmglml) (Roche, Viet Nam) and 
35111 SDS 20% (w/v) (Sigma, Viet Nam) was added to the extraction tube, vortexed to 
mix and incubated at 55°C for 30 minutes. Then 100111 SM NaCl (Merck, Viet 
Nam)and 100111 5% crAB solution (Sigma, Viet Nam) was added to the mixture, 
vortexed until opaque and incubated at 6SoC for 15 minutes. 
The tube was left to stand to cool to room temperature· before adding 700111 
chloroform:isoamyl alcohol (24:1) (Sigma, Viet Nam), vortexed and centrifuged at 
12,OOOrpm for 5 minutes. At this stage, the mixture inside the tube has separated into 
three phases: aqueous phase (top), interphase (middle) and the organic phase 
(bottom). The top aqueous layer, containing DNA, was carefully transferred to a fresh 
Eppendorf (600111). DNA precipitation was followed by adding 360Jl1 (0.6 volume) of 
isopropanol to the Eppendorf. The solution was mixed well by inverting several times, 
left at -20°C for at least 30 minutes, then centrifuged at 12,OOOrpm for 15 minutes. At 
this stage, the precipitated DNA was gathered at the bottom of the Eppendorf and is 
visible by eye. 
The supematant was discarded and the pellet washed again with 1.0 ml of cold 
70% ethanol to dissolve the salts remaining in the pellet without dissolving the DNA. 
Then the tube was centrifuged for 7 minutes at 12,OOOrpm. The supernatant was 
discarded again and the tube was left to stand with the lid open at room temperature 
67 
until the last traces of liquid evaporated. An appropriate volume of TE was added to 
each tube and left at room temperature for 2 hours or placed at 4°C overnight until the 
pellet was completely dissolved. All extracted DNA was stored at -20°C for later 
analysis. 
2.1.7 Polymerase Chain Reaction (PCR) 
PCR reaction mix contained lO-l00ng of extracted genomic DNA (section 
2.1.6), lOmM Tris pH 8.3, 50mM KCI, J-3mM MgCh, 200 flM dNTPs, 200nM of 
each primer and 0.75 unit of Taq DNA polymerase. The concentration of individual 
reagents and annealing temperature was optimized for each PCR test. 
To investigate RIF resistant isolates and amplify RIF resistance associated 
gene, rpoB, the primers and condition in Table 2.1 were used. 
Table 2.1: Primers for rpoB PCR and sequencing for RIF resistance 
Primer Sequence (S'-3') Ta Cone Target in Product 
(oC) (oM) rpoB e:ene length 
RPOBF GGG AGC GGA TGA CCA CCC A 65 ISO FlankRRDR 3S0bp 
RPOBR(l) GCG GTACGG CGTTTC GAT GAAC 65 150 
TB 146-F crr CTC CGG GTC GAT GTC GTT G 64 300 N-terminal 365bp 
TB 146-R (2) CGC GCT TGT CGA CGT CAA ACT C 64 300 region 
RpoB-C3F GAG TAC GTG CCC TCG TCT GA 56 300 rpoB cluster 319bp 
RooB-C3R ACT TGC GCA TCC GGT AGG TA 56 300 3 region (lr • (2). 
• (Kapur, Li et al. 1994), • (Heep, Brandstatter et al. 2001) 
To investigate INH resistant isolates and amplify the genes associated with 
INH resistance, the primers and condition in Table 2.2 were used. 
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Table 2.2: Primers for PCR and sequencing of INU-resistance associated 
regions in M.tuberculosis 
Primer Sequence (5' -3') Ta Conc. Target Product 
names "C (nM) length 
katGwl!Fl GTC CTC TAT ACC GGA CTA CGC 61 120nM huG whole gene 2899bp 
katGw2Rl TeG CAC ATe CAG CAC A TT Te each 
katGP5 GGT CGA CAT TeG CGA GAC GTT 68 150nM IwtG codon 315, 519bp 
katGP6!lT CGG TGG ATe AGC TTG TAC CAG each sequencing primers 
1'892 CCT CGC roe CCA GAA AGG GA 56 150nM inhA promoter 248bp 
1'893 (2) ATe CCC CGG TTT CCT CCG GT each region 
AhDCl GCC TGG GTG TTC GTe ACT GGT 56 150nM oxyR-ahpC 359bp 
AhPC2 (3) CGC AAC GTe GAC TGG CTe ATA each intergenic regi on 
(I):(Marttila, Soini et al. 1996), (2): (Telenti, Honore et al. 1997), (3):(Silva, Senna et al. 2(03) 
To investigate NAT2 genotype, NAn gene was PCR with two primers 
NAT2F 5'-TGGGCfTAGAGGCfATIT and NAT2R 5'-GAGTTGGGTGA-
TACAT ACAC which flank the area of 768bp, with the best annealing temperature of 
this primer pair is 65°C. 
All of the reactions were amplified under the same thermocycling program: 
95°C for 1 min, following by 30 cycles of 95°C for 10 sec, the right annealing 
temperature (or TaoC, Table 2.1 and Table 2.2) for 30 sec, nOc for 30 sec and a final 
step of noc for 5 mins. 
Negative control (distilled water instead of DNA template) was included in 
every 'batch' of PCR to control and detect cross-contamination during processing. 
PCR products were analysed by electrophoresis on 1% agarose gel at 150V 
from 30-60 mins and visualise in UV light. 
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2.1.8 Sequencing 
Prior of sequencing process, the target DNA fragments were PCR in order to 
obtain enough material for sequencing. 
RIF resistance gene 
RIF resistant isolates were sequenced in the RRDR and N-terminal of the rpoB 
gene with primers showed in Table 2.1. Half volume of CEQ Quick Start kit 
(Beckman Coulter) was used to sequence from both strands of a 350bp fragment 
containing the 81 bp sequence of RRD R. 
INH resistance genes 
INH resistant isolates were sequenced in katG gene. The resistant isolates with 
no mutation in the katG gene were also sequenced at the junction in oxyR-ahpC 
intergenic region and a junction in the inhA promoter. Using half volume of CEQ 
Quick Start kit (Beckman Coulter), DNA was sequenced from both strands of a 519bp 
fragment of katG, 359bp fragment of ahpC and 248bp fragment of inhA. 
Acetylator NATI ~ene 
The DNA of 37 healthy volunteers enrolled into the caffeine study was 
sequenced 768bp region in the second exon of NA12 gene which contains most 
poiymorphisms associated with changes in acetylator phenotype. Using half volume 
of BigDye Terminator v3.1 Cycle Sequence Kit (Applied Biosystem), sequence was 
obtained from both strands of this NA12 gene. 
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2.1.8.1 CEQ Quick Start Kit (Beckman Coulter, Singapore) 
The CEQ8000 is a capillary electrophoresis sequencing machine which 
analyses sequencing reactions generated by CEQTM Quick Start IGt. PCR products 
were used as templates in the sequencing reactions after an initial purification process. 
• Template preparation 
DNA templates used for sequencing in this thesis were generated from PCR 
products. The QIAquick PCR purification IGt (Qiagen, UK) was used to purify PCR 
products generated by a standard PCR. The concentration of purified PCR product 
was estimated by electrophoresis along with mass standard ladder (Biorad, USA) or 
by UV absorbance measured by NanoDrop (Thcrmo Fisher Scientific, USA) (Figure 
2.1). Approximately 50 - lOOng of purified PCR products were used for one 
sequencing reaction. 
(a) (b) 
Figure 2.1: a) Mass standard ladder. b) NanoDrop equipment and 
software to measure DNA concentration. 
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• Preparation of the DNA sequencing reaction 
Each fragment of DNA of interest was sequenced from both strands to confirm 
the accuracy of sequencing results. Each sequencing reaction contained SO-IOOng of 
purified PCR product (depending on the length of PCR products), 3.21lM of primer 
(21l1 of 1.61lMlJlI primer), 4111 of DTCS Quick Start Master Mix (Beckman Coulter, 
Singapore) and dH20 to make a total volume of 20Ill. The thermal cycling was 
carried out with the standard CEQ program of 30 cycles of 96°C for 20 second 
initially, followed by SO°C for 20 second, and then 60°C for 4 minute. Finally the 
PCR reactions were held at 4°C. 
• Ethanol precipitation ofsequencing products 
The purpose of this step is to eliminate any unwanted chemical, protein or 
primer which could interfere with the analysis on the sequencing machine. Unwanted 
PCR reagents were removed from solution by ethanol precipitation in the presence of 
sodium acetate. The precipitation was performed in O.Sml tubes for each sample. Four 
microlitre of Stop solution (3M NaOAc and lOOmM EDTA) and Illl of 20mglml 
glycogen was aliquoted into O.Sml tubes before adding 20lll of each sequencing 
reaction. Sixty microlitre of cold 9S% (v/v) ethanol (kept at -20°C) was added and 
mixed thoroughly. The mixture was immediately centrifuged at 14,000 rpm for IS 
minutes at _4°C and the supernatant was discarded. The collected pellet was rinsed 
twice with 200111 of 70% (v/v) ethanol (kept at -20°C). For each rinse, samples were 
centrifuged immediately at 14,000 rpm for a minimum of 2 minutes and the 
supematant was discarded. The pellet was dried under vacuum for 40 minutes, then 
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resuspended in 40JlI of Sample Loading Solution (supplied in DTCS Quick Start kit). 
The resuspended samples were then ready for analysis using the CEQ8000 sequencer. 
The sequencing results were recorded and analysed by CEQuence Investigator 
software. 
2.1.8.2 BigDye Terminator v3.1 Cycle Sequence Kit 
Similar to the process using CEQ Quick Start Kit, sequencing using BigDye 
Terminator v3.1 Cycle Sequence Kit has the following steps: 
• Template preparation (as for CEQ, above) 
• Preparation ofthe DNA seguencing reaction 
According to the manufacturer, the BigDye method can sequence a fragment 
from 500bp-lOOObp. Like other sequencing methods, each fragment of DNA of 
interest was sequenced from both strands to improve the accuracy of the results. Each 
sequencing reaction contained 5-20ng of purified PCR product, 3.2JlM of primer, 2Jll 
of BigDye Terminator (Applied Biosystem, Hitachi), I Jll of ABI buffer and dH20 to 
make a total volume of IOJlI. The thennal cycling was carried out with the standard 
ABI program of 25 cycles of 96°C for 10 second, followed by 50°C for 5 second, and 
then 60°Cfor 4 minutes. Finally the PCR reactions were held at 4°C. 
• Ethanol precipitation ofseguencing products 
The ftrst steps of precipitation of sequencing products were similar to CEQ. 
The only modiftcation being: after the pellet was dried under vacuum for 40 minutes 
it was resuspended in 40111 of HiDi fonnamide solution (supplied with BigDye kit). 
The resuspended samples were then ready for analysis using the 3130xl Genetic 
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Analyzer (Applied Biosystem, Hitachi). The sequencing results were recorded and 
analysed by Sequencing Analysing 5.3 software. 
2.2 Development of rapid diagnostic tests 
2.2.1 Isolates 
An existing archive collection of RIF/INH resistant M.tuberculosis isolates 
was used to develop and evaluate rapid molecular tests for drug resistance. 
Consecutive M.tuberculosis isolates routinely identified as resistant to either INH or 
RIF at PNT microbiology laboratory were collected for this study. One hundred and 
thirty one isolates were collected in total between January and March 2005. DST 
testing is not routine for new TB patients in the Vietnamese NTP and is only 
perfonned on request by the treating clinician, usually after treatment failure (smear 
positive after 5 months of treatment or more) or relapSe/re-treatment cases. 
Infonnation on individual reasons for DST was not available. Resistant isolates were 
transferred to IITD and were sequenced prior to this thesis in rpoB, katG, inhA and 
ahpC genes (Caws, Duy et al. 2(06). In these 131 resistant isolates, 104 isolates are 
RIF resistant, 129 isolates are INH resistant. 
All 104 isolates identified as RIF resistant (102 of which were MDR, 98.1 %) 
which had been sequenced in the RRDR of rpoB gene, as previously described (Caws, 
Duyet al. 2006) were used to develop and evaluate the Multiplex Allele Specific PCR 
(MAS-PCR) for RIF resistance. 
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Only the first 1001129 consecutive INH resistant isolates which had been 
sequenced in katG, inhA and ahpC genes (Caws, Duy et al. 2006) were used to 
develop and evaluate the MAS-PCR for INH resistance. 
In addition to the resistant isolates, 50 fully sensitive isolates were used as a 
control group for the analysis. These were archived isolates from TBM patients in a 
clinical trial of adjunctive dexamethasone at HTD with DST results available from 
previous research (Thwaites, Nguyen et al. 2004). Both drug susceptible and resistant 
isolate collections were used to evaluate the tests developed in this thesis by 
comparing the novel MAS-PCR tests with the commercial MTBDR and MTBDRplus 
LPA tests (Hain lifesciences, Germany) using the phenotypic DST results as the gold 
standard. 
2.2.2 MAS-PCR for RIF resistance (MAS-RIF) 
Multiplex PCR was used to detect point mutations in the M.tuberculosis 
genome. For RIF resistance, three separated MAS-RIF tests were used for each 
isolates that need to be tested. Each of three MAS-RIF reactions had the same outer 
primers RPOBF and RPOBR to amplify the RRDR of rpoB and one of the three inner 
primers RIF2R, RIF3F and RIF4R, which targeted to wild type at each hot spot 
codons 516, 526 and 531, respectively (Table 2.3). 
Each MAS-RIF reaction contained 0.75 Unit of Taq DNA polymerase 
(Bioline), lOmM Tris pH 8.3, 50mM KCl, 0.2mM of each dNTP (Roche) and 125 -
400nM of primers (Table 2.3) and 2mM MgCb. Fifteen nano-grams of genomic DNA 
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was added. All of the reactions were amplified under the same thermocycling 
program: 95°C for I min, following by 35 cycles of 95°C for lOs, 68°C for 20s, noc 
for 20s and a final step of nOc for 5 mins. A negative control (distilled water) and a 
positive control for each of the 3 target codons were included with each batch 
processed. PCR products were analysed by electrophoresis on 1% agarose gel at 150V 
for 45 minutes. 
Table 2.3: Primers used for MAS-PCR for detection of RIF and INH 
resistance 
Primer Sequence (5'-3') Ta Conc Target Product 
(0C) (nM) inrpoB length (bp) 
JZ;ene 
RPOBF GGG AGe GGA TGA CCA CCC A 68 125 AankRRDR 350 RPOBR(I) GCG GTA CGG CGT TI'C GAT GAA C 125 
RIF2R GAC AGe GGG TTG TI'C TOO T 300 Codon 516 \39+ 
RIF3F CCG CTG TCG GGG TAG ACC CA 400 Codon 526 219++ 
RIF4R CCG CCG GGC CCC A TC GCC G 300 Codon 531 184+ 
HSP65FI GCG GTA GAG GTG ACA TTG GG 62 150 HSP65 656 
HSP65R2 TT A CCG GCT CCG A TG ACC T 150 
KatG2F GGT AAG GAC ACG ATC A TC AGT 300 katG 315 329 
katGP6 (2) CGG TOO ATC AGC TTG TAC CAG 200 
TB92 (3) CCT CGe TGC CCA GAA AGG GA 150 inhA -15 174 
inhARrnut (4) AGTCACCCCGACAACCTA TTA 150 
+ 
amplicon generated with pnmer RPOBF 
++ 
amplicon generated with primer RPOBR 
OI:(Kapur, Jj ctal. 1994) 
(3): (Telenti, Honore et al. 1997) 
(2): (Martti1a, Soini et al. 1996) 
(4): (Herrera-Leon, Molina et al. 2005) 
2.2_3 MAS-PCR for INH resistance (MAS-INH) 
The reaction was performed in a single tube with three pairs of primers. Each 
PCR reaction contained I Unit of Taq DNA polymerase (Bioline), IOmM Tris pH 8.3, 
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50mM KCl, O.2mM of each dNTPs (Roche) and 150 - 250nM of primers (Table 2.3) 
and 2mM MgCh. Fifteen nanograms of genomic DNA was added. All of the reactions 
were amplified under the same thermocycling program: an initial denaturation step at 
95°C for 2 mins, followed by 35 cycles of 95°C for 20s, 62°C for 20-60s (60s in the 
first 10 cycles, 20s in the latter 25 cycles), nOc for 40s and a final step of nOc for 5 
mins to complete all reactions. 
Positive and negative controls (distilled water) were included in every batch of 
PeR to ensure that the reaction was performed correctly and to detect cross-
contamination during processing. PCR products were analysed by electrophoresis on 
1% agarose gel at 150V for 30 minutes. 
2.2.4 GenoType MTBDR and MTBDRplus 
The MDRTB and MTBDRplus kits are commercial LP As of Hain 
Lifesciences company (Nehren, Germany). These tests were performed according to 
the manufacturer protocol. Briefly, 15ng of sample DNA was used as a template to 
amplify rpoB and katG (and inhA for MTBDRplus) target sequences with biotin-
labeled primers. Amplification products were analyzed by reverse hybridization to 
membrane-bound probes. Colorimetric detection gave purple bands, read by eye. A 
negative control (water) was included with each run. 
The shaking waterbath was prewarmed to 45°C (±loC). Solutions 
hybridization buffer (HYB) and the stringent wash solution were placed in the 
waterbath to warm to 37°C - 4SoC so that the reagents were free from precipitates. 
77 
The remaining reagents except the conjugate concentrate (CON-C) and substrate 
concentrate (SUB-C» were warmed to room temperature. 
Diluted conjugate solution was prepared by diluting 1: 100 CON-C with 
conjugate denaturate (CON-D) (lOul CON-C plus 990u1 CON-D for each tested strip) 
in the required volume. The solution was mixed well and brought to room 
temperature. This solution was prepared before each use. 
Diluted substrate solution was prepared with I: 100 of SUB-C diluted into 
SUB-D (l01l1 SUB-C plus 990IlI SUB-D for each strip). The solution was mixed well 
and warmed to room temperature. Diluted SUB-C solution was stable for 4 weeks at 
room temperature and was stored in the dark. 
Hybridization reaction 
The strips were taken out of the tube using tweezers and labelled with a pencil 
underneath the coloured marker. Twenty microlitres of denaturation (DEN) solution 
was dispensed in a corner of each tray used. Twenty micro litres of amplified sample 
(PeR product) was added and mixed well by pipetting up and down. The mixture was 
left at room temperature for 5 minutes to denature all of the amplified products. 
Prewarmed HYB buffer (lml) was added to each well and the tray gently shaken until 
the solution had a homogenous color. Each strip was placed in a well with the coated 
side (the side with color marker) facing upward, ensuring the strip was completely 
submerged in solution. The tray was then incubated in a shaking waterbath for 30 
minutes at 45°C at 6Orpm. The tray was submerged in the water at least one third of 
its height. After 30 minutes of incubation, HYB buffer was aspirated completely with 
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a pasteur pipette. One milliliter of prewarmed stringent solution was added to each 
strip and the tray was incubated for 15 minutes at 45°C in a shaking waterbath. 
The following steps were performed at room temperature. The washing 
stringent solution was discarded completely by pouring out the solution, then turning 
the tray upside down and gently striking it on absorbent paper. The strip was washed 
again with Iml rinse (RIN) solution for I minute on a shaking platform. 
One milliliter of diluted conjugate solution was added to each strip and 
incubated for 30 minutes on a shaking platform before washing twice with Iml of 
RIN solution and Once with I ml of distilled water for I minute on the shaking 
platform. 
One milliliter of diluted substrate solution was added to each strip and 
incubated in the dark without shaking for 10 minutes. The colour development 
reaction was stopped by briefly rinsing twice with distilled water. Strips were 
removed from the tray and dried between two layers of absorbent paper. The strips 
were pasted on the result-report sheet to analyse the results and stored protected from 
light. 
2.3 The association of katG315 and Beijing lineage with higher MIC to INH 
2.3.1 INH resistant isolates for MIC test 
In the archive collection (described in section 2.2.1) of M.tuberculosis 
phenotypically resistant to INH, 90 isolates representing the three main lineages of 
M.tuberculosis found in Vietnam were selected: Beijing, Indo-Oceanic and Euro-
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American, 10 isolates of each genotype were selected which carried either a katG315 
mutation or a mutation in the inhA promoter or no identified mutation at either the 
katG and inhA regions. 
2.3.2 MIC test for INH 
This technique was developed by modifying the automatic DST of the 
BACTEC960 system (Becton Dickinson, USA). 
The BACTEC MGIT SIRE kit is a commercial phenotypic DST test which 
can be performed on either isolates or primary specimens. Based on the growth of 
M.tuberculosis in drug containing tubes (STR, INH, RIF, EMB) in comparison with 
control tube (without the drug), the system reports the drug susceptibility profile of 
tested isolates (section 2.1.5). Using the same reporting system, MIC was tested using 
4 drug-containing tubes with varying concentrations of only one drug and a control 
for COmparison of the growth. MIC was defined based on the lowest concentration of 
drug which inhibited the growth of M.tuberculosis. 
This technique was chosen in order to standardize the results through objective 
result reporting. 
Preparation ofINH stock 
Stock of INH (Sigma, USA) was prepared to a final concentration of O.II1g/ml, 
O.5I1g/rnl, 111g/ml, 211g/rnl, 411g/ml, 811g/ml, 1611g/ml and 3211g/ml in the MGIT media. 
INH was diluted in ELGA water, filtered to sterilize, and 320111 aliquots stored 
at -20°C until use. 
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Clean sterile tubes were arranged and labeled in appropriate order, set one 
included: Growth control (GC), 0.11lg/ml, 0.51J,g!ml, 1.01lg/ml, 2.01lg/ml of INH 
tubes; and set two included: GC, 4.01lg/ml, 8.01lg/ml, 161lg/ml, 321lg/ml of INH tubes. 
All isolates were tested with set one; only isolates which showed resistance to all INH 
concentrations in set one were tested with the higher concentrations in set two. The 
prepared INH solutions were thawed to room temperature before each use. One 
hundred microlitre of appropriated INH stock solution were added to the labeled 
MGIT tubes. Then 8001ll of OADC (supplied with SIRE kit) was added into each 
prepared MGIT tube. 
.. direct Inoculum dilute (1 :4) inoculum •• 
r'-'-' 
Day 0 Day 1 Day 2 Day 3 Day 4 Day S 
Figure 2.2: The process of inoculation dependent on the testing day after 
the test isolate became positive in MGIT. 
Dilution and inoculation: 
Isolates in the log phase were used for inoculation, having the number of post-
positivity day greater than 1 and less than 6 reported by BACTEC960 (Figure 2.2). 
The positive tubes were vortexed 30 seconds to mix well and left to stand for about 15 
- 20 minutes . 
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Isolates positive at day 1 or 2 were used directly for inoculation. Those with 
longer positive days (from day 3 to 5) were diluted 1:5 by transferring I ml organism 
suspension (avoiding clumps) to the prepared 4ml saline tube. The dilution was 
pipetted several times to mix and then used for inoculation. The purpose of this step 
was to bring the bacilli to a concentration between 0.8 x 105to 3.2 x 105 CFU/ml. Five 
hundred microlitre of this inoculum was used in drug contained tubes (4 tubes). 
In this 1 % proportion test of INH resistance, the control tubes should contain 
less bacilli, 1/100 the concentration of inoculation used in drug contain tubes. Thus 
the inoculation for GC tube was diluted by adding 100111 normal inoculum suspension 
into 9.9ml of sterile saline. This dilution was vortexed to mix and 500J.11 was used to 
inoculate GC tube. 
The tubes were capped tightly and inverted 2-3 times to mix well. Five tested 
tubes were installed into a 5 slots rack with SIRE code bar in the order of INH 
concentration: GC, O.lllg/ml, O.5I1g/ml, 1.01lg/ml, 2.01lg/ml for set 1; and GC, 
4.01lg/ml, 8.01lg/ml. 161lg/ml, 321lg/ml for set 2. The bar code of the rack was scanned 
and put into 5 indicated consecutive slots in BACTEC960 machine. 
Result interpretation 
The BACTEC system reports a drug susceptibility profile for the test organism 
based on the growth index in drug-containing media compared with the drug-free 
control tube. At the time the growth index of the GC tube reaches 400 units. the 
growth index of any drug-containing tubes is determined. If a drug-containing tube 
has a growth index of 400 or above. the isolate is reported as resistant. Results were 
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reported between 3 and 14 days post-inoculation. If a result is reported in less than 3 
days, a contamination event is likely to have occurred and if the growth control has 
not reached positivity within 14 days, an error has occurred with the inoculum 
concentration, or the bacilli are not viable. The MIC was categorized in 9 groups: 
susceptible to INH, resistant at O.II1g/ml, O.5I1g/ml, l.OI1g/ml, 2.011g/ml, 4.011g/ml, 
8.011g/ml, 1611g/ml or 3211g/ml of INH. 
2.3.3 Spoligotyping 
Spoligotyping is one of the earliest typing techniques for M.tuberculosis. This 
is a PeR-based method, which depends on the amplification of a highly polymorphic 
direct repeat (DR) locus in M.tuberculosis genome. The numbers of DR elements vary 
among different strains of M.tuberculosis and the region may also contain one or 
more IS6110 elements. Standard spoligotyping is used for detecting the presence or 
absence 43 variable spacers of known sequences in DR region which intersperse with 
the non-variable repeat sequence by h)bridizing the PCR amplified spacer DNA to 
the set of 43 oligo-nucleotides embedded on a membrane (Figure 2.3). Evolution of 
the DR region is unidirectional through loss of segments of DNA in the DR region. 
Re-acquision of spacers does not occur, although convergent evolution of 
spoligotypes is theoretically possible, there is little evidence that it has occurred. 
Spoligotyping was performed following the international standard protocol 
(Kamerbeek. Schouls et al. 1997), using the spoligotype membrane (Isogen 
Bioscience B.V., Maarsen, The Netherlands), incubated with streptavidin-peroxidase, 
and detected with the ECL system (Amersham, United Kingdom). PCR to amplify the 
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spacers between DRs of M.tuberculosis strains was done with primers: DRa: biotin-
5'GGTTITGGGTCTGACGAC and DRb: 5'CCGAGAGGGGACGGAAAC. The 
PCR reaction contained 15ug of genomic DNA, lOmM Tris pH 8.3, 50mM KCl, 
2mM MgCh, 200 J.lM dNTPs, 300nM of primer DRa and DRb and 0.5unit of DNA 
polymerase. The thermal cycling was carried out with an initial denaturing step of 
94°C for 3 minutes, followed by 20 cycles of 94°C for 1 minute, 55°C for 1 minute, 
72°Cfor 30 seconds and a final step at nOc for 3 minutes before holding at 4°C 
(Kamerbeek, Schouls et al. 1997). 
The PCR products were then denatured at 99°C for 10 minutes, cooled on ice 
immediately and transferred to the miniblotter for hybridization for 60 minutes at 
60°C. Any unbound PCR products were washed away and finally, bound products 
were detected by streptavidin-peroxidase and ECL development. 
____________ ~~~C~·~·~ __________ ... 4' 
1111111111111111111 1111111III1 II11II1 HlTRv 
11 1111I 111111 1II1111111111111111111 BCG 
11I11I111 Be~ng 
I1111111111I11111111111111111111 1111111 S2 
11I1111111111I1 I1111111II11111 1I11111 A 
11 11111I1I1111 I1111111111I111 1I11II1 B 
Figure 2.3: Representative spoJigotype patterns obtained using 43 spacers 
in M.tuberculosis. SpoJigotypes of H37Rv, BCG, a Beijing strain and 3 other 
cHnical isolates are shown. 
Note: this technique was performed by Vo Sy Kiet. 
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2.3.4 Statistical analysis for MIC 
Log-transformed MIC values were compared using analysis of variance 
(ANOV A). If there was a significant difference on ANOV A, pairwise comparisons of 
the groups was performed. As the global ANOV A acts as a 'gatekeeper', no 
multiplicity adjustment for the pairwise comparisons is necessary. As a sensitivity 
analysis. the Kruskal-Wallis test was used instead of parametric ANOV A. Two-way 
ANOV A was used for pairwise comparisons. 
All statistical analysis were performed using R. version 2.10.1 (R: A language 
and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.) with Dr 
Marcel Wolbers (Head of biostatistics. OVCRU). 
2.4 The influence of INH resistance on the outcome of TBM 
2.4.1 Archive samples for the analysis 
Patients enrolled into two consecutive studies of HIV-associated TBM who 
had M.tuberculosis isolated from the CSF were included in the analysis. 
The first study was an observational cohort study of 58 HIV-associated TBM 
admitted to the HTD, HeM city between November 2004 and September 2005 
(Torok, Chau et al. 2008). 
The second study was a randornized. double-blind. placebo-controlled trial of 
immediate versus delayed ART in adults with HIV-associated TBM (PI: Estee Torok. 
trial registration number: ISRCTN63659091). Two hundred and fifty three HIV-
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infected patients with TBM who were antiretroviral naive were randomly assigned to 
receive immediate or deferred (2 months) initiation of ART between September 2005 
and December 2008. TBM patients randomization was stratified according to the 
MRC grade I, 11 or ill of TBM at presentation. The primary trial end point was 9-
month mortality. The trial was conducted at two sites in HCM city: HTD and PNT 
hospitals (Torok, Yen et al. 2011). 
Both studies were approved by the Oxford Tropical Research Ethics 
Committee (OXTREC), the Institutional Review Boards of the participating hospitals 
and the Health Services of HCM city. 
2.4.2 Anti-tuberculous therapy 
According to PNT and Vietnamese NTP guidelines, TBM patients were given 
4 first-line antituberculous drugs daily: INH (Smglkg), RIP (lOmglkg), PZA 
(25mglkg), and EMB (2Omglkg). After 3 months, the patient continued to receive RIP 
and INH at the same dosage for a further 6 months. 
Intramuscular STR (20mglkg) was added for patients previously treated for 
TB, or if drug resistance was suspected due to clinical deterioration. Additional drugs 
or second-line antituberculous agents were not given as they were not routinely 
available in Vietnam. 
All patients were treated with adjunctive dexamethasone. A reducing dose of 
dexamethasone was administered on study entry, according to the grade of TBM at 
presentation (Torok, Yen et al. 2011). 
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2.4.3 Anti-retroviral therapy 
Antiretroviral treatment was not generally available in Vietnam at the time of 
the observational study and therefore only 7/58 patients in the fIrst cohort study 
received ART. All patients who survived to hospital discharge were referred to the 
National HIV Programme for HIV treatment and care, according to local procedures 
(Torok, Chau et al. 2008). 
In the RCT, ART or identical placebo tablets were commenced as soon as 
possible after study entry. The antiretroviral regimen was zidovudine 300mg, 
lamivudine 150mg (as a fixed dose combination tablet) and efavirenz 800mg (if taken 
with RIF) or efavirenz 600mg (if taken without RIF) taken daily. After 2 months all 
patients were receiving ART (Torok, Yen et al. 2011). 
2.4.4 TBM sample processing 
CSF samples were transferred to the laboratories at HTD and PNT for initial 
processing. Samples were stored securely in freezers at HTD and PNT prior to 
transfer to the OUCRU for further investigations and long term storage (archived 
samples). 
2.4.5 Statistical analysis of DK study 
We visualized survival by anti-TB drug resistance group or M.tuberculosis 
lineage, respectively, with Kaplan-Meier curves. Formal comparisons of 9-month 
survival between groups were based on the log-rank test. 
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Comparison of resistance was based on three prospectively defined resistance 
groups: fully susceptible or STR mono-resistance; INH resistance with or without 
STR-resistance; and MDR. We also performed exploratory analyses to determine if 
ignoring SM-resistance in the grouping was consistent with the study data. 
In addition, we compared the three groups with a Cox regression model with 
indicator variables for the different groups and adjustment for MRC TBM stage at 
presentation, CD4 cell count (log-transformed), and the cohort group (observational 
cohort study, RCT - immediate ART, RCT - deferred ART). The proportional 
hazards assumption of Cox regression was tested based on scaled Schoenfeld 
residuals. If it was violated for a covariate, we alternatively fitted separate (time-
dependent) regression coefficients for the intensive TB treatment phase (first 3 
months) and thereafter. 
Analyses were performed both with and without inclusion of patients 
receiving STR treatment. CD4 cell counts were missing for 18 subjects and TBM 
grade for one patient of the 186 participants included in the analysis and the adjusted 
Cox regression analyses were based on multiple imputation of missing covariates. 
All statistical analyses were performed with the statistical software R version 
2.l1.1 (R_DevelopmenCCore_Team 2010) and the companion R package mice 2.8 
(White, Royston et al. 2011). 
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2.5 The correlation of acetylator phenotype and NAT2 genotype 
2.5.1 Healthy volunteers for caffeine study 
The study was approved by OXTREC (reference number: 09 09). Participants 
had not taken any medication for at least one month prior to participation and were in 
good general health. Staffs at OUCRU and health care workers at HTD were invited 
to enroll in this healthy volunteer study through a presentation at the weekly academic 
meeting and information session. 
Data collection 
All volunteers were provided with a participant information sheet, given the 
opportunity to ask any questions, and if willing to participate in the study asked to 
sign a consent form and complete a questionnaire (Figure 2.4). 
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Section B - to be completed on caffeine metabolism day 
ILLNESS HISTORY - SECTION B 
1. Have you b~en sick in the last 2 wew? Yes O NoO 
2. Have you taken any prescription drugs in the last 2 Yes 0 NoO 
weeks? 
3. Have you drunk coffee. Coke. Pq>si. Red-Bull. Sting. YesO NoO 
tea Of chocolate in the last 3 days? 
- Coffee 1.. .2 ... 3 .. . >3 ... OlP(S) 
- Coke I Pq>si 1.. .2 ... 3 ... >3 ... can(s) 
- Red-Bull I Sting 1...2 .. . 3 . .. >3 ... can(s) 
- Tea 1.. .2 . .. 3 . .. >3 ... cup(s)lbottle(s) 
-Chocolate 1...2 . . . 3 ... >3 ... rup(s}ibar(s) 
4. Do you drink coffee? Yes 0 NoO 
If yes. how many cup of coffee a day do you drink? 
5. DD you drink alcohol? YasO NoO 
6. Do you smoke? YasO NoO 
If yes. how many cigarettes a day do you smoke? 
Figure 2.4: Questionnaire for caffeine metabolism study 
Sanwle collection 
Each volunteer was asked to provide an initial baseline urine sample, take two 
tablets of caffeine (lOOmg total dose) and provide another urine sample after 6 hours. 
Five mJ of blood was drawn into EDT A tubes (Beckton Dickinson, USA). Samples 
were stored in a fridge for no longer than 24 hours before DNA extraction or kept in 
freezer -20oe for further analysis. 
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2.5.2 Extraction of human chromosomal DNA from whole blood 
Nucleon Genomic DNA extraction kit (GE Healthcare, Amersham 
Biosciences) was used for DNA extraction. Blood was collected in sodium EDT A 
tubes (Becton Dickinson, USA) to prevent clotting. 
The extraction process was prepared by dispensing 20ml reagent A (lOmM 
Tris-HCl, 320mM sucrose, 5mM MgCh, I % (v/v) Triton X-lOO, pH 8.0) into 50ml 
Falcon tubes. Whole blood sample (5ml) was transferred into the falcon with a pasteur 
pipette, vortexed and left to stand at room temperature for 10 minutes. The Falcon 
tube was centrifuged at 1300rpm for 5 minutes before discarding the supematant. 
Two milliliters of reagent B (protein lysis buffer) was added to the pellet, vortexed for 
30 seconds and incubated at 37°C for 20 minutes. The solution was transferred to a 
15ml tube with addition of 500fll of 5M sodium perchlorate solution. The tube was 
tightly capped and mixed by inverting 7-10 times. Three milliliter of chloroform was 
added and mixed by inverting the capped tube until opaque and left to stand for 5 
minutes. Three hundred milliliters of Nucleon resin was gently added to the mixture 
without remixing the phases. The tube was capped and centrifuged at 2400rpm for 3 
min. 
After the centrifugation, the solution was divided in to three layers, 3ml of the 
top aqueous layer contain soluble DNA was carefully pipetted to a fresh ISml tube. 
Two milliliters of isopropanol was added to the new tube to precipitate the DNA. The 
tube was mixed well by inverting several times and left at -20°C for at least 30 
minutes before being centrifuged at 2400rpm for 10 minutes. The supematant was 
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removed by pouring-out gently. The remaining pellet was washed by adding 2 ml of 
cold 70% ethanol, centrifuging for 5 minute at 2400rpm and removing the ethanol 
solution. 
The tube was left to stand with the lid open at room temperature until the last 
traces of liquid had evaporated. Three hundred microliters of ELGA water or TE 
buffer was added to the tube, mixed by hand and left at room temperature for 2 hours 
or placed at 4°C overnight for the optimal resolution of the DNA. All extracted DNA 
were stored at-20°C for later analysis. 
Human DNA were used for genotyping NAT2 by sequengcing. The DNA also 
used to develop PeR-RFLP assay. 
2.5.3 MeaSUring caffeine metabolism in healthy volunteers 
Reagents 
1- methyluric acid (1 U), I-methylxanthine (1 X), 1,7 -dimethyluric acid (l7U), 
7-beta hydroxyethyltheophylline (J3-HT) (Internal Standard IS) were purchased from 
Sigma (Sigma-Aldrich, Singapore), 5-acetylamino-6-formylamino-3-methyluracil 
(AAMU) from SynFine Research (Richmond Hill, Canada). All other solvents and 
chemicals were purchased from Merck, Vietnam. 
Caffeine metabolites are quite complex that have more than one enzyme 
involve in the process. In order to measure the clearance process of caffeine by 
NAT2, we used the ratio of AAMU/(AAMU+IX+IU) to tell how fast of NAT2 
activities in comparison with other enzyme (mostly CYFIA2) (Figure 2.5). 
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H,C" /--XNH N "-I COCH, 
---... O~N NH, 
H 
Cllflelne 
CYP2AS (10%) ~ 
17U lU 
Figure 2.5: Caffeine metabolites 
HPLC perfOrmance 
The chromatographic apparatus (Merk, Vietnam) was composed of Hitachi 
modules: two L-2130 pumps. one L-2200 refrigerated autosampler. one column oven 
L-2350. and one diode array detector L-2455. The software EZ-ChromElite 
(EZChrom Elite for Hitachi Version 318b) was used to pilot the HPLC instrument and 
to process the data throughout the method validation and the sample analysis. 
The caffeine metabolites were separated on a Ascentis RP-Amide (250 mm x 
4.6 mm ID. 5~) column (Supelco. USA) equipped with an Ascentis RP-Amide 
guard column (20 mm x 2.1 mm ID. 51lJ11). This configuration allowed performance 
of the extractionless analysis of the caffeine metabolites from urine with the best 
selectivity. accuracy and precision. The mobile phase consisted of 20 mM acetic acid 
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(HAc), acetonitrile (ACN) and was delivered at a flow rate of I ml.min· l . For all 
caffeine metabolites and internal standard, a stepped gradient elution was developed 
using HAc-ACN (100:0) at 0 min -7 (96:4) at 2 min -7 (88:12) at 13 minutes 
maintained for 3 additional minutes. The chromatographic separation was performed 
at 55"C and monitored simultaneously at 264 nm for AAMU, IX, LS and 284 nm for 
1U and 17 U. 
Stock solutions of metabolites at a concentration of 5 mM were prepared 
separately in different solutions: AAMU, I X in 5.0 mM NaOH solution; 17U in 
NaOH 2.5 mM, I U in water-methanol (70-30 v/v). All metabolites needed the 
addition of 20 ~l NaOH IM to be dissolved completely. The stock solution was 
neutralized by adding 20 Jll HCl IM. All stock solutions were stored at -20'C and 
thawed prior to use. Sets of working solutions containing all metabolites (AAMU, IX. 
1 U, 17U) were diluted in water. These standard mixtures were diluted 10 times to 
achieve 5, 12.5, 25, 50, 125, 250 J.1M in blank urine (obtained from one healthy 
volunteer after 3 days xanthine-free diet) and were used for the calibration. 
For qUality control samples, working solutions were diluted 10 times in a 
blank urine to yield final concentration of 20JlM, lOOJlM and 200 ~M, corresponding 
to quality control at low (QCL), medium (QCM) and high concentration (QCH), 
respectively. 
P- hydroxyethyltheophylIine (P-HT) was used as an internal standard (IS). A 
stock solution of J>-HT at 1 mg/ml was prepared in water-methanol (70-30 v/v). Prior 
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to spiking the samples, a solution at 10 f.lglml was freshly prepared by dilution in 
water. 
One hundred microlitres of urine sample was added to 200 fJl of internal 
standard. After 20 s vortex mixing, 100 fJI of NaOH O.lN was added to the mixture to 
fully convert AFMU into AAMU. After 10 min of incubation at room temperature, 
100 f.ll of HCI O.lN was added to neutralize the excess of base. Finally an aliquot of 
10 fJI of sample was injected onto HPLC column. 
These experiments were conducted by Hoang Thi Thu, of the OUCRU 
pharmacology group. 
2.5.4 Statistical analysis 
R-package "mclust" was used for normal mixture mode ling via the EM 
algorithm. The number of components in the best-fitting mixture was chosen by the 
Bayesian information criterion (BIC). We considered both models with equal variance 
(denoted as "E" in the BIC plot) in each group and those with unequal variance 
(denoted as "V" in the BIC plot). Of note, this approach is statistically better justified 
than methods based on probit plots. 
The statistical tests were performed by Mann-Whitney test with Prism 5 for 
Windows, version 5.02. 
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2.5.5 PCR-RFLP for NAT2 genotyping 
PCR was done to amplify 628bp fragment of the second exon in human NAT2 
gene with two primers NATIFa (5'-CCAGTTAACAAATACAGTAC-3') and 
NATIR (S'-GAGTTGGGTGATACATACAC-3'). Each SOul of PCR mix contained 
SO-IOOng of genomic DNA (section 2.5.2), lOmM Tris pH 8.3, SOmM KCl, 2mM 
MgCh, 200 JlM dNfPs, 200nM of each primer and I Unit of Taq DNA polymerase. 
The amplified PeR run under the following thermocycling program: 95°C for 
Imin, follOwing by 30 cycles of9SoC for lO sec, 6SoC for 20 sec, noc for 40 sec and 
a final step of noc for Smin. A negative control (distilled water) was included in 
every run. 
After the PCR finished, Sui of PCR product was used to check for the present 
of PCR product by electrophoresis on 1% agarose gel at ISOV for 10 minutes. 
Then ISul of PeR amplicons were aliquoted into three separate PeR tubes, 
5U of the respective restriction enzyme was added to each small Eppendorf tubes: 
TspRI, TaqI and BamHI (New England Biolabs, USA) and the tubes were then 
incubated at the appropriate temperature: 65°C, 6SoC and 37°C, respectively, for 3 
hours. The products were electrophoresed on a 1.5% agarose gel for 2 hours before 
viSUalise under DV light. 
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Chapter 3 
Development of rapid diagnostic tests for MDR and INH resistance 
3.1 Background 
The rise of MDR TB, which is defined as M.tuberculosis resistant to at least 
INH and RIP, threatens the success of TB control programs in many regions of the 
world (WHO 1997; Zignol, Hosseini et al. 2006). It has been demonstrated that MDR TB 
can successfully transmit within a community (van Doom, de Haas et al. 2006; Sun, 
Lee et al. 2(07) and therefore early detection of infectious cases is vital to interrupt 
chains of transmission (Blower and Chou 2004; Cohen and Murray 2004). MDR TB 
is difficult to treat, with treatment durations of 18 months or longer, using more toxic 
and less potent second line drugs (Caminero 2006; Resch, Salomon et al. 2006). 
Further, the cost of treating a MDR patient is many times the cost for a TB patient 
infected with a fully susceptible strain even with the help of the Green Light 
COmmittee, which has negotiated significant reductions in second line drug costs for 
government programs (Gupta, Irwin et al. 2004; Resch, Salomon et al. 2006). 
Besides, detecting drug resistance, particularly MDR TB, before instigation of 
inappropriate chemotherapy reduces morbidity, mortality, economic costs and 
unnecessary treatment with ineffective drugs. Conventional, phenotypic DST only 
return results after several weeks of culture in MGIT or U media. 
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Two commercial molecular LPAs (Baltussen, Floyd et a1. 2005) for MDR TB 
are currently available: the INNO-LiPA RIF TB test (Innogenetics, Zwijnaarde, 
Belgium) (Morgan, Kalantri et a1. 2005) and the MTBDR-Plus kits (Hain Lifescience, 
Nehren, Germany) (Hillemann, Rusch-Gerdes et a1. 2007). The MTBDR-Plus LP A 
has replaced the MTBDR assay. These kits perform well in research settings (De 
Beenhouwer, Lhiang et a1. 1995; Cavusoglu, Turban et al. 2006; Makinen, Marttila et 
al. 2006; Somoskovi, Dormandy et al. 2006). The newly developed Xpert MTBIRIF 
test for use with the GeneXpert system (Cepheid, USA) is a cartridge-based real time 
PeR test. The Xpert test requires minimal sample processing by automatically 
performing the extraction, purification, concentration, amplification and identification 
of M.tuberculosis genes directly from clinical samples (Boehme, Nabeta et al. 2010). 
The Green Light Committtee and FIND have negotiated preferential pricing of these 
tests for high-burden or developing country settings. However, at over 5USD per test 
strip (MTBDRplus test,) or around 17USD per test cartridge (Xpert MTBIRIF,), the 
tests are currently too expensive to be used routinely on all TB patients in developing 
countries like Vietnam. Scale-up of the use of these tests has focused on high-risk 
groups for MDR TB, such as failure and relapse patients. It is necessary to develop 
low-cost techniques which are accurate, simple and rapid for the identification of drug 
resistant TB to allow early identification and treatment of MDR TB. 
It has been shown that RIF resistance is a surrogate marker of MDR, because 
RIP mono-resistance is rare in most settings, including Vietnam, (Van Rie, Warren et 
al. 2001; Johansen, Lundgren et al. 2003; Caws. Duy et al. 2006) therefore a 
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molecular technique for the rapid detection of RIP resistance can be used to screen for 
MDR TB. RIP mono-resistance occurs more frequently in HIV positive TB cases 
(Sandman, Schluger et al. 1999) and therefore in areas of high HIV prevalence, RIP 
resistance may not be applicable as a surrogate marker of MDR TB and confirmation 
of both RIF and INH resistance may be necessary to confirm MDR TB. 
Resistance to RIF is conferred by single-step mutation in the 81 bp RRDR of 
the rpoB gene which encodes the beta subunit of the RNA polymerase. Single base 
substitutions, insertions or deletions in the rpoB gene can lead to RIF resistance 
(GilIespie 2(02). 
Studies in the literature have used various molecular mutation detection 
techniques to identify MDR TB, such as real-time PCR (Sajduda, Brzostek et al. 
2004; Wada, Maeda et al. 2004), Single Strain Conformation Polymorphism (SSCP) 
(Bobadilla-del-Valle, Ponce-de-Leon et al. 2(01) or sequencing to detect mutated 
nucleotides (Kapur, Li et al. 1994; Cavusoglu, Hilrnioglu et al. 2(02). However, these 
techniques require expensive equipment and technical expertise. 
Multiplex allele specific (MAS) peR is the most inexpensive method that has 
been deSCribed (Mokrousov, Otten et al. 2(02). In a previous study in Vietnam, we 
have demonstrated that the mutations in RRDR of the rpoB gene are located mostly at 
three hot spot codons 531 (43%),526 (31%) and 516 (15%) (Figure 3.1), concurring 
with prevalence reported worldwide (Van Rie, Warren et al. 2001; Gillespie 2002). 
To minimise post-amplification processing, we used 3 MAS PCR reactions for each 
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isolate, with two outer primers as positive control for each sample and one inner 
primer to detect the mutation. 
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Figure 3.1: The distribution of mutations in rpoB gene in M.tuberculosis 
in Our RIF resistance sample collection (Caws, Duy et al. 2006). 
Although detection and treatment of MDR TB has become a priority of 
international TB control efforts in the last decade, a focus on RIF resistance alone is 
inadequate since patients with other forms of ftrst-line drug resistance are also at 
higher risk of treatment failure and INH resistance is a precursor to MDR TB. The 
prevalence of INH resistance is always higher in comparison with MDR. In Vietnam 
particularly, the prevalence of INH resistance is extremely high, around 25% in new 
smear positive TB patients in HeM city (Quy, Buu et al. 2(06). Methods for the 
detection of INH resistance which can be applied in resource limited, high-burden 
settings are urgently needed. 
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There are various single mutations related to INH resistance which are mostly 
located in katG. inhA and ahpC as described in the literature (Marttila, Soini et aJ. 
1996; Telenti, Honore et al. 1997; Mokrousov, Otten et al. 2002; Silva, Senna et al. 
2(03). However, the role of some mutations in ahpC is unclear (Deretic, Song et al. 
1997; Baker, Brown et al. 2(05). The role of mutations in kasA in INH resistance 
which were previously reported (Slayden and Barry 2(02) has now been disproven 
but it is possible other mutations in kasA may be involved (Lee, Lim et al. 1999; 
Larsen, Vilcheze et al. 2(02). The study reported in this chapter focused on the two 
most dominant mutations for INH resistance in M.tuberculosis, one at codon 315 in 
katG (katG315) and another at the loci 15 upstream of the inhA promoter (inhA-15) 
(Guo, Seet et al. 2006). With the aim of developing a new test for routine use, a novel 
multiplex-PeR was developed, which is specific for M.tuberculosis and INH 
resistance conferring mutations at katG315 and inhA-15. 
The distribution of mutations responsible for resistance in M.tuberculosis 
varies geographically but the reasons for this are not known. A previous investigation 
of 104 RIF resistant isolates and lOO consecutive INH resistant isolates showed the 
frequency of these mutations in the Vietnamese M.tuberculosis population (Caws, 
Duyet al. 2006), and was used to develop and to evaluate the tests. 
The sensitivity and specificity of these two multiplex PCRs were compared 
with the commercial reverse-hybridisation MTBDR test. Fifty fully susceptible 
M.tuberculosis isolates were used as controls. The MTBDR test detects both RIF and 
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INH resistance in one strip. Phenotypic DST results were considered the gold-
standard. 
AIMS: 
1) Develop MAS-PCR test for RIP resistance. 
2) Develop MAS-PCR test for INH resistance. 
3) Evaluate these novel tests in comparison with commercial LPA using an 
archive collection of M.tuberculosis strains with well characterised DST 
profiles. 
3.2 Results 
3.2.1 Development ofMAS-PCR to detect RIF resistance 
Based on a previous study of the mutation prevalence among 104 clinical 
isolates resistant to RIF collected in HCM city, Vietnam (Caws, Duy et a1. 2006), 
88.5% of mutations for RIF resistance were located in three codons 531,526 and 516 
in the rpoB gene. Therefore a test was developed to analyse these 3 hot spot codons. 
Six primers were designed to target these three codons in both directions on 
rpoB template of H37Rv. These primers were designed with Primer Express version 
2.0 software (Applied Biosystems Inc, USA) to anneal to wild type DNA only but not 
to mutated strains. After serial tests on DNA of clinical isolates which had been 
sequenced and stratified as wild type and mutated isolates, three inner primers were 
selected (Figure 3.2). 
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Figure 3.2: Location of primers for MAS-RIF in the RRDR of the H37Rv rpoB gene. 
a, e: outer primers amplifying 350bp product. 
b,c,d: inner primers to detect wild type at codon 516,526 or 531 
A multiplex PCR was designed with the following principle: 
For RIF resistance, three different multiplex PCRs were used in order to identify mutation at the three hot 
spot codons. Each MAS- PCR was optimized individually for the best annealing temperature, magnesium and 
primer concentration (Figure 3.3, 3.4.3.5). 
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Figure 3.3: Gradient of temperature in MAS-RIF with RIF2R primer to 
identify mutation strain (strain 765) from wild-type strain (H37Rv) at codon 516 
Figure 3.4: Gradient of temperature in MAS-RIF with RIF4R primer to 
identify mutation strain (strain 675) from wild-type strain (H37Rv) at cod on 531 
With the final PCR condition that we found as described in method chapter, 
section 2.2.2, the MAS-PCR can work at a wider range of temperature (Figure 3.5). 
For tlti s reason, we could being able to use a same PCR programme for three MAS-
RIF reactions. 
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Figure 3.5: Gradient of temperature in MAS-RIF with RIF3F primer to 
identify mutation strain (strain 681) from wild-type strain (H37Rv) at codon 526 
After individual optimization al l three multiplex PCRs were combined for the 
final optimization using a single PCR program, in order to aUow the test to be 
performed in the single PCR programme, improving work-flow and practicality 
(Figure 3.6). 
Figure 3.6: Results of MAS-RIF peR on archived strains of 
M.tuberculosis resistant to RIF. Each strain was tested with three consecutive 
reaction for mutations at codon 516,526 and 531. 
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Each of three MAS-RIF reactions was performed with the same outer primers 
to amplify the RRDR of rpo8, and one of three inner primers targeted to wild type at 
hot spot cadons 516,526 and 531 (Figure 3.2). 
The 350bp fragment of the rpoB gene was amplified using outer primers 
RPOBF (5'-GGGAGCGGATGACCACCCA-3') and RPOBR (5'-GCGGTACG-
GCGTfTCGATGAAC-3'). The inner primers used to detect mutations at codon 5 16, 
526 and 531 were RIF2R (5'-GACAGCGGGTTGTTCTGGT-3'), RIF3F (5'-
CCGCTGTCGGGGTAGACCCA-3') and RIF4R (5'-CCGCCGGGCCCCATCG-
CCG-3'), respectively (Method chapter, section 2.2.2). The primers were designed 
using Primer Express version 2.0 software (Applied Biosystems Inc., CA, USA). 
The results were read with 2 bands for wild type isolates and only one band 
for mutant isolates (Figure 3.7). 
Sample 
Codon* 
Figure 3.7: Amplicon profiles in MAS-RIF of isolates carrying mutations 
at each site. 
*(a) : codon 516; (b) cadon 526; (c) codon 531. Sample: (1) mutation at codon 516; 
(2) mutation at codon 526; (3) mutation at codon 531; (4) cadon 516 and 526 
mutated; (5) wild type control sample; and (6) negative control; (M) l00bp ladder. 
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3.2.2 Accuracy ofMAS-RIF compared with MTBDR LPA 
The sensitivity and specificity of this MAS-RIF were calculated in comparison 
with the commercial MTBDR assay (Hain Lifesciences, Germany) using conventional 
1% phenotypic DST as the gold standard. Any discrepant results were evaluated by 
analysis of sequencing data to determine if mutations were present which had not 
been detected by the molecular assays. 
The results of the MAS-RlF, sequencing and commercial MTBDR tests are 
summarized in Table 3.1. Sequencing showed that among 104 RIF resistant isolates, 
92 isolates (88.5%) had mutations located at the 3 target codons: 531 (43%), 526 
(31%),516 (15%). Eight (7.7%) had mutations at other codons in the RRDR of the 
rpoB gene. Four (3.8%) had no mutation in the regions which were sequenced. 
Using the MTBDR test, 97 isolates (93.3%) were detected as resistant to RIF. 
Of the 7 resistant isolates returning a susceptible result, 4 had no mutations in RRDR. 
(Table 3.1), 2 had mutations outside the location of the primers (L533P and VI46F) 
and the remaining isolate had three nucleotides inserted at the end of a probe (514::F), 
thus hybridisation still occurred, returning a wild type result. The sensitivity and the 
specificity of MTBDR for RIF resistance was 93.3% [95% Cl 86.6-97.3%] and 100% 
[95% Cl 92.9-100%], respectively. In this selected sample set, the positive predictive 
value (PPV) was 100% [95% Cl 96.2-100%], and a negative predictive value (NPV) 
was 87.7% [95% Cl 80.0-93.6]. 
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Table 3.1: Comparison between MAS·RIF test and commercial MTBDR 
LPA in 104 RIF resistant isolates. 
Number of MTBDR test MA5-RIF test Mutation isolates 
Res SellS Res Sens 
S531L 46 46 0 45 1 
H526D/F/URlSN 28 28 0 28 0 
D516V 9 9 0 B 1 
D516V, H526Q 1 1 0 1 0 
D516A, H526N 1 1 0 1 0 
L511P, H526N 1 1 0 1 0 
Q513K, H526D 1 1 0 1 0 
D516G, 
1 1 0 1 0 522::SGL 
D516A L533P 1 1 0 1 0 
Q513K1L 3 3 0 0 3 
D516G, L533P 2 2 0 0 2 
L511P,D516G 1 1 0 0 1 
L511P, S512G 1 1 0 0 1 
L533P 2 1 1 0 2 
514::F 1 0 1 0 1 
V146F 1 0 1 0 1 
WT 4 0 4 0 4 
Total 97 7 87(83.65%) 17 104 L93.27%) (6.7%.1 116.3%.1 
The MAS·RIF test detected 87/104 (83.7%) of RIF resistant isolates. Of the 17 
discrepant results, 4 of the isolates carried no mutations in any sequenced region, 
eight had mutations in the rpoB gene but outside the three target codons (QSI3KIL 
x3, L533P x2, 514::F xl, VI46F xl and L511PISSI20 xl), two showed evidence of a 
mixed population of resistant and susceptible isolates on sequencing with double 
peaks at a single allele (Figure 3.8), which would be defined as wild type by the 
MAS-RIF test due to the generation of the wild-type band. The remaining three 
isolates had a D5160 mutation which primer RIF2R hybridises weakly with, 
generating a weak wild-type band and returning a false-susceptible result. 
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Figure 3.8: Double peak in the sequencing trace from sample DQ786 
showing a heterogeneous population of susceptible strain (wild-type, D516) and 
resistant mutant (D516V). 
The specificity of the MAS-RIF test was 100% [95% Cl 92.9-100%] with no 
sensitive isolates returning a false-positive resistant result (Table 3.2). Sensitivity was 
83.7% [95% c.1. 75.1-90.2%]. The PPV and NPV for RIP resistance in this sample 
set were 100% [95% Cl 85.8-100%], and 74.6% [95% C.I. 65.3-83.1 %], respectively. 
Table 3.2: Sensitivity of MAS-RIF and MTBDR with reference to 1 % 
conventional phenotypic DST as gold-standard. 
Conventional DST MAS-RIF MTBDR 
Resistant Sensitive Resistant Sensitive 
RIP 
Resistant (104) 87 (83.7%) 17 97 (93.3%) 7 (6.7%) 
Sensitive (50) 0 50 (100%) 0 50 (100%) 
Resistant (132) nla nla 109 (82.6%) 23 (17.4%) 
INH 
Sensitive (22) nla nla 0 22 (100%) 
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3.2.3 Development of MAS-PCR to detect INH resistance 
The majority of INH-resistant M.tuberculosis isolates carry mutations at either 
katG315 or inhA-15, although the proportion of each mutation varies geographically 
(Guo, Seet et al. 2006). A previous investigation of 100 consecutive INH resistant 
isolates showed that 90% of INH resistant isolates in Vietnam have at least one of 
these two mutations (Caws, Duy et al. 2006) 
A multiplex PeR to detect INH resistance (MAS-INH) was designed with 
three primer pairs named as HSP65Fl - HSP65R2, katG2F - katGP6, TB92-
inhARmut (Table 2.3). One pair targets hsp65 which is specific for M.tuberculosis 
and serves as the control. A second primer pair targets the inhA promoter region, with 
the reverse primer designed to detect mutation C-15T in this region. The third primer 
pair is located inside the katG gene where the forward primer will yield a PCR 
product if the isolate is wild type (Figure 3.9). 
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Figure 3.9: The principle of the MAS-INH test. 
Three primer pairs located on three different regions of the M.tuberculosis 
genome. The small arrows show the position of the primers. The cross over the 
arrow bead shows the lod at which a mismatch occurs and returns a 
disappearing band when the tested isolate carries any mutations at this position. 
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All primers were designed using Primer Express version 2.0 software (Applied 
Biosystems, USA). The specificity of the primers to M.tuberculosis was tested in-
silico and in the laboratory with some common enterobacteria: Chryseomonas LuteoLa, 
KLebsiella spp., KlebsieLla oxytoca, KLebsiella pneumoniae, E. coli, Enterobacter 
cLoacae. Citrobacter freundii, Pantoea spp. and atypical mycobacteria M.avium-
intracellulare. (Figure 3.10) 
Figure 3.10: Specificity of MAS·INH tested with different bacterial 
species. 
Two clinical M.tuberculosis (lanes 1,2): BCG (lane 3): M.avium·intracellulare 
(lane 4); Chryseomonas luteola (5): Citrobacter freundii (6): E. coli (7): 
Enterobacter cloacae (8): Klebsiella oxytoca (9): Klebsiella pneumoniae (10): 
Klebsiella spp. (11): Pantoea spp. (12); negative sample (13). 
Serial dilution of genomic DNA showed O.lSng of DNA of genomic DNA is 
required to obtain reliable identification of mutations (Figure 3.11). 
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Figure 3.11: Results of MAS-INH test using different genomic DNA 
concentrations 
Lanes 1,5: O.15ng 
Lanes 3,7: O.OO15ng 
Lanes 2,6: O.015ng 
Lane 4, ladder lOObp. 
Lanes 1,2,3: DNA from clinical isolate 694 
Lanes 5, 6, 7: DNA from clinical isolate 721. 
After optimization, the protocol for MAS-INH was established and described 
in Method chapter, section 2.2.3 
This PCR yielded three bands after electrophoresis on agarose 2% for 40min 
at 140V. The largest band of 656bp represents hsp65 of M.tuberculosis and serves as 
a control for the presence of M.tuberculosis in the sample. The second band of 329bp 
represents isolates with a wild type katG315, thus the isolates without this band carry 
a katG315 mutation, determining INH resistance. The lowest band of 174bp 
represents isolates carrying mutation inhA-15 in the promoter, which also confers lNH 
resistance (Figure 3.12). 
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Figure 3.12: Agarose gel electrophoresis of PCR amplicons from 
multiplex PCR for INH resistance. 
Lane 1: Isolate with mutation at inhA-15; 
Lanes 2, 5, 7: Isolates have wild-type at katG315 
Lanes 3, 4, 6, 8: Isolates with mutation at katG315; 
Lane 9: Isolate with mutation at both katG315 and inhA -15 
Lane 10: H37Rv (l5pg) 
L: 100bp ladder. 
Lane 11: M. avium intracellulare 
3.2.4 Accuracy of MAS-INH in comparison with MTBDR and MTBDRplus 
LPAs. 
All sensitivities and specificities were calculated in comparison with the gold 
standard of conventional 1% phenotypic DST. Discrepant results were evaluated by 
analyzing sequencing data. 
The results of MAS-INH, commercial MTBDR test and sequencing are 
summarized in Table 3.3. The fIrst 100 consecutive INH resistant isolates were 
sequenced in the katG gene, among which 21 isolates were wild type and were 
therefore further sequenced in the inhA, and oxyR-ahpC regions (Caws, Duy et a1. 
2(06). In general, 78 isolates carried mutations at katG315. Ten isolates which did not 
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have any mutation in the !wtG region carried a C -15 T mutation in the inhA promoter. 
One isolate did not give PCR product but had a M.tuberculosis specific spoligotype. 
This sample was retested by PCR with alternative primer sets (Table 3.4) covering an 
expanded region flanking the !wtG gene, but still no PCR product was obtained and 
this isolate was thus categorised as containing an unconfirmed !wIG whole-gene 
deletion. 
Table 3.3: Comparison of MAS-INH test with sequencing and the 
commercial tests MTBDR and MTBDRplus in 100 phenotypically INH resistant 
clinical isolates 
No. of MTBDR Sequencing Sequencing 
isolates katGeene inhA Rene mut atkatG 
71 
2 
2 
1 
1 
1 
1 
10 
1 
10 
Total 
100 
S315T N/A 71 
S315 I N/A 2 
S315N N/A 2 
S315G N/A 1 
S315T N/A 1 
T308T 
Delt N/A 0 
S315T N/A 1 
WT C -15T 0 
WT WT* 0 
WT WT 0 
78% 10% 78% 
(*: two peaks were detected in sequencmg results 
t: deletion was defined by PCR) 
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MTBDRplus MAS-INH 
kaIG inM katG inhA 
71 0 71 0 
2 0 2 0 
2 0 2 0 
1 0 1 0 
1 0 1 0 
1 0 1 0 
1 1 1 1 
0 10 0 10 
0 1 0 1 
0 0 0 0 
79% 12% 79% 12% 
90% 90% 
Table 3.4: Primers used to amplify the region flanking suspected katG 
whole-gene deletion. 
Primer Sequence PCR length 
PI Marttila AAC GGC TIC CTG TIG GAC GAG 24S8bp 
PlO Marttila GGG TCT GAC AAA TCG CGC CG 
katGw2FI GTC CTC TAT ACC GGA CTA CGe 2899bp 
katGwl!:RI TCG CAC ATC CAG CAC ATI TC 
katGwl!:F2 TAC TGG GGT CT A TGT CCT GA 2571bp 
katGw2R2 ATG AGe ATT ATC CCG TAC AC 
The MTBDR test detected all 78 mutants out of 100 phenotypically INH 
resistant isolates. All 50 phenotypically INH susceptible isolates had a susceptible 
result on MAS-PCR. Thus, the specificity and the sensitivity of the test for INH 
resistance were 100% [95% Cl 92.9-100%], and 78% [95% Cl 68.6-85.7%], 
respectively. 
The MTBDRplus assay detected all 90 mutants out of 100 INH phenotypically 
resistant isolates. All 50 INH susceptible isolates gave a susceptible result; the 
sensitivity and specificity of the MTBDRplus assay for INH resistance is therefore 
90% [95% Cl 82.4-95.1 %] and 100% [95% Cl 92.9-100%], respectively. 
The MAS-INH PCR test detected 79% (79/100) INH resistant isolates based 
on mutations in katG31S. In addition, this test also detected 12% (121100) INH 
resistant isolates based on mutations at inhA-15. One of these isolates was found 
carrying both mutations in katG and inhA genes. Another isolate showed a discrepant 
result between MAS-INH and sequencing, the former test found only a mutation in 
inhA, when a double peak at this upstream position was found by sequencing, as a 
result of heterogeneous infection For the MAS-INH PCR test, the overall sensitivity 
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and specificity were 90% [95% Cl 82.4-95.1%] and 100% [95% Cl 92.9-100%J, 
respectively (Table 3.5). 
Table 3.5: Number of isolates detected by MAS-INH test and 
MTBDRplus in comparison with phenotypic DST. 
Phenotypic test MAS-INH MTBDRplus 
Resistant Sensitive Resistant Sensitive 
Resistant (100) 90 (90%) 10 90 (90%) 10 
INH 
Sensitive (50) 0 50 (100%) 0 50 (100%) 
Resistant (78) N/A N/A 74 (%) 4 
RIF 
Sensitive (72) N/A N/A 0 72 (100%) 
3.3 Discussion 
Neither molecular test was 100% sensitive for the detection of drug resistant 
TB, however both the MAS-PCR assays and the LPAs are 100% specific and 
therefore useful as rapid detection tests for positive identification of RIF resistance 
and by proxy for MDR TB (for MAS-RIF) or identification of INH resistance (for 
MAS-INH). A negative result from either test cannot be used to "rule-out" drug 
resistant TB. 
Commercial LPAs, such as MTBDR and MTBDRplus, have been endorsed 
for use on smear positive sputum by WHO for use in high-burden settings, following 
effective demonstration projects in South Africa (WHO 2008). The MTBDRplus test 
strips are one of the technologies in the FIND portfolio, which aims to evaluate novel 
116 
diagnostic technologies for poverty-related diseases and promote uptake of those that 
are effective through public-private partnerships. However, the cost of these tests is 
around 5USD/test strip under preferential pricing for NTP of high burden countries. 
Wide-scale application of the test, with associated labour and infrastructure costs is 
not currently sustainable on a large scale for routine use of this kit in most developing 
settings, such as Vietnam. Therefore the need for cheaper, widely applicable routine 
screening tests remains. 
3.3.1 MAS-RIF 
In comparison with MAS-RIF, the commercial MTBDR test is more sensitive 
(93.3% vs. 83.7%) and allows the direct detection of INH resistant TB, directly 
confrrming the diagnosis of MDR TB in the majority of cases (n=801l 02, 78.4%). The 
MTBDR test used in this study was only able to detect INH resistance mutations at 
katG3l5. The new version of this test, MTBDRplus (Hillemann, Rusch-Gerdes et al. 
2007), has additional probes for mutations at inhA-15 (the 2nd most common INH 
resistance mutation) and for additional regions of the rpoB RRDR. Sensitivity for 
MDR TB detection should therefore be higher with the MTBDRplus test. The MAS-
PCR test evaluated here offers several advantages over the Hain test LPA in a high 
volume setting. Firstly, the cost for a batch of 10 samples is around 16USD using 
reagents from local suppliers without bulk discounts (1.6USD per sample), excluding 
salary and capital equipment costs. The equipment required is basic PCR equipment-
a thermocycler, gel electrophoresis equipment and UV trans-illuminator, which is 
now available in many reference TB laboratories. There is minimal post-amplification 
processing involved, considerably less hands-on time and the MAS-PCR does not 
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require adherence to a strict time protocol for post-amplification processing, which 
increases flexibility to incorporate the test into a routine diagnostic laboratory 
schedule. After DNA extraction, the MAS-PCR can be completed in two hours, 
whereas the MTBDR test requires 6 hours of post-amplification processing (including 
peR, electrophoresis and hybridisation). 
The performance of the MAS-PCR test in routine use as an MDR detection 
tool should be evaluated both on cultures and directly on clinical samples. However, 
molecular tests are only appropriate diagnostic tools in laboratories which have 
sufficient resources and expertise to implement quality control and assurance, 
particularly regarding contamination. 
There were 13 discrepant cases between sequencing and rpoB MAS-PCR. 
Eight of these isolates have mutations outside the three hot spot codons 516, 526 and 
531. Three had a D516G mutation, which is not detected by this test. The two 
remaining isolates probably contained a heterogenous population of sensitive and 
resistant isolates as they had a double peak at a resistance allele on the sequencing 
trace (Figure 3.8). These isolates were defined as wild type by the MAS-PCR test due 
to generation of the wild-type band. The MTBDR test is able to detect the resistant 
popUlation in these isolates, as hybridisation with the resistant band will occur. It is 
likely that for clinical purposes these isolates should be treated as resistant because a 
resistant popUlation is emerging. However it is possible that the patient may be 
successfully treated on a standard regimen, particularly if the organism remains lNH 
sensitive, therefore the clinical implications of such results remain unclear. 
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Molecular tests will not have 100% accuracy until all the relevant mutations 
have been described. Thus, a sensitive result returned by a molecular test cannot yet 
be used to exclude RIP resistance. Ideally DST should be performed on every patient 
at the time of diagnosis, however in high volume developing settings where this is not 
feasible priority should be given in cases where the index of suspicion is high, such as 
HIV positive patients, MDR contact cases and re-treatmentl relapse cases, where a 
susceptible result returned by molecular screening methods should be confirmed by 
DST or other phenotypic methods. However, with high specificity (100%), molecular 
techniques allow the early detection of MDR cases, potentially reducing morbidity, 
mortality and interrupting chains of transmission, when combined with effective 
MDR treaUDent programs. 
3.3.2 MAS.INH 
The sensitivity and specificity of both MTBDRplus and the MAS-INH test 
were 90% and 100% in identify INH resistance. respectively against conventional 
phenotypic DST. 
The convenience of this MAS-INH test is that it can detect the two most 
common mutations in one reaction. One pair of primers targets hsp65 gene. which is 
specific for M.tuberculosis. This primer pair was used as a control band of the 
reaction as well as the presentation of the pathogen in samples. This primer pair 
showed specific for M.tuberculosis when it yielded no specific product on other 
bacteria, such as M.avium and M.fortuitum. 
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The MAS-INH detected 79% (791100) INH resistant isolates based on 
mutations in katG315 and detected another 12% (12/100) INH resistance based on 
mutations at inhA-15 promoter. One of these isolates was found carrying both 
mutations in katG and inhA genes. Thus, the total detection rate rose up to 90%, much 
higher than 78% in commercial MTBDR test. 
One study recently looking at other regions in katG identified many mutations 
at codon 4 of katG (Siqueira, Freitas et al. 2(09). This indicates that the resistant 
isolates which do not carry any mutation at katG315 nor inhA-15 may carry mutations 
elsewhere in katG, outside the investigated area. 
The multiplex-PCR test is a simple single PCR test which will give the result 
of INH resistance after 2 hours. In addition, because of the considerable difference 
between the lengths of PCR products in each sample, the electrophoresis needs only 
20-40 minutes to report a clear result. The performance is simple and can be done in 
any general molecular laboratory with appropriate quality control measures. 
Several MAS-PCR tests have been described and evaluated (Mokrousov, 
Otten et al. 2002; Herrera-Leon, Molina et al. 2(05). However, the techniques either 
did not detect mutation -15 C~T in inhA promoter, or detected only mutation G944C 
at codon katG315. Thus, detection rate of mutations in INH resistance of these tests 
would be lower than this multiplex-PCR. The MAS-PCR described here will 
additionally detect other rarer mutations at katG315, thus increasing the sensitivity 
(+6% in this study). 
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This multiplex-PCR test requires 0.15ng of chromosomal DNA to amplify and 
identify the mutations correctly. Increasing the number of cycles in the thermocycling 
program will increase the sensitivity of the test. but face a higher risk of 
contamination in the laboratory. 
This test could potentially be used to screen for INH resistance in 
M.tuberculosis isolates and. if used in combination with a MAS-PCR for RIF 
resistance, to identify MDR TB. WHO recommends adding EMB to the continuation 
phase for TB treatment in regions with a high prevalence of INH resistant TB 
(2HRZEJ4HRE) (WHO 2009) but the recommendation is based on expert opinion 
only. Cattamanchi et af. compared the difference in outcome of fully sensitive and 
INH mono-resistance showed no difference in two groups (Cattamanchi, Dantes et al. 
2009), however, the comparison was biased with different regimens and longer 
periods of treatment in INH mono resistant cases. The WHO drug resistance data 
shOWed that the prevalence of INH resistance is extremely high in relapse cases (50%) 
(WHO 2009), suggesting that INH resistance could probably reduce treatment 
success. The new WHO treatment guideline recommends that countries with high 
prevalence of INH resistance should used EMB in addition to RIF and INH in 
continuous phase (even with weak evidence). The daily dose in continuous phase 
could help by reducing the risk of INH resistance development during TB treatment 
(WHO 2009). The most effective regimen for the treatment of INH-resistant TB is 
still unknown. Patients carrying INH resistant strains are likely to have a higher risk 
of developing MDR on standard NTP treatment regimens and should be monitored 
more intensively for treatment failure and acquired MDR TB. 
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To sum up, two multiplex-PCRs were successfully developed that can 
differentiate wild type and mutated isolates. By combining the MAS-PCR for INH 
test described here (Tho, Lan et al. 2011) with MAS-PCR for RIF resistance (Tho, Ha 
et al. 2008), MDR TB can be accurately detected in M.tuberculosis isolates. 
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Chapter 4 
The association of katG315 mutations and Beijing lineage with 
higher MIC to INH 
4.1 Background 
INH is a key drug in TB treatment with excellent bactericidal activity which is 
responsible for the rapid reduction in bacterial load during the first few days of 
treatment on standard flfst line therapy. 
From a pharmacological perspective, the effectiveness of INH is described by 
the ratio of Cmax:MIC, thus INH activity is highly dependent on the MIC of the 
M.tuberculosis isolate to INH (Srivastava and Gumbo 2011). 
The MIC is defined as the lowest concentration of antibiotic which inhibits the 
growth of a microorganism. Mutations for INH resistance which increase the MIC 
arise spontaneously in M.tuberculosis with a frequency of approximately I in 106 to 1 
in 108 and are selected under drug pressure. The two most commonly occurring INH 
resistance mutations are katG315 and inhA-15, as described in the introduction 
(section 1.18.2). There are a number of mutation types at katG gene which confer 
different level of resistance to INH in M. tuberculosis. While mutation of katG 
(normally at codon 315) confers resistance to INH at a relatively high MIC, deletion 
of the whole katG gene (normally rare with <l % of INH resistant clinical isolates) 
confers complete resistance to INH since the catalase peroxidase enzyme (encoded by 
katG) that is required for activation of the pro-drug is removed. Moreover, mutation 
in the inhA promoter has been shown to confer an intermediate level of resistance to 
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INH, approximately 1-2ug/ml (Lavender, Globan et al. 2(05). The relative 
proportions of katG and inFrA mutations among INH resistant isolates appears to vary 
geographically and the reasons for this are still unclear (Lavender, Globan et al. 2005; 
Caws, Duy et al. 2006; Dalla Costa, Ribeiro et al. 2009). In Vietnam, we have 
described a very high prevalence of the katG315 mutants among phenotypically INH 
resistant isolates from patients with pulmonary TB (79%). 
This dominant mutation in the INH resistant M.tuberculosis population may 
suggest that the katG315 has a relatively low fitness cost in this setting, which has 
been shown in a number of in vitro and epidemiological studies (van Soolingen, de 
Haas et al. 2000; Pym, Saint-Joanis et al. 2(02). 
In HCM city, the Beijing lineage of M.tuberculosis is responsible for 40% of 
TBM cases in HIV-uninfected patients and is associated with MDR TB (Caws, 
Thwaites et al. 2(06). It has been hypothesized that this lineage is 'hypervirulent' and 
may have a mechanism or intrinsic property that renders its less susceptible to 
chemotherapy (de Jong, Hill et al. 2008; Hu, Ma et al. 2010). Many studies have 
shown that the Beijing lineage is associated with the katG315 mutation for INH 
resistance, in preference to the inhA promoter mutation (Hu, Hoffner et al. 2010). We 
hypothesized that the Beijing lineage may either preferentially develop the katG315 
mutation or retain the mutation which increased frequency once it is acquired, due to 
a lower relative fitness cost of this mutation in the Beijing lineage backbone. As a 
result, the Beijing lineage could be associated with high MIC for INH resistance 
compared to INH-resistant strains of other lineages. The association of the Beijing 
lineage and high MIC to INH, if demonstrated, could help to explain the high 
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prevalence of this specific lineage in Vietnamese TBM patients and the high 
prevalence of primary INH resistance in this setting. 
The relationships between mutations conferring INH resistance and lineages 
of M.tuberculosis to MIC for INH were investigated in this chapter. 
Aims: 
1) Determine the association between MIC to INH and specific mutations 
conferring INH resistance. 
2) Determine if the lineage backbone of an INH resistant M.tuberculosis 
isolate affects the MIC independently of the mutation. 
4.2 Results 
Seventy two archived isolates of 1NH resistant M.tuberculosis from pulmonary 
TB and TBM patients admitted to the HTD from Feb 2001 to Jan 2005 were analysed 
in this study. 
Seventy two sequenced isolates were taken from previous studies (see 
materials and methods section 2.3.1), of which 33 isolates carried a katG3i5 
mutation, 17 isolates had a mutation at mM-i5 and 22 isolates had no mutation at the 
sequenced regions (katG, mM promoter, oxyR-aphC intergenic region). In this 
sample set, 32 isolates were Beijing lineage, 25 isolates were Indo-Oceanic lineage 
(East-African-Indian by spoligotyping) and 15 isolates were Euro-American lineage 
strains. 
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All samples were tested for MIC to INH at concentrations of O.IIlg/ml, 
0.25/lg/ml, 0.5/lg/ml, 1.0/lg/ml, 2.0/lg/ml, 4.01lg/ml, 8.0/lg/ml, 16/lg/ml and 32/lg/ml 
of INH. The MIC technique was developed by modifying the automatic DST of the 
BACTEC960 system as described in the methods, chapter 2, section 2.3.2. 
In general, katG315 mutated isolates had a median [interquartile range- IQR] 
MIC to INH of 2.0 [1.0-4.0]/lg/ml, inhA-15 mutated isolates had a median [IQR] MIC 
to INH of 0.25 [O.I-O.5]/lg/ml and INH resistant isolates without any identified 
mutation had a median [IQR] MIC to INH of 0.1 [O-O.I]/lg/ml (Figure 4.1). 
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Figure 4.1: Comparison of the median !NB MIC among M.tuberculnsis 
isolates resistant to INH, by INH-resistance mutation: katG315, inhA-15 and 
wild-type (WT). 
Box plots show the median and IQR of MIC associated with each INH 
resistance mutation. 
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When the lNH MIC of the isolates were stratified according to the three major 
M.tuberculosis lineages, median [IQR] MIC to 1NH were 0.25 [O-2.0]llg/ml for Euro-
American lineage strains, 0.5 [O.I-l.OJllg/ml for Indo-Oceanic lineage strains and 1.0 
[0.625-4.0] Ilg/ml for Beijing lineage strains (Figure 4.2). 
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Figure 4.2: Comparison of the median INH MIC among phenotypically 
INH-resistant isolates of the three major M.tuberculosi lineages (Beijing, Indo-
Oceanic and Euro-American). 
Box plots show the median and IQR of MIC associated with each lineage. 
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The MIC test was performed with serial 2-fold dilutions of INH concentration. 
therefore most of the MIC results were under lllg/ml of INH. For all statistical 
analyses, log-transformed MIC data were analyzed which showed a more symmetrical 
distribution and a better homogeneity of variance between subgroups than 
untransformed values. 
An overall comparison between the (log-transfonned) MICs to INH in the 
three groups of mutations based on ANOVA was highly significant (p<O.OOl). 
Pairwise comparisons using t-tests showed that katG3i5 isolates had significantly 
higher INH MIC compared to wild-type isolates (p<O.OOI). and inhA-i5 isolates 
(p<O.OOI). Wild-type strains showed relatively lower INH MIC in comparison with 
inhA-15 mutants (p=O.04). 
An alternative analysis based on the non-parametric Kruskal-Wallis test 
confirmed a highly significant overall difference between INH MIC of the three 
groups of INH resistance mutation (p<O.OOI) and pairwise comparisons (based on the 
Wilcoxon test for comparing independent groups) gave almost the same results as the 
parametric test with p<O.OOI for the comparison between INH MIC of katG315 and 
wild-type, p<O.OOl between katG3i5 and mM-i5, and p=O.OO8 between wild-type 
and inhA-i5 mutated isolates (Figure 4.3). 
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Figure 4.3: Comparison of the median of log transformed INH MIC 
among INH-resistant M.tuberculosis isolates with different INH resistance 
mutations. 
Box plots show the median and IQR of MIC associated with each INH 
resistance mutation. 
Differences between the MIC for each mutation type were calculated 
pairwise by Wilcoxon test. 
* significant at p=O.OO8, *** significant at p<o.OOl 
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A comparison of the log transformed MIC to INH among strains of the three 
M.tuberculosis lineages using ANOVA was highly significant with p=O.OO9. Pairwise 
comparison using t-tests showed that the MIC to INH in Beijing lineage strains were 
significantly higher in comparison with Indo-Oceanic and Euro-American lineage 
strains with p=O.OO4 and p=O.025, respectively. There was no significant difference 
between the MIC to INH of Indo-Oceanic and Euro-American lineage strains 
(p=O.73). 
An alternative analysis based on the Kruskal-Wallis test confirmed the 
significant differences among INH MIC of the three lineage groups with p=O.02. 
Pairwise comparison using WiIcoxon tests showed that the MIC to INH in Beijing 
lineage strains were significantly higher in comparison with Indo-Oceanic with 
p=O.OO4; whereas no significant difference was found between the MIC to INH of 
Beijing and EUro-American, or Indo-Oceanic and Euro-American lineage strains with 
P=O.088 and p=O.92, respectively (Figure 4.4). 
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Figure 4.4: Comparison of the median of log tmnsformed INH MIC 
among three major M.tuberculosis lineages. 
Box plots show the median and IQR of MIC for each lineage. 
Comparisons between lineages were calculated pairwise by Wilcoxon test • 
.. significant at p=O.OO4, NS: no significant 
When comparing the INH MIC by both mutation and strain lineage. the results 
clearly showed that isolates carrying kat0315 mutation always confer high MIC to 
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INH. Moreover, Beijing isolates tended to have higher MIC in comparison with other 
isolates of Indo-Oceanic and Euro-American lineages irrespective of mutation status 
(Figure 4.5). 
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Figure 4.5: Comparison of the medians of log transformed INH MIC with 
INH-resistance mutation grouped by M.tuberculosis strain Uneage. 
Comparison by two-way ANOVA for mutation and Uneage showed statisticaUy 
significant differences, p<:O.OOl. 
Eu_Am: Euro-American 
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A two-way ANOVA of MIC including both strain lineage (p=0.OO3) and 
resistance mutation (p<O.OOl) showed highly significant independent effects of both 
factors on MIC level. However. there was no evidence of an interaction between the 
lineage backbone and resistance mutation (p=O.49). i.e. no evidence of a different 
effect of strain lineage on (log-transformed) MIC level depending on the mutation 
responsible for resistance to INH. Moreover. the model predicted isolates with 
mutations at katG315 and inhA-15 to have W.85-fold (95% Cl 6.04-19.48. p<O.OOI) 
and 2.14-fold (95% Cl 1.07-4.27. p=O.03) higher MIC to INH. respectively. compared 
to wild-type isolates after adjusting for strain lineage. The independent effect of the 
strain lineage on INH MIC was predicted to correspond to a 2.68-fold (95% Cl 1.52-
4.73. p<O.OOI) increase for Beijing lineage strains and a 1.40-fold (95% Cl 0.72-2.74. 
P=O.32) increase for Euro-American lineage strains in comparison with strains of the 
Indo-Oceanic lineage. 
4.3 Discussion 
Mutation at katG315 is the predominant mutation among INH resistant 
M.tuberculosis isolates worldwide (Caws. Duy et al. 2006; Lipin. Stepanshina et al. 
2007; Dalla Costa, Ribeiro et al. 2009). It has been demonstrated that this mutation 
has a low or no fitness cost (Pym. Saint-Joanis et al. 2002) and confers a high level of 
resistance to INH. M.tuberculosis isolates carrying katG315 mutations can be 
sUccessfully transmitted within the community and are also often associated with 
resistance to other first-line drugs and MDR TB. (van Soolingen. de Haas et al. 2000). 
134 
Our results showed that different mutations result in different levels of 
phenotypic resistance to INH in vitro. The results from this study showed that 
katG315 mutated isolates possessed the median [lQR] of INH MIC of 2.0 (1.0-4.0) 
J.1g/ml; whereas inhA-15 mutated strains had a resistance to INH only at 
concentrations around O.l-O.5flg/ml. The data are in accordance with a study 
conducted in South America (Dalla Costa, Ribeiro et al. 2009), despite the difference 
in proportion of katG mutation among INH resistant isolates in different geographical 
areas, such as Brazil (81.3%) and Peru (82.4%) (Dalla Costa, Ribeiro et al. 2009), 
Russia (95%) (Lip in, Stepanshina et al. 2(07). 
Some studies have shown that patients with INH resistant TB can be treated 
with a high dose of INH dose (Katiyar, Bihari et al. 2008; Van Deun, Maug et a!. 
2010). However it is possible that this high dose regimen could be effective only if the 
isolate that the patient is infected with is resistant to only a low dose of INH and 
further studies are required to clarify which patients may benefit from high dose INH. 
There are many reports in the literature which show that mutations at the inhA 
promoter confer resistance to low levels of INH (Zhang and Telenti 2000; Lavender, 
Globan et al. 2005), thus patients infected with these isolates are the most likely to 
benefit from INH high-dose therapy. However, isolates with a mutation at inhA-15 do 
not always have a low-level of INH resistance as shown in a study by Vijdea et al. 
(Vijdea, Stegger et al. 2(08). In the study reported here, this phenomena was also 
observed with some isolates carrying an inhA-15 mutation without any other 
identified resistance mechanism were resistant to INH at a high level. Interestingly, 
these isolates belonged to the Beijing lineage; and the abnormally high INH resistant 
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phenotype of these isolates may be explained by an as yet unidentified mechanism 
intrinsic to the Beijing lineage backbone. Whole genome sequencing studies of 
M.tuberculosis isolates with different resistance profiles and different lineage 
backbones will help to unravel the underlying mechanisms. Literature review showed 
that a katG whole gene deletion leads to a high level of INH resistance (Vijdea, 
Stegger et al. 2008). However, katG whole gene deletion a very rare mutation in the 
INH resistant M.tuberculosis population (less than 1%), probably due to the fitness 
cost of this mutation, (Caws, Duy et al. 2006; Lipin, Stepanshina et a!. 2007; Dalla 
Costa, Ribeiro et al. 2(09). 
Some isolates in our collection of phenotypically INH resistant M.tuberculosis 
did not show any mutation in either katG or mM promoter regions studied. Other 
mechanisms of INH resistance (eg. mutations in other genes such as kasA, oot) were 
not investigated in the scope of this thesis. Efflux pump systems may also play a role 
in INH resistance for these isolates and those with levels of resistance to INH not 
explained by a single inhA promoter mutation (Siddiqi, Das et al. 2004). 
An alternative explanation for these wild-type INH resistant isolates could be 
the emergence of an INH-resistant mutation during the treatment leading to a mixed 
wild-type/mutant population at the time of sample collection. Re-infection, or super-
infection by a second isolate which is resistant during treatment appears to be is rare 
among mv negative patients (Glynn, Yates et al. 2004). During isolation and 
archiving, it is possible the mutated sub-popUlation with a lower relative fitness would 
be selected out and the final isolate contained only the wild-type sub-strain. This 
population selection would lead to a final isolate susceptible to INH (10 isolates in 
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this study). This explanation is supported by the fact that many wild-tWe isolates in 
this study had MIC <O.I~glmI, or categorised as INH susceptible when re-tested on 
MOIT MIC. Alternatively, the original classification of these isolates as INH resistant 
by 1% U proportion method may have been an error, or there may be differences in 
determination of resistance by liquid and solid methods which resulted in the 
discrepancy. 
Genotyping of M.tuberculosis discriminates lineages base on a limited number of 
characteristics. However, the divergent characteristics of these lineages have not yet 
been fully described and there is growing evidence of different virulence determinants 
between the lineages, including the ability to maintain mutations (Hu, Hoffner et al. 
2010) or differences in disease severity, and associations with drug resistance (Caws, 
Thwaites et al. 2006; Lipin, Stepanshina et al. 2007). This study contributes to the 
evidence that there are, as yet unidentified mechanisms intrinsic to the lineage 
backbone Which influence the acquisition of drug resistance. 
The Beijing lineage has attracted a lot of attention from researchers all over 
the world. It has been reported as a lineage with 'hyper-virulence' and associated with 
drug resistance and MDR (Lipin, Stepanshina et al. 2007; Dalla Costa, Ribeiro et al. 
2009; Niemann, Diel et al. 2010). One study in China showed that there was an 
association of Beijing lineage with extra-pulmonary TB; however, the number of 
extra-pulmonary patients infected with Beijing lineage in that study was relatively 
small (n=8) and the results was not statistically significant (p=O.0617) (Kong, Cave et 
al. 2(07). In a previous study at HTD reported by Thwaites et al., there was no 
significant association of INH resistance (non-MDR), HJV infection and pathogen 
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lineage with in-hospital mortality in TBM (Thwaites, Chau et al. 2002). The reason 
for this may be that the number of each analysis groups was too small (9 INH 
resistant, I I mv positive, 16 Beijing lineage infected patients) to be able to show 
significant association with mortality. A later larger study with a revealed that HIV 
infection increased the relative risk of death RR= 2.91 (95% Cl, 2.14-3.96) in TBM 
patients (Thwaites, Duc Bang et al. 2005). Overall data on disease phenotype 
differences of the Beijing lineage have been conflicting and inconclusive. 
Other studies at HTD have shown that Beijing lineage was also significantly 
associated with MDR in mY-associated TBM patients (Caws, Thwaites et al. 2006) 
and that the Euro-American lineage strains were less likely to disseminate than Indo-
Oceanic and Beijing lineage strains. Another study in China showed that the Beijing 
lineages associated with MDR belonged to a subgroup of Beijing lineages (Hu, Ma et 
al. 2010). In our study. two Beijing lineage isolates without mutation at katG315 or 
inhA-15 had very high MICs to INH. These isolates had Beijing, thus could belong to 
this subgroup of Beijing lineage. Further research is needed to identify and investigate 
this subgroup of Beijing lineage. 
In this study. we did not have a large number of Euro-American lineage strains 
in the comparison. However. the difference between Beijing and Euro-American 
lineages were significant with p=O.025. This result was supported by other studies 
which have described a selective transmission advantage of MDR strains of the 
Beijing lineage over Euro-American lineages (Kong. Cave et al. 2007; Niemann, Diel 
et al. 2010). 
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The majority of the Indo-Oceanic lineage strains in this study are a subgroup 
of the EAI lineage (EAI4_ VNM by spoligotype classification) which has only been 
reported in Vietnamese patients. Data from this study showed that the INH resistant 
strains of the Indo-Oceanic lineage and Euro-American lineage share a similar level 
of INH resistance with the median [IQR] of INH MIC of 0.5 (0.1-1.0) ~glmI and 0.25 
(0-2.0) ~g/ml. respectively (p=O.7 by ANOVA and p=O.9 by Kruskal-Wallis test). 
The results also showed a significant difference between Beijing and Indo-
Oceanic lineage strains (p=O.OO4). The effect of the Beijing lineage backbone on to 
the increase of INH MIC was predicted by the model as 2.68 (95% Cl 1.52-4.73. 
P<O.OOl) fold higher in comparison with the Indo-Oceanic lineage backbone. 
Collectively this data and the data in the literature (Lipin. Stepanshina et al. 
2007). show that as yet unidentified lineage factors influence the MIC to INH and by 
extension may have an influence on the effectiveness of INH in TB treatment. The 
lineage backbone of M.tuberculosis strains may also be important for resistance to 
other anti-TB drugs and should be investigated. 
139 
ChapterS 
The influence of INH resistance on the outcome of 
HIV-associated TBM 
5.1 Background 
mv infected individuals are more likely to develop severe disseminated forms 
of TB disease (Schutte, Van der Meyden et al. 2(00). TBM is the most severe form of 
TB infection with high mortality and morbidity, though TBM occurs in only 
approximately 1 % of clinical TB cases, (Garg 1999; Murthy 2010). TBM is rare in 
developed settings with a low TB prevalence but is seen more frequently in settings 
with a high prevalence of TB or both TB and HIV (Verdon, Chevret et al. 1996). 
Chapter 4 showed that both the mutation and lineage of M.tuberculosis exert 
an independent effect on MIC to INH. These results suggest that some M.tuberculosis 
lineages could be more resistant to TB treatment at standard doses. Additionally, 
some studies suggest that BCG vaccination does not offer equal protection against all 
M.tuberculosis lineages, such as Beijing (Abebe and Bjune 2006; Tsenova, 
Harbacheuski et al. 2(07). 
Resistance to one or more first-line anti-tuberculous drugs is becoming an 
increasingly common clinical problem, and the consequences of MDR TB, resistant to 
both INH and RIF, are well described in pulmonary TB. MDR TBM is fatal without 
the benefit of second line drugs (Thwaites, Lan et al. 2(05) but the impact on outcome 
in TBM of INH resistance without resistance to RIF is uncertain. An earlier study at 
HTD suggested that INH resistance, HIV infection and M.tuberculosis lineage were 
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not associated with in-hospital mortality in TBM patients (Thwaites, Chau et al. 
2(02). However, the lack of a significant effect was probably due to small sample size 
(n=160). A subsequent study showed that HIV coinfection increases the risk of 
treatment failure in TBM and reduces the survival rate with a relative risk of death 
2.91 [95% Cl, 2.14-3.96] in comparison with HlV uninfected TBM patients 
(Thwaites, Duc Bang et al. 2005). MDR TBM also showed 100% mortality without 
second-line drugs in another similar study in HlV co infected TBM patients at HTD 
(Torok, Chau et al. 2(08). However, there are limited data describing the influence of 
drug resistance (except MDR and XDR) or more specifically different resistance 
mutations of the bacilli which are known to influence the MIC level, on treatment 
outcome for TBM patients. This study was therefore conducted to investigate 
bacterial factors associated with outcome from TBM. 
AlMS 
1) Determine the impact of INH resistance without RlF resistance on 
outcome among TBM patients treated with a standardized fIrst-line drug 
regimen. 
2) Determine if specific mutations conferring INH resistance are associated 
with increased mortality. 
3) Determine if specific M.tuberculosis lineages are associated with increased 
mortality for TBM. 
4) Examine the influence of prior BCG vaccination on the infecting 
Mtuberculosis lineage among patients with HlV-associated TBM. 
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The study was conducted with a collection of M.tuberculosis isolates from two 
studies conducted in HCM city. The fIrst was an observational cohort study of 58 
patients with HIV-associated TBM (Torok, Chau et a1. 2(08) and the second was a 
RCT in which 253 patients with HIV-associated TBM were randomized to receive 
either immediate or delayed (8 weeks) ART for HIV-associated TBM (Torok, Yen et 
al. 2011) (see details in chapter 2, section 2.4.1) in collaboration with the HTD and 
PNT. 
5.2 Results 
The primary analysis of both studies has been reported elsewhere (Torok, 
Chau et al. 2008; Torok, Yen et al. 2011). We included all patients from these studies 
who had M.tuberculosis isolated from the CSF available for analysis of drug 
reSistance: 46/58 (79%) from the cohort study and 1411253 (56%) from the RCT. We 
further excluded one duplicate patient from the cohort study who was subsequently 
enrolled into the randornised trial leading to a total sample size of 186 patients. 
Baseline characteristics of these patients are reported in Table 5.1. 
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Table 5.1: Baseline characteristics of the 186 patients with a CSF culture 
for M.tuberculosis. 
Prospective Immediate ART Deferred ART 
descriptive study N=77 N= 64 
N=45 
Age in years, 27 (23-31) 28 (25 - 34) 29 (25 - 33) 
median (lQR) 
---_._------ --
Male sex, 41 (91.1 %) 71 (92.2%) 57 (89.1%) 
number (%) 
Weight in kilograms, 50 (45-51) 45 (40-51) 46 (40-50) 
median (lQR) 
Previous TB, number (%) 8142 (19.1%) 8n6 (10.5%) 6/63 (9.5%) 
TBMgrade 
I 11 (24.4%) 25 (32.9%) 18 (28.1%) 
n 14 (31.1%) 29 (38.2%) 25 (39.1%) 
ill 20 (44.4%) 22(29.0%) 21 (32.8%) 
CD4 T-lymphocyte count, 32 (12-59) 28 (16-108) 32 (14-78) 
cells~, median (lQR)* 
CSF ZN stain positive, 32 (71.1%) 38 (49.4%) 37 (57.8%) 
number (%) 
* Mlssmg for 181186 patlents (8, 4, and 6 ID the three groups, respectively). 
Of the included 186 patients, 112 patients died during the nine months of 
follow-up of the study and 55 survived; the remaining 19 patients were lost to follow-
up and censored at the time they were last known to be alive. The overall nine-month 
mortality in the study population was 63.9% (95% Cl 55.8 to 70.4%); it was higher in 
the patients from the cohort study (75.6%) but similar for the patients from the 
immediate and deferred ART group of the RCT (61.3% vs. 58.6%). Thirty-five 
patients (4 from the cohort, 31 from the RCT) received STR in addition to the 
standard treatment regimen. 
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S.2.1 Anti-tuberculous drug resistance 
Overall, 98 patients were infected with an M.tuberculosis isolate which was 
sensitive to all five drugs (INH, RIP, STR, EMB and PZA), 28 isolates were STR-
resistant only, 12 INH-resistant only, 40 resistant to both STR and INH, and 8 MDR. 
Of the MDR isolates, two were resistant to INH and RIP, five were resistant to INH, 
RIF and STR, and a single isolate was resistant to INH, RIP, STR and EMB). No 
isolates were resistant to PZA (Table 5.2). 
Table 5.2: DST profiles of CSF M.tuberculosis isolates from 186 patients 
with mv -associated TBM for RIF, INH, STR, PZA and EMB. 
Drug susceptibility profile 
Fully susceptible 
STR resistant 
INH resistant 
INH, STR resistant 
INH, RIF resistant 
INH, RIF, STR resistant 
INH, RIF, STR, EMB resistant 
PZA resistant 
Total 
98 (52.7%) 
28 (15.1 %) 
12 (6.5%) 
40 (21.5%) 
2 (1.1 %) 
5 (2.7%) 
1 (0.5%) 
0(0%) 
186 
Of thirty-five patients who received STR, eighteen isolates were sensitive to 
all drugs, three were resistant to STR, three were resistant to INH, ten were resistant 
to lNH and STR, and one was resistant to INH, STR, and RIF. 
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Kaplan-Meier survival curves for patients in five resistance categories (fully 
sensitive, STR mono-resistant, INH mono-resistant, INH + STR resistant, and MDR) 
is displayed in Figure 5.1. Overall log-rank test showed significant difference between 
these groups, p=O.03. 
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Figure 5.1: Kaplan.Meier survival curves of UIV-associated TBM 
patients infected with M.tuberculosis stratified by 5 drug resistance categories. 
The difference among survival time for 5 drug resistance categories was 
statisticaUy significant overall (log-rank test, p=O.03). 
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Based on the weak effect of STR in TBM treatment that the additional STR 
resistance might not affect the outcome; we pre-defined resistance pattern groups: 
group I: fully susceptible or STR mono-resistant (n= 126). group 2: INH resistant +/-
STR resistant (n= 52). group 3: multidrug resistant (n=8). as showed in Figure 5.2 
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Figure 5.2: Kaplan-Meier survival curves of RIV-associated TBM 
patients infected with M.tuberculosis, stratified by 3 drug resistance categories. 
The difference among survival time for 3 drug resistance categories was 
statistically signfficant (log-rank test, p<O.OOl) 
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There was a significant difference between survival curves of patients with 
different antituberculous drug resistance patterns base on three drug resistance 
categories (log rank test p<O.OOI). Patients with fully susceptible or STR mono-
resistant isolates had the highest survival rates, whereas those with MDR TBM had 
the lowest survival, with all MDR TBM cases dying within 41 days of study 
enrolment. For patients with INH-sensitive isolates median survival was 192 days 
with a nine-month mortality of 54.2% [95% Cl 44.1-62.5%]. For patients with INH 
resistant (non-MDR) isolates median survival was 89 days with a nine-month 
mortality of 81.5% [95% Cl 66.0-90.0%] (Figure 5.2). 
After adjusting for the effect of TBM grade at presentation, baseline CD4 cell 
COunt and cohort group in a multiple Cox regression analysis, the drug resistance 
pattern remained an independent predictor of mortality. The adjusted hazard ratio for 
MDR patients in comparison with fully susceptible or STR-monoresistant isolates was 
5.21 [95% Cl 2.38-11.42], p<O.OOOI compared with HR= 1.78 [95% Cl 1.18-2.66], 
P=O.OO5 for patients with INH resistant isolates (+I-STR resistance). The addition of 
STR-resistance as an additional covariate did not significantly improve the fit (hazard 
ratio 1.02 [95% Cl 0.66-1.59], p= 0.91). There was also no evidence of an interaction 
between drug resistance status and TBM grade (p=O.29), CD4 cell count (p=O.63), or 
study group (p=0.61). However, there was evidence of a time-dependent effect of 
INH resistance (+I-STR resistance) on survival with p=()'o3. Fitting separate INH 
resistance effects for the first three months (during the intensive TB treatment phase) 
and subsequently, gave adjusted hazard ratios (in comparison with fully susceptible or 
mono-resistant isolates) of 1.45 [95% Cl 0.87-2.40], p= 0.15 for the first three months 
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and 5.05 [95% Cl 2.23-11.44], p=(WOOl thereafter. Exploratory analyses showed that 
the model with a cut-point at three months for modeling INH resistance lead to a 
better fit (in terms of the likelihood) than models with a cut-point at other months. 
Exclusion of 35 patients who received streptomycin did not substantially alter 
the adjusted hazard ratio for MDR patients (HR=4.86 [95% Cl 2.11-11.22), 
P=O.OOO2) or INH-resistant patients (HR=1.90 [95% Cl 1.20-3.00], p::O.006). 
5.2.2 M.tuberculosis INH resistance mutation 
Characterisation of the mutations responsible for INH resistance in the 60 
isolates phenotypically resistant to INH using the MAS-PCR technique developed in 
chapter 3 showed that 59/60 (98.3%) isolates carried a katG3J 5 mutation. Therefore it 
was not possible to further examine the effect of specific mutations for INH resistance 
on outcome, as originally planned. 
5.2.3 M.tuberculosis lineage 
M.tuberculosis genotype data were available for 122 isolates (HTD patients 
only). Of these, 18 were of the Indo-Oceanic lineage (15%), 22 (18%) of the Euro-
American lineage and 82 (67%) East AsianlBeijing lineage (Table 5.3). 
Kaplan-Meier survival curves of the patients in the three lineages are 
displayed in Figure 5.3. 
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Figure 5.3: Kaplan-Meier survival curves of UIV -associated TBM 
patients infected with M.tuberculosis by lineage of the M.tuberculosis strain for 
all patients. 
The survival time among dift'erent lineage groups was not statistically 
significant overall Oog rank test, p=O.lO) 
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Table 5.3: M.tuberculosis lineage and drug susceptibility profiles of 122 
patients with HIV -associated TBM. 
M. tuberculosis Drug susceptibility profile 
lineae:e 
Fully STR mono- INH mono- STRIINH MDR Total 
susceptible resistant resistant -resistant 
n (%) n (%) n(%) n (%) n (%) n __ 
Beijing 39 (47.6) 16 (19.5) 6 (7.3) 18 (22.0) 3 (3.7) 82 
BUTo- 9 (40.9) 5 (22.7) 
American 
1 (4.6) 5 (22.7) 2 (9.1) 22 
Indo-Oceanic 14 (77.8) 0 1 (5.6) 1 (5.6) 2(11.1) 18 
Total 62 (50.8) 21 (17.2) 8 (6.6) 24 (19.7) 7 (5.7) 122 
In the crude analysis (n=122), M.tuberculosis lineage had no significant effect 
on outcome (log rank test p=O.lO, Figure 5.3). Any impact of lineage on outcome is 
likely to be confounded by drug resistance phenotype. There were only two INH-
resistant and two MDR-resistant Indo-Oceanic isolates (Table 5.3) and we therefore 
further analysed the impact of lineage on outcome including only patients infected 
with fully susceptible or STR-monoresistant strains (n=83, Figure 5.4). 
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Figure 5.4: KapIan-Meier survival curves of UIV-associated TBM 
patients infected witb M.tuberculosis by the lineage for patients infected with 
strains susceptible to all drugs or STR mono-resistant strains. 
The survival time among different lineages was statistically significant, 
log rank test, p=O.Ol. 
In patients with fully susceptible or STR mono-resistant isolates (n=83) there 
was a significant difference between the survival curves of patients infected with 
different M.tuberculosis lineages (log rank test p=O.OI). A Cox regression analysis 
adjusted for CD4 count, TBM grade at presentation and cohort group showed lower 
mortality in the East AsianlBeijing lineage compared to Indo-Oceanic lineage strains 
with an adjusted hazard ratio of 0.29 [95% Cl 0.14-0.61], p=O.OOI. There were no 
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significant differences between East AsianlBeijing versus Euro-American strains 
HR=O.64 [95% Cl 0.27-1.52), p=O.31 or between Euro-American versus Indo-
Oceanic strains; HR=O.45 [95% Cl 0.17 -1.18], p=O.I1. Adjusted pairwise comparisons 
in patients with only fully susceptible isolates after exclusion of patients receiving 
streptomycin (n=62 patients remaining) were HR=O.27 [95% cr 0.12-0.60), p=O.OOI 
for East AsianlBeijing lineage compared to Indo-Oceanic strains, HR=0.74 [95% Cl 
0.28-1.92), p=O.53 for East AsianlBeijing lineage versus Euro-American strains, and 
HR=O.37 [95% Cl 0.13-1.05), p=O.06 for Euro-American versus Indo-Oceanic strains. 
5.2.4 BCG vaccination 
Previous BCG vaccination (assessed by visible scar) was recorded in patients 
recruited to the RCT and data were available for 74/81 (91 %) of patients with 
M.tuberculosis genotype data. In these patients, we also analysed the influence of 
previous BCG vaccination on the lineage of the infecting strain and duration of illness 
prior to presentation. 1bere was a significant association between prior BCG 
vaccination and lineage (Fisher's exact test p=O.Ol). Patients with a prior BCG 
vaccination were more likely to be infected with a Euro-American strain. Beijing 
genotype was less common among those with BCG vaccination (Table 5.4). 
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Table 5.4: Association between prior BCG vaccination M.tuberculosis 
lineage isolated from the CSF for 74 patients with mY-associated TBM. 
M.tuberculosis Iinea~e 
East Euro-American Indo-Oceanic Total 
AsianlBeijing n (%) n (%) n 
n (%) 
BCG vaccinated 11 (22.9) 10 (62.5) 4 (40.0) 25 
Not BCG 37 (77.1) 6 (37.5) 6 (60.0) 49 
vaccinated 
Total 48 (lOO) 16 (lOO) 10 (lOO) 74 
There was no evidence for an association between lineage and duration of 
illness prior to presentation (Kruskal-Wallis test p=O.76) or for duration of illness and 
BCG vaccination (Mann-Witney test p=O.42). There was also no evidence for an 
asSOciation between BCG vaccination and survival in univariate analyses (p=O.95) or 
after adjustment for lineage and resistance category (p=O.61). 
5.3 Discussion 
The effect of MDR on the outcome of TBM is well documented; however the 
role of INH mono-resistance in TBM is less clear. A recent retrospective study in the 
United States shOWed that INH resistance, mv positive status and CSF culture 
positive are associated with increased mortality among TBM patients (Vinnard. 
Winston et al. 2010). These results are consistent with the data presented in this 
chapter. The retrospective analysis by Vinnard et al. was not able to examine 
standardized mortality endpoints or treatment regimens. In our collection of culture 
positive samples from mY-associated TBM patients. INH resistance without 
concurrent RIF resistance had a significant impact on outcome among mY-associated 
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TBM patients treated with standard fIrst-line anti-TB therapy (adjusted HR= 1.78 
[95% Cl 1.18; 2.66], p=O.OO5). 
Analyses modeling a time-varying effect of INH-resistance and Kaplan-Meier 
survival curves (Figure 5.lb) showed that the detrimental effect of INH-resistance 
was most pronounced from month 3 onwards, when treatment with PZA and EMB is 
stopped and patients continue on INH and RIF only. This suggests that these patients 
effectively on RIF monotherapy during the continuation phase, a RIF resistant sub-
POpulation was able to emerge once EMB and PZA were discontinued, resulting in 
treatment failure and increased mortality (time adjusted for the continuous treatment 
period, HR=5.05 [95% Cl 2.23-11.44], p=O.OOOl). In this situation, extension of the 
dUration of the intensive phase of treatment alone beyond three months may not be 
sUfficient to achieve complete sterilization of the CSF and it is likely that an 
alternative or additional bactericidal agent will be required. Of the currently available 
drug classes for TB, a FQN is likely to represent the best option since the later 
generation FQNs (levofloxacin, gatifloxacin and moxifloxacin) have good CSF 
penetration, are well tolerated and have comparable early bactericidal activity to INH. 
I...evofloxacin for the treatment of TBM is currently being explored in a treatment trial 
at OUCRU (trial registration number: ISRCTN61649292) (Heemskerk, Day et al. 
2011). Ongoing multicenter RCTs in pulmonary TB are testing whether FQs can 
reduce the standard regimen for pulmonary TB to four months. The Remox TB study 
(Trial registration number: NCTOO834383) is testing the replacement of INH and 
ETH with moxifloxacin and has completed recruitment, with reporting expected in 
2014. It has been shown that rifapentine and rifabutin can be used as substitution for 
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RIP, which have less drug-drug interaction with ART (Loeliger, Suthar et al. 2012), 
and a longer halve-life which thus could extend the intermittent time between each 
dose (SirgeI, Fourie et al. 2005). Rifabutin penetrates the CSF (Nau, SorgeI et al. 
2010) and has been used successfully to treat a case of mY-associated M.avium 
meningo encephalitis (Malessa, Diener et al. 1994); thus may be alternative to RlF in 
HIV-associated TBM treatment. Novel agents such as PA-824 and TMC207 also 
show promise in the treatment of pulmonary TB and should be evaluated in TBM 
(Ma, Lienhardt et al. 2010). The TB alliance has announced a trial of PZA, 
moxifloxacin and PA-824 in combination for the treatment of both drug sensitive and 
drug resistant pulmonary TB and novel drug combinations may also be effective for 
the treatment of drug resistant TBM and trials should be considered if regimens prove 
effective in pulmonary TB. Since the morbidity and mortality of TBM is significantly 
higher in }flV infected cases than HIV uninfected cases (Katrak, Shembalkar et al. 
2000), a smaller trial size would be required to demonstrate efficacy in mv-
associated TBM, however, mortality of 25% in HIV-uninfected TBM cases remains 
unacceptable and both groups should be included in future trials of novel anti-
tuberculous drug regimens. 
Only 35 patients in this study were given STR in addition to the standard 
treatment regimen. The inclusion lexclusion of 35 patients who received STR as an 
additional drug in the therapy did not significantly alter the findings. This shows that 
STR did not have a detectable effect on TBM outcome. STR resistance is most 
prevalent form of mono resistance (15.1%) in this study, however the standard 
treatment regimen did not include STR therefore resistance to STR is unlikely to have 
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an effect on outcome. The small number of patients who received STR and were 
infected with an isolate resistant to STR meant that it was not possible to examine the 
impact of STR resistance on outcome. HIV-uninfected TBM patients infected with 
STR resistant M.tuberculosis had a slightly lower mortality than patients infected with 
fully susceptible M.tuberculosis in a previous study at HTD (16.7% vs 28.7%), 
however this difference was not significant (Thwaites, Lan et aJ. 2005). The role of 
STR resistance in outcome from TBM remains to be defined. In accordance with 
previous studies, this study showed that MDR-TBM was uniformly fatal in this HIV 
patient population treated with standard antituberculous therapy (Thwaites, Duc Bang 
et al. 2005; Heemskerk, Day et al. 2011). The rapid detection of drug resistance in 
TBM cases is extremely difficult due to the paucibacillary nature of the disease. 
Molecular diagnostic tests for Mtuberculosis are relatively expensive and are not yet 
routinely available in resource-limited settings. Molecular diagnostic tests, such as 
MAS-PCR, or commercial LPAs (Chapter 3), may present an alternative but they 
have poor sensitivity on paucibacilIary samples and in-house tests are difficult to 
standardize (Greco, RulIi et al. 2009). The wide-spread ongoing implementation of 
GeneXpert MTB/RIF (Cepheid, US) in high-TB burden settings may enable rapid 
diagnosis of MDR TBM, but data are not yet available on the accuracy of the 
technique in TBM cases. Even if the diagnosis of MDR-TBM is confirmed, there is 
no data from RCTs to guide clinical management (Byrd and Davis 2007; Donald 
2010). This is also true for patients with INH-resistant but RlF-susceptible TBM. 
In pulmonary TB, recent meta-analyses have shown that outcomes are worse 
in patients infected with INH-resistant, RlF-sensitive M.tuberculosis but treatment 
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guidelines for INH-resistant pulmonary TB vary and none are based on high quality 
evidence from RCI's (Lew, Pai et al. 2008; Menzies, Benedetti et al. 2009). The 
WHO recommends adding EMB to the continuation phase in regions with a high 
prevalence of INH resistance (WHO 2(09), or to use a RZE continuation phase for 6-
9 months in cases of confIrmed INH resistance, with the note that 'a FQN may 
strengthen the regimen for patients with extensive disease' (WHO 2008), the 
American Thoracic Society recommends adding a fluoroquinolone in "extensive 
cavitatory disease" and the British Thoracic Society recommends an extended 
continuation phase of 7 months, with EMB and RIP. These recommendations 
probably should not be extrapolated to the treatment of TBM due to the need for high 
CSF penetration of bactericidal agents and further studies are required to improve the 
early detection of drug-resistant bacteria in patients with TBM and to determine the 
optimal treatment for both INH-resistant and MDR TBM cases. 
This study did not quantify M.tuberculosis in CSF. The impact of drug 
resistance may be greater in patients with higher bacterial loads, particularly to a 
single agent such as INH mono-resistance, since a larger population of M.tuberculosis 
will have a higher chance of containing bacilli with spontaneous resistance mutations. 
We also did not examine the impact of NAT2 status on outcomes. The majority of 
Asian patients are fast acetylators for INH (Kita, Tanigawara et al. 2001; Cho, Koh et 
al. 2007) and this may result in lower CSF INH concentrations and consequently 
increase the impact of INH resistance. As INH penetrates the blood:brain barrier into 
the CSF very well while RlF penetrates poorly (approximately 20% of serum 
concentrations, the role of NAT2 acetylator status in the outcome of these HIV-
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associated TBM patients might be greater than on pulmonary TB patients (Donald, 
Parkin et al. 2(07). The next study in outcome of TBM patients should also examine 
the role of NA T2 status on the concentration of INH in the CSF. Further stud y is 
required to demonstrate the role of NA T2 in both pulmonary and disseminated TB 
disease, including TBM. 
The multivariate regression model suggests the lineage of the infecting 
M.tuberculosis strain influenced outcome of patients infected with fully-susceptible 
strains. Interestingly, patients infected with the modem Beijing lineage strains had a 
lower mortality risk than those with the ancient Indo-Oceanic strains. This finding 
Contradicts previous reports in the literature of increased mortality in patients infected 
with Beijing lineage strains (Sun, Lee et al. 2007; de long, Hill et al. 2008; Parwati, 
Van Crevel et al. 2010); however, none of these studies were done in HlV-associated 
TBM patients. A previous study at OUCRU showed no impact of M.tuberculosis 
lineage on mortaIity for 160 TBM patients, who were HIV-uninfected, although a 
higher proportion of patients infected with Beijing lineage strains were dead or 
severely disabled at nine months, this difference did not reach significance (34.3% vs. 
25.6% for Euro-American and Indo-Oceanic strains combined, p=O.236) (Thwaites, 
Caws et al. 2(08). The number of patients examined in this study is relatively small 
and this finding needs to be confirmed in a larger study. 
The higher event rate for mortaIity among HIV-associated TBM in this 
population may have strengthened the power of the study to detect a difference 
between the lineages of M.tuberculosis. Alternatively, the difference may be due to 
variable pathogenesis with HIV co-infection. The 'modem' Beijing genotype and 
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Euro-American lineages have a pro-inflammatory profile, inducing more TNF-a and 
IL-l f3 in-vitro and also show higher growth rates and propensity to disseminate in a 
mouse model, compared to the 'ancient' Indo-Oceanic strains (Krishnan, Malaga et al. 
2011). There is increasing evidence of differences in virulence between the major 
lineages of M.tuberculvsis in different host populations (Gagneux, DeRiemer et al. 
2006; Gagneux and Small 2007; Caws, Thwaites et al. 2008; de Jong, Hill et al. 2008; 
Thwaites, Caws et al. 2008; Nahid, Bliven et al. 2010). The mechanism responsible 
for these differences remains unclear but may be due to differential immune 
modulation by strains of the major lineages (Wang, Peyron et al. 2010; Portevin, 
Gagneux et al. 2011); it is possible that the pro-inflammatory effect, while detrimental 
in immune-competent patients and resulting in increased propensity to disseminate 
conversely reduces the severity of TBM in the severely immune-compromised. 
A previous study at OUCRU has shown an association between the Beijing 
genotype and mY-associated TBM in this setting (Caws, Thwaites et al. 2006) and in 
this thesis we have demonstrated the association of Beijing genotype with higher MIC 
to INH (chapter 4) which implies that there are significant lineage-associated 
variations in virulence relating to drug resistance and pathogenesis. The data 
presented in this chapter shows HIY-associated TBM patients infected with a Beijing 
lineage do not have a higher mortality but in fact a lower mortality. This result 
demonstrates that the bacterial lineage is one factor independently affecting the 
outcome of TBM. 
HIV-infected TBM patients who have been previously BCG vaccinated were 
more likely to be infected with a Euro-American strain of M.tuberculvsis and less 
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likely to be infected with a Beijing strain. This is an unexpected finding as it has been 
previously hypothesised that the success of the Beijing strain is attributable to a lower 
Protective efficacy of BCG against Beijing lineage strains and that Beijing lineage 
could be emerging under selection pressure following wide-spread application of 
BCG vaccination, although the evidence to support this theory remains weak (Abebe 
and Bjune 2006; Tsenova, Harbacheuski et al. 2007; Parwati, van Crevel et al.). The 
patients in this study were severely immune suppressed which may alter the protective 
dynamics of the immune response to BCG. Improved understanding of the differential 
immune evasion mechanisms of M.tuberculosis lineages is vital to the development of 
a globally effective vaccine (Gagneux and Small 2007). 
In conclusion. this study demonstrates that INH resistance, MDR and bacterial 
lineage play an important role in outcome from TBM. Methods to improve the rapid 
diagnosis of drug-resistant TBM and clinical trials to determine optimal antimicrobial 
treatment strategies are urgently required. 
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Chapter 6 
The correlation of acetylator phenotype and NAT2 genotype 
in Vietnamese Kinh population 
6.1 Background 
The efficacy of INH is dependent upon drug concentration and therefore it is 
explained by the ratio of Cmax:MIC (Jayaram, Shandil et a!. 2(04). The drug can be 
taken intermittently without compromising the efficacy, unlike other time-dependent 
antibiotics, such as f3 lactam group and vancomycin which must maintain a consistent 
serum concentration for efficacy (Rybak 2006). The Cmax value can be changed 
actively by altering the dose of INH administered. Inter-individual variation has been 
shown by their age, gender, dietary habits (Schaaf, Parkin et al. 2(05). However the 
most significant factor in inter-individual variation in INH serum Cmax is due to 
variations in genotype of the NAT2 genotype (Donald, Parkin et al. 2(07). 
Individuals can be grouped into one of three acetylator types: homozygous 
fast-fast (FF), heterozygous fast-slow (FS) and slow-slow (SS) acetylator types, which 
may also be defined as fast, intermediate or slow, respectively. People with fast 
acetylator status eliminate INH relatively quickly. An individual with fast acetylator 
status will have lower serum concentrations of INH comparing with others using the 
same dose (Kinzig-Schippers, Tomalik-Scharte et al. 2005; Donald, Parkin et a!. 
2007), which may decrease the efficacy of INH. A study by Donald showed when all 
TB patients received the standard dose ofINH (5mg/kg), 100% SS acetylators, 96.3% 
PS acetylators and only 33% FF acetylators reached the optimal EBA90 of INH with 
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the AUC of l0.52llglmVhour INH in the sera (Donald, Parkin et al. 2(07). Therefore, 
fast acetylators status decreases the efficacy of INH in TB patients. In contrast, 
individUals with a slow acetylator phenotype take a longer time for the drug clearance 
process. An individual who metabolizes INH slowly has been shown to accumulate 
INH in the body, and thus could be at increased risk of hepatotoxicity (Higuchi, 
Tahara et al. 2(07). 
The distribution of fast and slow acetylators varies in different ethnic 
populations. The majority of Asian populations are predominantly fast acetylators and 
the Vietnamese Kinh are likely to be predominantly fast acetylators as are the Chinese 
(Zhao, Seow et al. 2000), Japanese and Thai ethnic groups (Kukongviriyapan, Prawan 
et al. 2(03), in contrast to the Caucasian and the African American population of the 
United States, where the majority are slow (Walker, Ginsberg et al. 2009). The high 
prevalence of fast acetylators may play an important role in the development of 
M.tuberculosis resistant to INH or the outcome of TB treatment with standard 
regimens through its effects on the INH clearance process. 
NAT2 is a human acetylator enzyme that is predominantly found in liver and 
extrahepatic tissues, known to detoxify chemicals in mice (Sugamori, Wong et al. 
2(03). The enzyme is encoded by the NA12 gene which defines the acetylator 
phenotype of each individual. NAT2 is known to be responsible for the INH 
elimination process in humans and affects the serum concentration (Donald, Parkin et 
al. 2(07); therefore, it may have an impact on the efficacy of INH and INH-based 
therapies. 
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A TB drug resistance survey in HCM city-Vietnam showed that a quarter of 
new smear-positive TB patients had INH resistant TB (Quy, Buu et al. 2006). The 
finding is consistent with WHO data which ranks Vietnam as a country with a high 
prevalence of INH resistance (more than 20% INH resistance among new TB cases) 
(WHO 2008). If there is a predominance of NAT2 fast acetylator phenotypes in the 
population, it may influence the M.tuberculosis drug resistance pattern in this region; 
however, the correlation between NAT2 genotype and acetylator phenotype has not 
been established in the Vietnamese population and this data is necessary for further 
investigation of the role of NA 1'2 genotypes in TB therapy. 
INH and caffeine share the same pathway of NAT2 metabolism; as a result, 
caffeine metabolism is a surrogate indicator that has been used to determine the 
acetylator phenotypes of healthy volunteers (Conte, Golden et al. 2002). When 
acetylator phenotypes are defined, genotype data can be used to predict INH clearance 
activities. Caffeine can be administered at a dosage equivalent to a large cup of coffee 
oOOmg) which is considered safe and consumed regularly by the majority of western 
adults. Metabolites of caffeine such as I-methyluric acid (1 U), l-methylxanthine 
(lX), 1,7-dimethyluric acid (l7U), 1,7-dimethylxanthine (l7X), 5-acetylamino-6-
formylarnino-3-methyluracil (AFMU) are excreted in urine. AFMU is spontaneously 
degraded to 5-acetylamino-6-arnino-3-methyluracil (AAMU). The ratio 
AAMU/(AAMU+IX+IU) was shown to be more stable than 
AFMu(AFMu+lX+lU) (Nyeki, Buclin et a1. 2(03); thus was used to study NAT2 
phenotype in Vietnamese healthy volunteers. 
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The aim of this study was: 
1) To detennine the correlation between the NA T2 phenotype and NAT2 
genotype in Vietnamese healthy volunteers via a caffeine assay. 
2) Develop a rapid test to genotype the NAT2 gene (RFLP method) which 
can be used in place of sequencing and is feasible in most laboratories 
equipped with a PCR machine. 
6.2 Results 
Thirty seven healthy volunteers consented to participate in the study, of which 
12 were males and 25 were females. All volunteers were non-smokers and the 
majority did not drink tea or coffee on a regular basis (65%). All volunteers were 
asked not to conSUme tea, coffee, chocolate or other caffeine products 36 hours prior 
to the caffeine administration and until after urine sample collection. 
6.2.1 Acetylator phenotype results 
The HPLC method provided a rapid extraction less procedure to determine 
and quantify accurately IU, IX, 17U, and AAMU. The retention times for AAMU, 
IU, IX, 17U and 7-beta hydroxyethyl theophylline (used as the internal standard) 
were 4.8 mins, 9.3 mins, 10.2 mins, 13.1 mins and 15.3 mins, respectively. 
Calibration curves of AAMU, IU, IX, 17U were linear over the concentration 
range (5 IlM to 250 IlM). The correlation coefficients (goodness of fit, R2) were 
greater than 0.99 for all the metabolites. The intra-day and inter-day (mean relative 
standard deviation, SD) for the 4 metabolites was less than 3.1% and less than 5.9% 
164 
respectively. The accuracy ranged from -6.4% to +4.4% for all the metabolites for all 
the occasions (repeatability and intermediate precision). The limit of detection was 
estimated at 2 IlM for AAMU, IX, and I IlM for I X, 17U. The lower limit of 
quantification was set at 5 flM for all metabolites. 
The subjects were classified according to the estimated value of the ratio 
AAMU/(AAMU+IX+IU). The best fitting model classified 13/37 (35.1%) 
individuals in the slow acetylator group and 24/37 (64.9%) in the fast acetylator 
group. The frequency distribution of NAT2 activities had a cut-off value of 0.3 with 
the ratio AAMU/(AAMV+ 1 X+ I U) (Figure 6.1). 
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Figure 6.1: Acetylator phenotype results of 37 Vietnamese healthy 
volunteers showed a clear cut-otT between the ratio of fast and slow acetylators. 
Individuals with metabolic ratios <0.3 were classified as slow acetylators and 
those with the ratios >0.3 as fast acetylators. The mean metabolic ratio (±SD) was 
0.19±O.03 and 0.54±O.09 for slow acetylator and fast acetylator group, respectively. 
The NA T2 fast and slow activities were compared between males and females. The 
median values of the NAT2 ratio were not different between males and females of 
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slow acetylators with 0.19 and 0.18, respectively (p-value >0.05). Similarly there was 
no significant difference in NAT2 ratio between males and females of fast acetylators, 
with the median 0.55 and 0.58, respectively (p-value > 0.05). 
6.2.2 Genotype of NAT2 
In this study, 24 of 37 people (64.9%) expressed the fast acetylator genotype. 
Among this fast acetylator group, the most frequent genotype was NAT2*4/4, 
accounting for 29.7% (11137), followed by NAT2*4/6A with 24.3% (9/37) and 
NAT2*4nB with 8.1 % (3/37). In the slow acetylator group, genotypes NAT2*6A16A 
and NAT2*6Af7B were at higher frequency with 18.9% (7/37) and 8.1 % (3/37), 
respectively (Table 6.1). 
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Table 6.1: Genotype and the associated phenotype results from caffeine 
metabolism analysis among 37 healthy Vietnamese Kinh volunteers. 
Acetylator 
Status 
Slow 
Fast 
Genotype 
NAT2 combination 
"6A/6A 
"6A/7B" 
"7B/7B 
"SB/6Ab 
*SB/7Bc 
Total 
"4/4 
"4!13A 
"4!6A 
*4/7B 
Total 
N 
7 
3 
1 
1 
1 
13 
11 
1 
9 
3 
24 
Phenotype 
" 
AAMU/(AAMU+IX+1U) 
Mean - range 
18.9% 0.19 0.17-O.2S 
8.1% 0.19 0.17-0.22 
2.7% 0.12 N/A 
2.7% 0.20 N/A 
2.7% 0.18 N/A 
35.1" 
29.7% 0.63 0.53-0.77 
2.7% 0.53 N/A 
24.3% 0.48 0.42-O.S8 
8.1% 0.49 0.47-0.50 
64.9% 
• Could be misclassifJCd as "J3N6J (fast acetyJata) without phenotype result 
b ahemative genotype of "SB/6A arc "SAl6C and "SGI6B 
c a1tcmative genotype of "SBnB are "SAne and "SGl7A 
b.c Genotype "5B/6A and "SBnB was defined base on the popularity of hapJotypcs "6A and '7B in 
Vietnamese population 
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When stratify according to NAT2 haplotypes, majority of Vietnamese healthy 
volunteers carry haplotype *4, accounting for 47.3% (35n4), following by haplotype 
*6A with 36.5% (27n4) and *7B with 12.2% (9n4). The others haplotypes take only 
a small POrtion in this population of the study (Table 6.2) 
Combining caffeine phenotypic and NAT2 genotypic results, we had a 
correlation between these two data. Phenotype results were fit with genotype (Figure 
6.2) 
Table 6.2: Distribution of NA 1'2 haplotype in 37 healthy Vietnamese Kinh 
volunteers 
Phenotype Haplotype N 
Fast *4 35 
*13A 1 
Slow *6A 27 
*78 9 
*58 2 
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Frequency (%) 
47.3 
1.3 
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Figure 6.2: Acetylator phenotype results and the associated NAT2 allele 
combinations in 37 Vietnamese healthy volunteers divided by FF, FS and SS 
acetylators. 
Box plots show the median and IQR of the ratio associated with NA T2 
genotype. 
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The caffeine phenotype study also showed that individuals who are 
homozygous fast acetylators (FF, *4/4 or *4/I3A) have a higher ratio of 
AAMU/(AAMU+IX+IU) (mean=O.62, 95% Cl 0.57-0.66) in comparison with 
heterozygous fast acetylators (FS, *4/6A and *4nB) (mean=0.48, 95% Cl 0.46-0.51). 
The heterozygote fast acetylation group represents 32.4% in our sampled population 
(2137). The difference in the FF and the FS phenotype is highly significant with p-
value <0.0001 (two-way ANOVA). The SS group showed a significantly difference 
from both FF and FS groups with p-value <0.0001 (Figure 6.3). The distribution of 
acetylator phenotype among the Vietnamese healthy volunteers is 35.1% (13/37) SS, 
32.4% 02/37) FS and 32.4% (12/37) FF acetylators. 
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Figure 6.3: Acetylator status from the AAMU/(AAMU+IX+IU) ratio and 
the corresponding genotypes deduced from polymorphism at NA T2 allele. 
Bars in the plots show mean and 95% Cl of the ratio associated with each 
NA T2 genotype. 
Differences between the ratio for each NA T2 genotype were calculated 
pairwise by two-way ANOVA and showed statistical significance p<O.OOOI • 
•••• significant at p<O.OOOI 
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6.2.3 Development of PCR-RFLP to detect fast/slow acetylators 
Analysis of the acetylator haplotype database showed that acetylator status 
was influenced when there are polymorphisms at nucleotide number T341C, G590A, 
G857 A. By looking at these three SNPs, instead of seven SNPs as reported elsewhere 
(Rihs, John et al. 2007), we could define the acetylator phenotype status in this set of 
Vietnamese healthy volunteers. These SNPs lead to amino acid changes; and thus 
could have a potential impact in acetylator enzyme activities. This is concordant with 
other studies performed on Asian ethnic groups which focus only on three SNPs 
T341 C, G590A, G857 A (Kita, Tanigawara et al. 200 I; Kukongviriyapan, Prawan et 
al. 2(03); whereas studies in European (Caucasian) ethnic groups show an influence 
of a greater number of polymorphisms: GI9lA, C282T, T341C, C481T, G590A, 
A803G, G857 A (fanira, Simsek et al. 2003; Rihs, John et al. 2007) on the definition 
of fast/slow acetylators. NAT2 polymorphisms vary geographically (Garcia-Martin 
2008; Sabbagh, Langaney et al. 2008); thus, a simplified test for NAT2 acetylator 
status will be region or ethnicity specific. 
PCR RFLP is the simplest method that can detect polymorphism in different 
haplotype. However, none of the test in literature was designed for only the three 
polymorphisms at nucleotide number T341C, G590A, G857A. Some authors used an 
adapted technique from a PeR RFLP that was designed for six polymorphisms 
G191A, C282T, C481T, G590A, A803G and G857A. The unique T341C was 
detected only by MAS-PCR. It is because the cleavage site at position 341 was not 
available in wide type. So I had to use 341C mutation sequence template to design the 
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test. TspRI was the only available restriction enzyme for that site. Then I found that 
the cutting sites of from TspRI were close to each other which make it difficult to tell 
the different between wild type and T341C. A mismatch PCR was carefully designed 
to cover one cleavage site and make the PCR-RFLP simple. hand-on time short and 
very easy to interpret. The principle of PCR-RFLP was showed in Figure 6.4 
TspRl I 
341 
I 
,
57be, 435be .f 136b!:! , T341C 
492be II 136b!:! I 341wt 
S90 
Taql I I I 
74bp 
~, 226bp l70bp tI 1S8bp I 590wt 
~, 3S6bp II 158b!:! , G590A 
1S7 
BamHl1 I 
566~ 1~857wt 
628be G857A 
Figure 6.4: The principle of PCR·RFLP to detect SNPs at nucleotide 341, 
590 and 857. 
Bold lines are PeR products with restriction sites marked. The thin arrow lines 
show the length of restriction fragments. 
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The inner 628bp fragment of the second exon in human NAT2 gene was 
amplified with two primers NAT2Fa (5'-CCAGTTAACAAATACAGTAC-3') and 
NAT2R (5'-GAGTTGGGTGATACATACAC-3'). The PCR amplicons were 
aliquoted into three separate PeR tubes, 5U of the respective restriction enzyme was 
added to each: TspRI, TaqI and BamHI (New England Biolabs, USA) and the tubes 
were then incubated at the appropriate temperature: 65°C, 65°C and 37°C, 
respectively, for 3 hours. The products were electrophoresed on a 1.5% agarose gel 
for two hours (Figure 6.5 and Figure 6.6). 
Iaddor 
lOObp 
laddPl' 
_______ ~_mH_l ____ ~lOObP 
'l341Iff) 'l341C/T IFS) n<lC(SS) GS9O-"'-lf"'"'F)-GY1OA/-:-:-'-;-G:-:(f-:"S):-GS=!IOA:""C(=SS) 6157IFf) 6157A/G IfS) G&57A (SS) __ IIlOObp 
TspRl 
---
----
----
492 bp 492 bp 3% bp 3% bp 628 bp 628 bp .... size of PCR.RFLP 
435 bp 435 bp 226 bp 
136 bp 136 bp 136 bp 151 bp 
226 bp ~bp ~bp ~~~ 
151 bp 158 bp 
Flgure 6.5: The representation of PCR-RFLP results for different SNP 
patterns in the NA 1'2 gene. 
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Figure 6.6: Results of PCR-RFLP on samples from individuals with the 
most frequently occurring NAT2 genotypes. 
Lane I , 1 I : 100bp ladder. 
Lanes 2-4: digested with TspRI. 
Lanes 5-7: digested with TaqI. 
Lanes 8-10: digested with Bamlll. 
Lane 2,5,8: wild type (FP acetylator). 
Lane 3,4: F/S acetylator at SNP 341. 
Lane 6: F/S acetylator at SNP 590. 
Lane 7: SS acetylator at SNP 590. 
Lane 9: F/S acetylator at SNP 857. 
Lane 10: SS acetylator at SNP 857. 
The PCR-RFLP test was repeated with samples from the initial 37 healthy 
volunteers and the results were 100% concordant with the sequencing and phenotypic 
results. 
6.3 Discussion 
The correlation between acetylator phenotype and NA T2 genotype has been 
clearly shown in thjs chapter, in accordance with studies in other ethnic populations. 
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A clearly defined difference between individuals with FP, FS, and SS acetylator status 
was shown by genotype results (sequencing) and phenotype results (p<O.Oool). We 
found that Vietnamese healthy volunteers of Kinh ethnicity are predominantly fast 
acetylators (64.9%). 
The determination of phenotypic acetylation analysis using 
AAMU/(AAMU+IX+IU) gave reproducible results. With the same cut-off value 
(ratio AAMUI (AAMU+IX+l U)= 0.3) as reported in a previous study (Nyeki, BucHn 
et al. 2003), the NAT2 phenotypic results clearly classified fast and slowacetylator 
groups and the results were concordant with the NA T2 genotype results from 
sequencing. 
The caffeine phenotype study showed that people who were homozygous fast 
acetylator had a higher ratio of AAMu/(AAMU+IX+IU) in comparison with 
heterozygous fast acetylator group. The heterozygote fast group is considered as the 
"intermediate" acetylator group (Kuznetsov, McDuffie et al. 2009), and represented 
32.4% in our sampled population (14/37). The difference in the caffeine metabolites 
ratio between the homozygous fast (FP) and the heterozygous fast (FS) groups was 
highly significant with p-value <0.0001 (two-way ANOVA). 
The prediction of the acetylator phenotype based only on NA T2 haplotype 
polymorphism database can lead to inaccurate prediction of phenotype status as 
shown with four samples (10.1 %) in this study. This is due to the potential for 
inaccurate haplotype prediction. More than two polymorphisms found in one 
genotype will complicate the analysis. The phenotype of these individuals could be 
alternatively predicted as FS acetylation status using the genotype data, whereas the 
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measured phenotype was slow. Alternative haplotypes can be predicted from the 
database when they are taken as new NA T2 genotypes in studies without phenotype 
confIrmation, such as haplotypes NAT2*5J and NAT2*6J (Tanira, Simsek et al. 2003; 
Sabbagh, Langaney et aI. 2008) as shown in this study. Four SS acetylators (3 with 
*6AJ7B and one with *5B/6A) could have been misclassified as genotypes 
NAT2*13N6J and NAT2*12C/5J, (respectively) or FS acetylators. However, the 
phenotype of the four volunteers showed slow acetylators phenotype; thus should 
carry 2 copies of slow/slow acetylator in NAT2 gene (SS). This illustrates the need to 
determine the haplotype structure of individual populations before using genotype 
data alone to determine phenotypic acetylation status 
For example, two genotypes were found with 5 polymorphisms in the NAT2 
gene. We found that there was more than one combination of haplotypes which could 
fIt to these genotypes, such as NAT2*5A16C, NAT2*5B/6A, NAT2*5G/6B and 
NAT2*12C/5Jhave the same combination of polymorphism. Similarly, 
NAT2*5A17C, NAT2*5BnB and NAT2*5GnA share another polymorphism 
combination. As NAT2*6A and NAT2*7B are the haplotypes with the highest 
prevalence in this population (36.5% and 12.2%, respectively), suggesting that the 
haplotype combination of these two polymorphisms should be NAT2*5B/6A and 
NAT2*5BnB (Table 6.1). With the result from this study, knowing the prevalence of 
each NAT2 haplotype in the Vietnamese Kinh population allows the correct 
interpretation of the genotype results. Other studies have also shown that only 
mutations at nucleotide positions 191, 341, 590 and 857 result in a signifIcant 
decrease of acetylator activity (Kita, Tanigawara et al. 2001; Patin, Barreiro et aI. 
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2006; Ribs, John et al. 2007). This phenomenon was also observed in the present 
analysis which showed that any person carrying homozygous mutations at one of 
these loci or heterozygous mutations at two of these loci would have a slow 
acetylation phenotype. The prediction of acetylator phenotype should be based on the 
number of mutations at these nucleotide positions (191,341,590 and 857) in using 
the NAT2 haplotype database to predict the haplotype. As mutation at nucleotide 191 
has never, to our knowledge, been reported in NAT2 genotypes of individuals of 
Asian ethnicity, including Vietnamese (Cavaco, Asimus et al. 2007), Japanese (Kita, 
Tanigawara et al. 2(01), and Chinese (Garcia-Martin 2008; Dai, Leng et al. 2009), 
this suggests further study of NAT2 genotype in Vietnamese Kinh could focus only 
on 3 nucleotide sites (341, 590 and 857) to discriminate NAT2 genotypes, however a 
larger sample size should be examined to confirm this. Based on this analysis, we 
developed a PeR RFLP assay to detect fast/slow acetylators in Vietnamese Kinh 
(section 6.2.3). 
Twenty four of 37 people (64.9%) expressed fast acetylator phenotype in this 
study. The predominance of fast acetylators in Vietnamese Kinh was similar to the 
results of other studies in Chinese (Zhao, Seow et al. 2000) and Japanese (Walker, 
Ginsberg et al. 2009). 
Another study conducted in 72 Vietnamese in northern Vietnam also showed a 
similar pattern that fast acetylation genotypes were predominant in Vietnamese 
(Cavaco, Asimus et al. 2(07). The study showed that 90% of participants carry at 
least one NAT2 fast allele, whereas only 64.9% volunteers in our study carry either 
fast alIeles NAT2*4 or NAT2*13A. The reason for the discrepancy between that 
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study and the present analysis are not clear, however the study in northern Vietnamese 
did not confIrm genotype predictions with phenotypic data. Alternatively there may 
be geographical variation (the two study sites are approximately 2,OOOkm apart). The 
analysis of NAT2 alleles in the present study was not consistent with Hardy-Weinberg 
equilibrium and the proportion of slow acetylators was higher than it should be, 
suggesting that the sample size was not large enough to represent for the whole 
country. However, this is true with all other studies which have examined both 
genotype and phenotype of NAT2 (Kita, Tanigawara et al. 2001; Kinzig-Schippers, 
Tomalik-Scharte et al. 2(05). Given these limitations, and the discrepancy with the 
report from northern Vietnam, the actual prevalence of fast acetylators in the 
Vietnamese Kinh population is still unknown and requires further investigation with a 
larger sample size. 
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Figure 6.7: The prevalence of first-line drug resistance among 
M.tuberculosis isolates from pulmonary TB patients in HCMC (1998-2000) (Quy, 
Buu et aI. 2006) 
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It is possible that the high prevalence of fast acetylators in the Vietnamese 
Kinh population could be a contributing factor to the high prevalence of INH resistant 
M.tuberculosis in this population (Figure 6.7) (Quy, Buu et al. 2(06). Data from 
M.tuberculosis isolates analysed in HCM city showed that around only 10% of INH 
resistant isolates carry inhA(C-lST) mutation (Caws, Duy et al. 2006), which confers 
a low-level of INH resistance, as illustrated in chapter 4. With a standard 
administration dose of INH (Smglkg), slow acetylators may accumulate a sufficient 
lNH concentration in their sera (Kinzig-Schippers, Tomalik-Scharte et al. 200S) to 
effectively kill isolates with an inhA mutation but not those with a katG315 mutation, 
which confers high-level resistance. This would favour the selection of INH resistant 
isolates with katG31S mutations in slow acetylators. Whereas, fast acetylators rapidly 
metabolise INH and these patients often do not reach the optimal EBA90 of INH 
concentrations in their sera (Donald, Parkin et al. 2(07). Speculatively, INH resistant 
strains may be selected in fast acetylators in whom the efficacy of INH is decreased. 
The interplay of factors between treatment programs, acetylator status of populations 
and the emergence of different drug resistance patterns in M.tuberculosis is complex 
and will be difficult to untangle. 
The influence of N A T2 genotype on TB treatment was illustrated in a stud y by 
Higuchi et al. which showed Japanese individuals with slow NAT2 genotypes 
(NA T2*6A) had an increased likelihood of adverse events with anti-tuberculous drug 
therapy (Higuchi, Tahara et al. 2(07). A pharmokinetic study by Donald et al. showed 
that at normal INH dose for TB patients (5mg/kg), many FIF acetylators did not 
achieve a serum concentration of 2.l9fJ.glrnl after 2 hours, which is the concentration 
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for optimal early bactericidal activity of INH (Donald, Parkin et al. 2007). The high 
prevalence of fast acetylators in the Vietnamese Kinh population may have 
implications for the TB control programme. It is possible a higher dose of INH should 
be applied in FIF acetylators to ensure optimal early bactericidal activity, however the 
cost and risks of toxicity may outweigh the benefits. The most common adverse event 
from INH therapy is hepatotoxicity which has been described in all populations 
carefully (Ohno, Yamaguchi et al. 2(00). A RCT in India suggested that high dose of 
INH is safe and can improve outcome in MDR TB patients (Katiyar, Bihari et al. 
2(08). Further studies should investigate the efficacy and toxicity of high-dose of 
INH in TB patients. It is possible that high dose INH will also be beneficial in TBM 
cases, where INH is one of the few drugs which has both high EBA and good CSF 
penetration. 
WHO recommends that intermittent administration of chemotherapy should 
not be applied for patients with INH resistant TB (WHO 2009), and the drawbacks of 
intermittent INH therapy are likely to be exaggerated in populations with both a 
predominance of fast acetylators and high prevalence of INH resistant TB, such as 
Vietnam. 
A simple technique which can determine acetylator status of TB patients 
would simplify studies of targeted high dose INH therapy. The novel peR RFLP 
developed here could be used to rapidly determine NAT2 genotypes for stratified 
randomization to high or standard dose INH therapy. Further studies should focus on 
the influence of host acetylator status on INH resistance in TB patients and treatment 
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outcome. This could be a contributing factor to geographic variations In the 
prevalence of drug resistance 
Only the correlation of caffeine metabolism and NA T2 genotype was 
investigated in this study. The correlation between phenotype of INH metabolism and 
NAT2 genotype is unlikely to be different since INH and caffeine share the same 
clearance pathway. However, further study should confirm accurate correlation of 
genotypes with INH metabolism phenotype in TB patients. 
This study focused on caffeine metabolism as a surrogate marker for INH 
metabolism. TB therapy requires multiple drugs and further studies are also required 
to determine host genetic factors which influence the metabolism of other key drugs. 
Improved understanding of drug metabolism enables targeted therapy to minimize 
adverse events, optimize efficacy and improve drug adherence, ultimately reducing 
the potential for the emergence of drug resistance. However, although individualized 
therapies are not currently feasible in high-burden, resource limited settings where 
standardized regimens are applied, basic research is required to enable us to preserve 
efficacy of drugs such as INH, which has been the cornerstone of TB treatment for 
over fifty years. 
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Chapter 7 
Discussion 
INH has a critical role in drug therapy for TB and is likely to remain a key 
drug for decades to come. It has high early bactericidal activity, is active against latent 
TB and is well-tolerated and inexpensive. Despite this, research on drug resistant 
M.tuberculosis has largely focused on RIP resistance as the important determinant of 
MDR TB. Much remains unknown about both the mechanism of action of INH and 
the mechanisms of drug resistance for this drug. Globally, it is estimated 7% of 
M.tuberculosis strains are now resistant to INH and it is vital that we better 
understand the development, and transmission of INH resistant TB, as well as 
improving tools for rapid detection and optirnizing treatment. This thesis has focused 
on several aspects of INH resistance in M.tuberculosis in Vietnam. Each chapter in 
this thesis addressed a different aspect of INH resistant TB to improve our 
understanding of some fundamental aspects of INH resistance and its impact on 
treatment outcomes. 
A previous study showed that the rate of INH resistant M.tuberculosis was 
very high in HCM city, the biggest city in Vietnam, with 25% of primary TB patients 
infected with INH resistant strains (Quy, Buu et al. 2006). The resistance rate in 
previously treated TB patients was much higher with almost 50% of patients infected 
with INH resistant M.tuberculosis (Quy, Buu et al. 2(06). These findings showed the 
urgent need for a feasible alternative to phenotypic DST for earlier detection of INH 
resistance and MDR M.tuberculosis in Vietnam. A previous study at OUCRU in 100 
183 
INH resistant isolates showed that the majority of the strains carried mutations at just 
two positions katG315 and inhA-15 (Caws, Duy et al. 2006). The first study in this 
thesis therefore developed MAS-PCR tests for RIF resistance (Tho, Ha et al. 2(08) 
and INH resistance (Tho, Lan et al. 20ll), and the results were comparable with the 
with commercial LPA MTBDRplus. The major drawback to these MAS-PCR tests 
was the need for DNA from an isolate of M.tuberculosis, meaning that they cannot yet 
be performed directly on clinical samples such as sputum. The Xpert MTB/RIF test is 
a close cartridge based system which has major advantages in the field in high burden 
settings but it remains expensive for wide-scale screening of all TB suspects and is 
currently only able to detect RIF resistance and is therefore being targeted to high-risk 
groups for MDR TB. The need for a rapid, robust and economically feasible screening 
test for INH resistant TB remains. 
Several studies from other regions in the world have reported that the 
katG315 mutation confers a higher level of INH resistance than inhA-15 mutation 
(van SooIingen, de Haas et al. 2000; Vijdea, Stegger et al. 2(08). Chapter 4 of this 
thesis showed a similar result that isolates carrying katG3l5 mutation had 
significantly higher MIC to INH in comparison with isolates carrying inhA-15. In 
addition with our previous finding that 90% of INH resistance isolates from Vietnam 
carry katG315, this result implies that majority of the INH resistant isolates have high 
MIC to INH and the application of high dose of INH to MDR patients might not be 
effective in Vietnamese population. No studies have as yet addressed the question of 
which host and pathogen characteristics are important in determining the benefit of 
high-dose INH. 
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There are a number of reports demonstrating differential virulence properties 
of different M.tuberculosis strains, both in vitro and in vivo such a~ CDC 1551 
outbreak strain from the USA (Tsenova, Ellison et al. 2005). Epidemiological studies 
have also shown a relationship between M.tuberculosis lineages and drug resistance 
patterns. In chapter 4, a strong association of Beijing lineage with a high MIC to INH 
was shown which was not accounted for solely by the mutation conferring resistance. 
This association may give INH resistant Beijing strains a selective advantage under 
programmatic treatment conditions. A report in 2003 suggested the Beijing lineage 
had a 'hypermutator' phenotype resulting from mutations in DNA repair genes 
(mutn. mutT4 (Ebrahimi-Rad, Bifani et al. 2003). However. the evidence for this 
theory remains weak and it is likely these mutations are simply phylogenetic 
mutations in Beijing lineage. The underlying mechanism of increase resistance in 
Beijing lineage may be an inherent resistance property or may be the result of the 
ability to acquire compensatory mutations more rapidly to mitigate the fitness cost of 
resistance mechanisms. It also remains unclear if this is an attribute of Beijing lineage 
strains. or a sub-group. The result in chapter 4 suggests that further study should be 
done to reveal the mechanism behind the increase resistance level of Beijing 
genotype. Whole genome sequencing of a diverse collection of Beijing lineage 
isolates now underway will help to address these questions. The study in chapter 5 
shOWed that INH resistance has a strong impact on outcome from HIV-associated 
TBM. While the high mortaIity in all forms of TBM indicates that current treatment 
regimens are sub-optimal, this study highlights the increased risk in patients with non-
MDR strains that are resistant to INH. Notably. the results of this study showed that 
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the adjusted hazard ratio for mortality of patients infected with INH resistant 
M.tuberculosis was 1. 78 [95% Cl 1.18-2.66], p=O.005 and that there was a time-
dependent effect of INH resistance with an adjusted hazard ratio of 1.45 [95% Cl 
0.87-2.40], p= 0.15 for the first three months and 5.05 [95% Cl 2.23-11.44], p=O.OOOI 
thereafter, in comparison with patients infected with fully susceptible of STR mono-
resistant strains. 
The data clearly show that treatment with the standard first line regimen is 
inadequate in these patients and alternative regimens must be evaluated. While this 
study focused on HIV-associated TBM, a group with very high mortality, a 
retrospective study from the United States has also shown excess mortality in TBM 
patients with INH resistant, non-MDR TB. It is known from recent meta-analyses 
that treatment outcomes are also worse in pulmonary TB patients with INH resistant, 
non-MDR strains when treated with standard regimens (Lew, Pai et al. 2008; 
Cattarnanchi, Dantes et al. 2009; Mattbys, Rigouts et al. 2(09). With the report that 
25% of new TB cases in HCM city have INH resistant pathogen (Quy, Buu et al. 
2006), this high prevalence of INH resistant M. tuberculosis is likely to have an 
impact on the success of NTP in Vietnam. Further study should investigate the impact 
of INH resistance in other groups of patients, especially pulmonary TB and determine 
which patients are at highest risk of treatment failure to target interventions. 
IPT, which is used to treat latent TB, especially in HIV patients, could also 
have an impact on INH resistance prevalence. !PT is being scaled up in many regions 
of the world, including Viet Nam. Due to the need for the use of INH for a long 
period in the prevention therapy, the initial TB infection rate could be reduced, but the 
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long term consequences for the positive selection of INH resistant TB are not clear. 
Recently life-long IPT has been advocated in broader populations, including 
prisoners, miners and others who live in high TB transmission settings (WHO 2011). 
This could make the control of INH resistance more difficult. A RCT in South Africa 
is examining the impact of IPT on TB amongst gold miners (Registration number 
ISRCTN63327174) (Fielding, Grant et al. 2011). The result of this and similar studies 
help us understand the risk and benefits of IPT. Preliminary results reported in 2012 
showed that IPT in gold miners failed to have a long-term impact on TB incidence; 
with a substantial reduction in TB incidence observed only during the therapy. 
(Churchyard, Fielding et al. 2012). 
It is likely that other factors besides resistance also play a role in outcome 
from HIV-associated TBM. The study in chapter 5 showed that pathogen lineage is 
also a determinant of outcome, but the mechanism again remains unelucidated. Many 
patients with HIV-associated TBM in HCM city also have other viral infections in the 
CNS (Torok, Chau et al. 2008) and we have not investigated the impact of these on 
outcome here. The prevalence of HBV infection in Vietnamese population is high 
with around 8.8-16.4% patients positive with HBsAg or in active HBV form (Nguyen, 
McLaws et al. 2007; Duong, Nguyen et al. 2009). This study has demonstrated that 
multiple pathogen factors are independent and significant determinants of mortality in 
HIV-associated TBM and highlights the urgent need for RCT to treat drug-resistant 
forms of TBM. 
In chapter 6, I investigated the association of NAT2 genotype with NAT2 
phenotype and the prevalence of fast acetylators in the Vietnamese Kinh population. 
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The strong correlation result between genotype and phenotype of NAT2 in 
Vietnamese Kinh healthy volunteers paves the way for further studies on the effect of 
acetylator status on the outcome of TB patients treated with INH. The study showed 
the majority of Vietnamese Kinh population are fast acetylators, which may reduce 
the serum concentrations of INH achieved with standard dosage. The result of this 
study implied that under DOTS therapy, many Vietnamese might not reach the 
appropriate INH concentration to achieve optimal EBA. High dose of INH might 
improve the efficacy of the drug in this particular population; however increased 
toxicity may be a problem, particularly in slow-acetylator patients with pre-existing 
liver damage or hepatotropic viral co-infections (Van Deun, Maug et al. 2010). As a 
result, the development and application of a NAT2 PCR-RFLP test presented here 
provides a useful tool that makes further clinical trials to investigate targeted 
application of lNH dosage dependent on NAT2 genotype become feasible. Further 
studies should focus on the effect of acetylator status on serum lNH level, EBA and 
treatment outcome and determine if targeted therapy which adjusts INH dosage 
dependent on acetylator status is beneficial. 
Overall, the studies presented in this thesis underline the importance of lNH 
resistance in TB therapy and highlight the need for further research developing 
diagnostic tools and optimizing treatment. To date, there is no standardized treatment 
for lNH resistant TB and different countries have different treatment 
recommendations. The mechanisms of lNH resistance are still not completely 
understood. Over 10% of lNH resistant M.tuberculosis strains do not contain any 
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identified mutations in either katG or inhA genes; indicating there are other unknown 
drug resistance mechanism which remain to be identified. Despite these significant 
outstanding questions, research on drug resistant M. tuberculosis continues to focus on 
MDR TB due to the fact that it is more dangerous form of the disease. However, INH 
resistance is the initial step which fuels the development to MDR TB or further XDR 
TB. Trying to understand and to control the initial development and reduce 
transmission of INH resistance will 'turn off the tap' on MDR TB and reduce further 
drug resistance amplification to MDR and XDR TB. To achieve this, further studies 
should include: 
RCTs to optimize treatment of INH resistant M.tuberculosis which remains 
susceptible to RIF. 
Fully characterize all mechanisms of INH resistance in M.tuberculosis through 
whole genome sequencing of larger globally representative collections and in vitro 
functional studies. 
Establish the long-term impacts of large-scale IPT on the development of INH 
resistance. 
Conduct RCTs to determine if targeted therapy dependent on NA T2 acetylator 
statu s is effective. 
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